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1. Huntington's disease 
 
The neurodegenerative diseases, a group of chronic and progressive neurological 
disorders, share many characteristics, such as onset in adult life, neuronal cell 
death and the association with high morbidity and mortality. Currently, few or no 
effective options are available for treatment. Despite the various causes of these 
chronic neurodegenerative illnesses, the selective vulnerability of specific 
neuronal populations is one of the most intriguing aspects of neurodegenerative 
diseases [1]. In Huntington's disease, the inherited neurodegenerative disorder 
studied in this thesis, there is a striking specificity of major neuronal loss that is 
restricted to the neostriatum, parts of the cortex and various subcortical nuclei. 
How and why the neurons die is unknown for most neurodegenerative disorders, 
but dysregulation of cell death may be involved in the pathogenesis. This is 
thought because in a broad spectrum of neurological diseases the mechanisms and 
execution pathways leading to neuronal cell death are quite similar [2-4]. 
 
 
Clinical features, classification and epidemiology of Huntington's disease 
 
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder 
and is clinically characterized by gradually evolving involuntary movements, also 
known as  chorea, progressive cognitive impairment and psychiatric disturbances 
[5-8]. Although this neurological disorder had been reported previously, in 1872 
George Huntington was the first to describe HD patients and their clinical 
symptoms in detail [9]. HD symptoms and signs begin insidiously and onset 
usually occurs during the fourth or fifth decade of life with a mean survival of 15 
to 20 years after disease onset. However, the age of disease onset can vary from 
childhood until old age and can be correlated with the length of the 
polyglutamine repeat in the huntingtin gene. In patients with juvenile-onset HD, 
with disease onset before the age of 20 years, the signs and symptoms are 
somewhat different; they include bradykinesia, rigidity and dystonia while chorea 
can be completely absent. Involuntary movements can take the form of tremor or 
myoclonus and affected children often develop epileptic seizures [1,6,8]. HD is a 
progressive disorder with a fatal outcome. At present there is no effective 
treatment. The only treatment options available in HD are symptomatic: they 
focus on neurological  and psychiatric symptoms and aim at  improvement of 
quality of life [10]. As to epidemiology: the incidence and prevalence of HD 
varies between ethnic groups. The disorder is more common among European 
populations with a prevalence of almost 1 in 10,000, in comparison with Japanese 
and African populations, where the prevalence may be  less than 1 in 1,000,000 
[6,8]. 
 
 
Neuropathological characteristics of Huntington's disease 
 
HD is characterized by a selective and progressive neurodegeneration that 
appears initially and primarily in the neostriatum, but extends to other brain 
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regions in more advanced stages of the disease [11] (see Fig. 1). Within the 
neostriatum, formed by the nucleus caudatus and the putamen, the medium-sized 
spiny GABAergic projection neurons are the population most sensitive to 
neuronal cell death in HD [6,8,12-14]. These early affected medium-sized spiny 
neurons show dendritic changes, including recurving of dendrites and altered 
density, shape and size of spines and by end stages of the disease up to 95% of 
these striatal neurons are lost [6]. Therefore, the most important HD 
neuropathological features are severe atrophy of the neostriatum with extensive 
neuronal loss and reactive gliosis, although a marked variation in the extent of 
neuropathology exists among HD brains [6,11,15-17]. In brains of late-stage HD 
patients, presenting severe atrophy of neostriatum and globus pallidus, additional 
loss of cortical volume has been demonstrated that particularly affects the large 
pyramidal neurons in layers III, V and VI [1,5,6]. Both macroscopic and 
microscopic examinations of striatum samples of 163 clinically diagnosed cases of 
HD, formed the basis for a neuropathological classification system into five 
grades, with ascending order of severity that correlate with clinical progression. 
In grade 0 HD striatum, the extent of neuronal loss is 30-40%, while it increases 
to more than 95% loss that is associated with marked astrogliosis and gross 
atrophy in grade 4 HD cases [6,11]. 
 
Figure 1. Macroscopic pictures of a control brain and HD brain (kindly provided by Dr. P. Wesseling, 
Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands). 
 
More recently, the presence in HD brains of neuronal intranuclear inclusions and 
cytoplasmic aggregates that contain the aggregated mutant huntingtin protein as 
well as ubiquitin demonstrates another specific bio-hallmark of HD 
neuropathology [8,18-20]. These inclusions can be found in the nucleus and 
aggregates are present in the perikaryon, dendrites and axons of neurons [12]. 
Nuclear abnormalities within HD neurons constitute a pathological feature that is 
shared by several other glutamine repeat neurodegenerative disorders, such as 
dentatorubral and pallidoluysian atrophy (DRPLA) and the spinocerebellar ataxias 
[21,22]. The nuclear inclusions and cytoplasmic aggregates that contain mutant 
huntingtin were first demonstrated in transgenic mouse models of HD that 
express the N-terminal part of huntingtin with an extended polyglutamine repeat 
[18,23]. In autopsy material from HD patients, the density of these intranuclear 
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inclusions in neurons is correlated with the length of the CAG repeat in the 
huntingtin gene. The number and size of cytoplasmic aggregates of mutant 
huntingtin was found increased in higher grade HD patients [18-22,24]. 
Interestingly, intranuclear inclusions can be detected long before neurological 
symptoms and neurodegeneration occur, suggesting that the aggregation of 
huntingtin is an essential step in neurodegeneration [18,25,26]. However, most 
neurons that contain inclusions do not correspond exactly to the neostriatal 
neurons that degenerate in HD. They are  enriched in the  population of striatal 
interneurons [27] and in the cerebral cortex of HD brains [18,19] – neuronal 
populations that are not among the early degenerating cell types. 
 
 
Pathogenesis of Huntington's disease and huntingtin protein 
 
Huntington's disease is caused by the abnormal expansion of a CAG-trinucleotide 
repeat in the N-terminal exon 1 of the huntingtin gene, which is located on the 
short arm of chromosome 4 (4p16.3) [5,28,29]. In the translated protein, 
huntingtin, this repeat encodes an expanded polyglutamine repeat sequence. 
Asymptomatic individuals have the wild type huntingtin gene with 29 or fewer 
CAG repeats, while HD is caused by expansions of 36 or more repeats [1,30]. 
There is an inverse relationship between the genomic CAG repeat size of the 
mutant huntingtin gene and the age of onset of signs. The larger the number of 
CAG repeats, the earlier the age of disease onset. Most adult-onset cases have 
CAG repeat sizes ranging from 40-50, whereas expansions of more that 55 
repeats frequently cause the juvenile form of the disease [6]. Since the discovery 
of the huntingtin gene, an explosion of research has led to many insights into the 
normal function of huntingtin and the molecular basis of the disease. 
The normal or wild type huntingtin protein is found mainly in the cellular 
cytoplasm. This cytoplasmic protein is ubiquitously and widely expressed in many 
different tissues but its expression is highest in neurons. Huntingtin protein has 
been found in vesicle membranes, the cytosol, the nucleus, mitochondria, and 
microtubules. It appears to be associated with clathrin through huntingtin-
interacting protein (HIP-1) [31-33]. These intracellular locations suggest that 
huntingtin may act as a molecular scaffold regulating several cellular processes 
including clathrin-mediated endocytosis, vesicle transport, synaptic transmission, 
transcriptional events and mitochondrial function [1,34-38]. Furthermore, 
huntingtin can protect neuronal cells from apoptotic stress and therefore may 
have a pro-survival role as well [39,40]. The number of huntingtin interacting 
proteins identified up to now exceeds 25 [41]. Collectively, the role of huntingtin 
is complex and it appears to be involved in various cellular functions both in the 
cytoplasm and nucleus (reviewed in [35,41]). 
The precise function of normal huntingtin is not yet fully understood and 
how mutant huntingtin exerts harmful effects remains unclear [34]. Various 
hypotheses have been proposed. For example, the mutant huntingtin protein may 
be neurotoxic through transcriptional dysregulation or it may make neurons 
susceptible to excitotoxicity, associated with an increase in cytosolic calcium 
[35,42]. Moreover, mutant huntingtin also dysregulates mitochondrial homeostasis 
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early in the disease [32] that may cause the release of cytochrome c and the 
activation of caspases. These proteins are involved in apoptosis [43]. 
Evidence is accumulating of both a toxic effect of mutant huntingtin 
fragments and a depletion of wild type huntingtin as part of the pathogenesis in 
HD [4,39,44-48]. Neurons of HD patients contain one copy of the wild type 
huntingtin allele and one copy of the mutant huntingtin allele. Possibly as part of 
normal proteolysis of huntingtin, a N-terminal fragment containing the expanded 
polyglutamine repeat is released. This expanded polyglutamine-containing 
fragment then undergoes a conformational change and this ultimately, through as 
yet unknown steps and structures, results in toxic protein aggregates that also 
recruit other proteins [12,45,49-52]. These huntingtin aggregates can be found in 
any part of a neuron, but primarily in the nucleus [35,41]. Huntingtin protein 
aggregates become ubiquinated, presumably because they are recognized as 
misfolded proteins that become targeted for proteasomal degradation. The 
process of toxic aggregate formation may thus be critical for the development of 
neuronal dysfunction and degeneration in HD [12]. However, a direct causative 
pathway from the huntingtin gene mutation to the neostriatal degeneration has 
not yet been established. For example, it is not clear whether the formation of 
cytoplasmic aggregates and nuclear inclusions, the presence of soluble aberrant 
mutant huntingtin fragments, or an intermediary structure is the crucial 
determinant of neuronal cell death and disease initiation and progression. 
Several other mechanisms that may contribute to neuronal dysfunction and 
cell death in HD, which are not directly related to mutant huntingtin, have been 
proposed to play a role in the disease process. These include impaired energy 
metabolism by mitochondrial dysfunction, glutamate-mediated excitotoxicity, 
oxidative stress, altered gene transcription abnormal protein interactions and 
inappropriate apoptosis [48,53]. Abnormal protein interactions of huntingtin and 
the involvement of apoptosis will be discussed in a following paragraph (see 
paragraph 2.4), while the other mechanisms are possibly a secondary event related 
to a defect in energy metabolism [54]. In neurons with compromised energy 
metabolism, the threshold for glutamate toxicity is reduced. This leads to 
activation of glutamate-mediated excitotoxicity, whereas induced oxidative stress 
increases the production of damaging and free oxygen and nitrogen radicals. 
Mitochondrial dysfunction also causes the release of cytochrome c and activates 
caspases, and thus, could be a central phenomenon in HD pathogenesis as it 
would explain the oxidative stress, excitotoxic processes and energy metabolism 
dysfunction observed in HD patients [43]. 
How cells die in HD is not clear and whether the dying cells have been 
dysfunctional for a considerable time before cell death is also unknown. The 
problem that investigators face is to distinguish primary from secondary events in 
elucidating the pathogenesis of HD. For now it is not clear whether 
mitochondrial dysfunction is a primary change or a consequence of the early 
neuropathological changes in HD [1,48,55-57]. The pathogenesis of HD could 
well be multifactorial as is the huntingtin protein, which may have many 
functions. 
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2. Apoptosis and Huntington's disease 
 
Cell death is a primordial event in cell life and occurs either by necrosis or by 
apoptosis – programmed cell death [58-60]. These two functionally distinct types 
of cell death are characterized by biochemical features, such as the activation of 
specific apoptotic genes and by typical morphological differences. In neuronal 
populations, both modes of cell death can either coexist or be sequential events, 
depending on the severity of the initiating insult [61]. Cellular energy reserves 
appear to play an important role in these two forms of cell death, with apoptosis 
favoured under conditions of mild insults and preserved adenosine triphosphate 
(ATP) levels. Apoptosis is part of normal development, involving a cascade of 
biochemical events that is tightly regulated and leads to the destruction of the 
cell. However, inappropriate or aberrant apoptotic cell death also occurs during 
certain pathological states, such as infarction, viral or chemical toxicity, and in 
acute and chronic neurological diseases [2,16,59]. In HD, inappropriate activation 
of apoptosis is thought to be the predominant form of cell death [62-64]. 
 
 
Two types of cell death, apoptosis versus necrosis 
 
In necrosis, the stimulus of cell death is itself often the direct cause of the demise 
of the cell. Therefore, necrotic cell death is always pathological, accidental and 
not very well regulated. It results in an extracellular inflammatory reaction caused 
by the uncontrolled release of intracellular contents. In the central nervous 
system necrotic cell death follows acute ischemia, traumatic brain or spinal cord 
injury, or a neurotoxic insult in which ATP is depleted [65,66]. It occurs in areas 
that are severely affected by the abrupt biochemical collapse of cells, which leads 
to the generation of free radicals and excitotoxins, such as glutamate, cytotoxic 
cytokines, and calcium. The histological features of necrotic cell death are 
mitochondrial and nuclear swelling, dissolution of organelles, and condensation of 
chromatin around the nucleus. These events are followed by rupture of nuclear 
and cytoplasmic membranes and degradation of DNA by random enzymatic cuts 
[59,67]. Given these mechanisms and the rapidity at which the process occurs, 
necrotic cell death is extremely difficult to treat or prevent. 
Apoptosis, or programmed cell death, is a biological phenomenon that 
results in the orderly and efficient removal of damaged or redundant cells. It 
occurs after DNA damage or during normal development, in immune regulation, 
in hormone-induced atrophy, in tumour regression and is part of tissue 
homeostasis [67-70]. Apoptotic cell death is a tightly regulated physiological 
process under the intrinsic control of individual cells. The term apoptosis was 
originally used to describe the morphological appearance and characteristics of 
dying eukaryotic cells during development. Features include shrinkage of the cell 
body, nuclear condensation followed by DNA fragmentation, blebbing of 
membrane-enclosed cellular debris, and preservation of organellar ultrastructural 
integrity [58,67,71,72]. After cell death, the remaining cell fragments are sealed 
into membrane-enclosed ‘apoptotic bodies’, while chromosomal DNA is 
enzymatically cleaved to 180 bp internucleosomal fragments. Other features of 
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apoptosis are a reduction in the membrane potential of the mitochondria, 
intracellular acidification, generation of free radicals, and externalization of 
protein phosphatidylserine residues [58,73,74]. 
Biochemically, apoptotic cell death was considered to be an active process 
that requires increased synthesis of specific proteins that kill the cell [71]. During 
the past decade, considerable progress has been made in understanding the 
process of apoptosis [73]. It involves the activation of specific caspases (cysteine 
aspartate-specific proteases) and the Bcl-2 family of proteins, mitochondrial 
release of death factors that results in the characteristic changes of nuclear 
morphology and DNA fragmentation, and the collapse of the cell [75]. All these 
factors that contribute to the apoptotic cascade (see Fig. 2) demonstrate each 
specificity of function, regulation, and pathway involvement [70,76,77]. The 
apoptosis cascade starts if a cell is provided with sufficient time to organize a 
series of intracellular events that lead to self-destruction. Apoptosis can be 
divided into three stages. In the first stage the cascade is induced by external 
death signals, such as ligand-receptor interactions, or by intracellular death 
signals. These lead to the first proteolytic events. The second stage starts with the 
activation of the executioner caspases. Their activation is called the point of no 
return, since once activated, these proteases degrade a variety of proteins, 
resulting in irreversible damage to the cell. Apoptotic death itself is the third 
stage. It results from the very complex cascade of events that finally leads to 
characteristic changes in nuclear morphology, DNA fragmentation and cell death 
[76,78]. 
 
 
Apoptotic pathways 
 
Apoptotic cell death can be triggered by activation of specific death receptors on 
the plasma membrane or by an array of intracellular death signals that use 
mitochondrial dysfunction in response to cellular stress, such as DNA damage, 
glucocorticoids, and loss of growth factors [75,79]. In 1993, a series of studies of 
the nematode Caenorhabditis elegans first elucidated the existence of a genetically 
controlled suicide program that underlies the apoptotic morphology. In this 
worm, four genes were identified that control the orderly execution of the 
developmental apoptotic program. The ced-3, ced-4, and egl-1 genes mediate cell 
death [80,81], while the ced-9 gene functions as an inhibitor of apoptosis. 
Homologues of ced-3 (caspases), ced-4 (Apaf-1), ced-9 (Bcl-2), and egl-1 (BH3-
only proteins) have been conserved in mammals and act as core components of 
the apoptotic program [80,82-87]. 
 In the subsequent years, many genes and proteins were characterized that 
appear to regulate and execute programmed cell death. In the nervous system, 
apoptotic stimuli can trigger various apoptotic pathways, such as the extrinsic and 
intrinsic pathways of caspase-mediated cell death, as well as activation of a 
caspase-independent signaling apoptosis pathway (see Fig. 3). Caspases are 
cysteine aspartate-specific proteases and constitute a family of intracellular 
proteins that play an important role in the initiation and execution of apoptotic 
cell death [70]. The caspase-mediated extrinsic pathway, or the cell-death receptor 
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Figure 2. Apoptosis cascade, a schematic representation after Huppertz et al. (1999) [76] and Vila (2003) 
[78]. 
 
pathway, is initiated by activation of the Fas receptor after binding to the Fas 
ligand. This interaction stimulates the autoproteolytic activation of proximal 
caspase-8, followed by the initiation of caspase executioners leading to cell death 
[88]. The activation of the caspase-mediated intrinsic pathway, or the 
mitochondrial pathway, is regulated by the interaction of mitochondrial proteins 
of the Bcl-2 family, such as Bax and Bcl-2. The intrinsic pathway is triggered by 
translocation of Bax, Bak, and other BH3-only members of the Bcl-2 family from 
the cytosol to the mitochondrial outer membrane. This leads to permeabilization 
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of the outer mitochondrial membrane and leakage of pro-apoptotic mitochondrial 
effectors into the cytosol, such as cytochrome c [89]. Cytochrome c interacts with 
two other cytosolic protein factors, apoptosis activating factor-1 (Apaf-1) and 
procaspase-9, forming the mitochondrial apoptosome [90]. This complex is ATP-
dependent, indicating that apoptotic cell death is an active process that requires 
energy and only occurs when a cell can produce sufficient ATP. The apoptosome 
activates caspase-9 [83,91], and subsequently proteolyses caspase-3. The 
activation of this down stream effector results in the activation of other caspases 
and in the cleavage of various targets, such as the DNA-repairing enzyme poly 
(ADP-ribose) polymerase (PARP). This sequence of processes results in nuclear 
fragmentation and eventually cell death [83]. Finally, the caspase-independent 
pathway of apoptosis is activated by translocation of apoptosis-inducing factor 
(AIF), a mitochondrial flavoprotein, from the mitochondria to the nucleus where 
it induces caspase-independent peripheral chromatin condensation and large-scale 
(50 kb) DNA cleavage strands [89,92,93]. 
This illustrates the important and essential role of mitochondria in 
controlling specific apoptotic pathways and regulating apoptotic cell death [75]. 
Mitochondria are involved in the release of pro-apoptotic mitochondrial effectors 
but function also in cellular energetics, while they control the energy state of cells 
that may be the decisive factor in apoptosis [94] (see also Fig. 2). In this thesis, 
we focus mainly on the caspase-mediated neuronal death or mitochondrial 
pathway that may contribute to delayed loss of neurons [89], as hypothesized to 
occur in HD.  
 
 
Apoptotic pathways: Proteins of the Bcl-2 family 
 
The Bcl-2 family constitutes a group of proteins that play important roles in 
apoptosis regulation, under both physiological and pathological conditions. 
Members of this family promote either cell survival, as in the case of Bcl-2 and 
Bcl-XL, or cell death, as in the case of Bax, Bak, Bid and Bok [95-97]. Structurally, 
they all share some degree of homology and can have up to four conserved 
regions, named Bcl-2-homology domains (BH1-BH4) [78,98]. Of these the BH3 
domain is critical for heterodimerization with other family members [99]. Bid, 
Bad, and Bik share sequence homology only with the BH3 domain and act as 
another class of death effectors. These so called BH3-only proteins serve as 
intracellular death ligands that connect death stimuli to multidomain Bcl-2 family 
members [99] or to proximal signal transduction pathways that use caspase-8 
[100]. 
Pro-apoptotic Bax was first identified as a Bcl-2 binding partner by 
immunoprecipitation [101]. Subsequently it was shown that overexpression of 
Bax can accelerate cell death in response to various apoptotic stimuli [101]. Bax 
possesses the BH1-BH2-BH3 domains [98] but Bax also has a hydrophobic 
sequence at the C-terminal end, which is sequestered inside a hydrophobic cleft 
[102]. For anti-apoptotic Bcl-2, this hydrophobic segment is required to anchor 
the protein to membranes of various organelles, including endoplasmic reticulum, 
mitochondria, and nuclear outer membrane [98,103]. In healthy cells, Bax and Bid 
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are predominantly soluble monomeric proteins, but during apoptosis a significant 
fraction of the cytosolic forms of Bax and Bid translocate to the membrane 
fractions, in particular, the mitochondria [104-106]. In contrast, Bcl-2 remains 
bound to the membranes. This translocation process appears to involve a 
conformational change in Bax, leading to exposure of its C-terminal hydrophobic 
domain that can be used for anchoring [107]. Bax may then assemble into large 
oligomers that form channels in the membrane to regulate the mitochondrial 
membrane barrier [108]. These oligomers are associated with cytotoxic activities 
[109], such as the release of the mitochondrial pro-apoptogenic factors 
cytochrome c, Smac/Diablo or AIF [78] and the loss of the mitochondrial 
membrane potential [110,111]. 
In healthy neurons, both Bax and Bcl-2 proteins are expressed at a basal 
level. Upregulation of Bax has been found to promote neuronal apoptosis under 
pathological conditions such as ischemia [97,112], whereas over-expression of 
Bcl-2 can inhibit apoptotic cell death [97,103,113-115]. Pro-apoptotic Bax can be 
counteracted by co-expression of pro-survival factors Bcl-2 and Bcl-XL, that 
through the formation of Bax/Bcl-2 heterodimers through interaction of their 
BH-3 domains block the translocation of Bax to mitochondria [116]. Therefore, 
the balance between competing pro-apoptotic and anti-apoptotic signals from the 
Bcl-2 family proteins and their subcellular localization, phosphorylation status, 
and proteolytic processing in neurons, determine whether they will undergo 
apoptosis or not [79,115,117,118]. 
 
 
 
Figure 3. Scheme showing key components of apoptotic pathways in the nervous system. 
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Apoptotic pathways: Cytochrome c has a crucial role in apoptosis 
 
Cytochrome c is a component of the mitochondrial electron-transport chain that 
is required for the generation of ATP. It plays an important role in cellular 
energetics and mitochondrial respiration [79]. Cytochrome c appears to be an 
important modulator of cell death within the intrinsic or mitochondrial apoptotic 
pathway. The release of cytochrome c from the mitochondria into the cytoplasm 
is a key step in the initiation of apoptosis [73,119] and is regulated by differential 
expression of pro-apoptotic and anti-apoptotic members of the Bcl-2 family 
[73,99,120]. Cytochrome c release leads to the assembly of the apoptosome that 
activates the caspase cascade leading to proteolysis of key cellular substrates and 
the demise of the cell [78,79]. 
 
 
Apoptotic pathways: Caspases and caspase-mediated cell death 
 
Caspases (cysteine aspartate-specific proteases) are intracellular proteins that play 
a crucial role in the initiation and execution of apoptotic cell death [70,73,121]. 
Caspases are homologous to the nematode ced-3 gene product. Thus far, 15 
members of the caspase family have been identified in mammals [4,80,122]. 
Caspases exist as latent precursors in the cell and directly and indirectly 
orchestrate the morphological changes of the cell during apoptosis. Caspases 
function in a hierarchical proteolytic cascade consisting of upstream initiators and 
downstream executioners and become active after cleavage [73,123]. The initiator 
caspases (caspases 2, 8, 9 and 10) are activated in a self-amplifying cascade, 
directly in response to apoptotic stimuli and cytochrome c release. Caspases are 
also regulated at the transcriptional level, which indicates that the degree of 
activation and the number of caspase molecules within the cell determine the level 
of caspase activity [44,51,124,125]. The downstream effector caspases (caspases 3, 
6 and 7) are activated through proteolytic processing by initiator caspases and are 
responsible for the destruction of the cell [4,73,123,126,127]. The systematic 
cleavage of key components of the cellular infrastructure is crucial and the death 
process begins its terminal phase when executioner caspases act directly by 
activating factors that degrade DNA eventually leading to apoptotic cell death 
[74,78,128-130]. In the core apoptotic program caspase-3 is an important 
executioner protease that activates other effector caspases. It also cleaves a broad 
array of proteins critical for cell survival, such as DNA-repair enzymes, DNA 
fragmentation factor, and nuclear membrane components – all events that lead to 
nuclear fragmentation [75,89,92]. The huntingtin protein itself, is also a substrate 
for caspase-3 as well as for caspase-1 [131] and nuclear translocation of mutant 
huntingtin N-terminal fragments up-regulates transcription of caspase-1 and 
caspase-3 [45]. Progressive caspase activation and increased cleavage of 
huntingtin may lead to neuronal dysfunction and cell death in HD [4]. 
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Detection of apoptosis 
 
Cells that undergo apoptosis show characteristic morphological features such as 
membrane blebbing and nuclear condensation. Biochemically, they can be 
detected by the appearance of 180 bp DNA fragments on gel electrophoresis 
[58,67]. Apoptotic cell death was first described as an electron microscopic (EM) 
observation by Kerr et al. (1972), and EM observations are still the golden 
standard for the detection of apoptosis. Unfortunately, such studies are quite time 
consuming. 
Most histological methods used to detect apoptotic cells are based on the 
morphological changes that occur at the nuclear cell level. Nuclear staining can be 
visualized at the light-microscopy level by using toluidine blue or by fluorescent 
labels such as Hoechst-33258 and propidium iodide. These dyes reveal condensed 
and fragmented chromatin that marks advanced nuclear damage. Another 
morphological method is the terminal transferase-mediated biotinylated-UTP nick 
end-labeling (TUNEL), which specifically labels 3’ hydroxyl terminals of DNA 
strand breaks in nuclei and apoptotic bodies that are formed during apoptosis 
[132,133]. The TUNEL method may detect DNA breaks before morphological 
changes of apoptosis are apparent. However, careful assessment of the cellular 
morphology of TUNEL-positive cells is necessary, because the TUNEL method 
detects extensive DNA damage due to some forms of necrosis as well [134-136]. 
The most sensitive method for detecting dying cells is the in situ end labeling 
technique (ISEL) [137], which is a modification of TUNEL and is applied in 
unfixed, frozen sections. Unfortunately, such sections are not always available for 
research. The redistribution of phosphatidylserine (PS) containing peptide 
residues from the inner leaflet to the outer leaflet of the plasma membrane is an 
early event in the apoptosis process. Such externalized PS residues in apoptotic 
cells can be readily visualized by binding to a fluorescent derivative of the protein 
Annexin V [138,139]. 
Initially, detection of apoptosis in neurodegenerative diseases was focussed 
on the presence of apoptotic cells in post mortem tissues. This method is 
complicated by many conceptual and technical factors. It is difficult to detect 
apoptosis in slowly progressive neurodegenerative disorders due to the presumed 
low daily rate of neuron [69]. Most postmortem specimens are typically derived 
from advanced stages of the disease, when most neurons affected by the 
pathological process are already dead and removed by phagocytosis. The majority 
of initial morphological postmortem studies relied on the TUNEL technique to 
document the presence of apoptotic cells, whereas TUNEL can recognize non-
apoptotic DNA damage as well [134-136]. The ability to visualize dying cells is 
restricted to a narrow window of time in which dead cells are present and 
detectable, prior to being removed by phagocytosis. The relatively low number of 
TUNEL-positive cells found in the nervous tissue suggests that apoptotic cells 
disappear quickly by phagocytosis [140-142]. Nowadays, many investigators have 
stopped using an exclusively morphological approach and instead include 
techniques that assess molecular components, such as activators, effectors and 
negative regulators that operate in the apoptotic cascade as well (see also Fig. 2). 
The expression of Bax and Bcl-2, or alterations in caspase expression can be 
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determined by in situ hybridization or with immunohistochemistry. Another 
biochemical approach to demonstrate apoptosis is to use inhibitors of protein 
synthesis of caspases in culture systems. If fewer cells die under these anti-
apoptotic conditions, then death was due to apoptosis [76]. Recently, research is 
focussed on transgenic mouse models that lack certain apoptotic genes, to 
demonstrate either promotion or prevention of apoptosis. All together, the 
combined approach of morphological and biochemical methods has led to an 
increase in research opportunities and to more diverse and complete research on 
apoptotic cell death and pathways. 
 
 
Apoptosis and Huntington's disease 
 
HD is caused by an abnormal expansion of a CAG-trinucleotide repeat in the 
huntingtin gene but the precise mechanism of the selective neurodegeneration in 
HD neostriatum remains unclear. It has been suggested that aberrant apoptosis is 
involved in the pathogenesis of Huntington's disease (HD) [7,143]. Initial studies 
demonstrated an increase in DNA degradation and typical apoptotic cells in 
postmortem HD brains [62,144,145]. In vitro studies have shown substantial 
evidence connecting apoptotic pathways and apoptosis with mutant huntingtin 
[146]. 
Although it is not known how mutant huntingtin promotes cell death, a 
self-amplification cascade of progressive caspase activation that leads to neuronal 
dysfunction and eventually cell death has been proposed [131,146]. Huntingtin is 
proteolysed by caspase-1 and caspase-3 [49,131]. In HD mouse models and in 
presymptomatic and early symptomatic stages of HD patients caspase-1 and 
caspase-3 gene expression is transcriptionally up-regulated [44]. This leads to an 
increase of caspase-mediated cleavage of huntingtin and increases the generation 
of N-terminal huntingtin fragments that are prone to form toxic aggregates in 
neurons [45,49,50,131], while depleting wild type huntingtin [45,46,147]. It 
appears that some features of HD result from the depletion of huntingtin protein 
function, whereas recent data have shown that the consequent N-terminal toxic 
fragments themselves may exert toxic effects on the cell by transcriptional 
disrupting of other genes [48,146,148]. This evidence suggests that caspases are 
not only mediators of cell death but also of cell dysfunction, possibly more 
important for HD pathogenesis than for apoptotic cell death alone. 
Moreover, in human HD striatal brain tissue, activation of several pro-
apoptotic proteins, such as Bax, caspases 1, 3, 8, and 9 and release of cytochrome 
c have been demonstrated [45,46,147,149]. Despite this, morphological evidence 
of apoptotic neuronal death in human HD is scarce. Which pathways are involved 
in apoptosis remains unclear. In this thesis, we studied apoptotic cell death and 
the expression of apoptotic markers in animal models of HD and in human HD 
brains that may contribute to the slowly developing death of medium-sized spiny 
GABAergic projection neurons in the striatum. 
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3. Animal models of Huntington's disease 
 
The first animal models of HD were based on HD neuropathology and used 
neurotoxins to induce specific neurodegeneration of medium-sized spiny neurons 
in the striatum. In 1993, Beal and colleagues reported the neurochemical and 
histological characterization of striatal excitotoxic lesions produced by the 
mitochondrial toxin 3-nitropropionic acid that mimicked HD neuropathological 
hallmarks [150]. When research for this thesis was started, we focussed on animal 
models of HD that demonstrated neurodegeneration in the basal ganglia to 
examine apoptosis and mechanisms of apoptotic cell death. Since 1994 transgenic 
mouse models became available but they produced an incomplete phenotype of 
HD that lacked specific cell death in the basal ganglia. Therefore transgenic 
mouse models were not suitable for our research project. Later, transgenic animal 
models and knock-in models were developed that were more realistic and 
revealed specific neurodegeneration and phenotypic features of HD. All these 
different animal models provided insights into normal huntingtin function and 
revealed potential pathogenic mechanisms of the HD mutation [1]. Recently, 
animal models of simple organisms, such as Caenorhabditis elegans and Drosophila 
melanogaster, or in vitro models using neuronal cells or organotypic brain slices are 
powerful tools for screening therapeutic strategies. 
 
 
Transgenic mouse models of Huntington's disease 
 
A breakthrough in HD research was the development of transgenic animal 
models. Because HD is an autosomal dominant condition caused by one mutated 
gene, it was possible to create transgenic mouse models [151]. Several different 
strains have been generated and these mouse models fall into three categories: (1) 
transgenic animals that express fragments of the mutant human huntingtin gene 
added to the normal mouse genome (the wild type homozygous state); (2) 
transgenic animals that express full-length mutant human huntingtin as a Yac 
transgene in addition to the wild type homozygous state; and (3) knock-in animals 
with abnormally long CAG repeats inserted into the murine huntingtin gene 
[1,152]. Both the transgenic R6/2 mice, which express exon 1 of mutant 
huntingtin containing 115-150 CAG repeats, and the N171-82Q mice that express 
the first 171 amino acids of mutant huntingtin with 82 CAG repeats represent the 
first category. They are the most thoroughly studied mouse lines. 
Many of these transgenic mouse lines that overexpress huntingtin 
fragments with an extended polyglutamine region show reduced survival, 
intraneuronal aggregates in nuclei and in neuronal processes of many brain 
regions and behavioural deficits similar to HD [1]. The R6/2 mouse line, that 
expresses a number of CAG repeats reminiscent of human alleles associated with 
very early childhood onset disease, produces a phenotype that consists of 
impaired and stereotypic movements, tremor and epileptic seizures [151]. The 
HD transgenic mice that express small N-terminal mutant huntingtin develop 
more severe phenotypes and show an early death, usually at 3-6 months after 
birth but lack prominent HD neurodegeneration [1,23,51,153-155]. In contrast, 
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HD transgenic mice expressing longer N-terminal huntingtin with a shorter 
repeat than 150 CAG repeats, such as N171-82Q mice, or at a lower expression 
level than that of endogenous huntingtin develop neurodegeneration despite their 
slow disease progression [156-158]. In HD repeat knock-in mice, a large repeat of 
150 CAG repeats appears to facilitate disease progression, giving rise to more 
detectable neurological phenotypes [159] and earlier occurrence of 
neurodegeneration than those in HD repeat knock-in mice with 80 CAG repeats 
[155]. In knock-in mice that express full-length mutant mouse huntingtin 
homologues later do develop inclusions that are confined to the striatum [154]. 
Yu et al. (2003) [160] reported that in HD transgenic mice context-dependent 
neurodegeneration may be mediated by different N-terminal huntingtin 
fragments. These different transgenic mouse models are not perfect 
neuropathological models of human HD, but they do represent other aspects of 
the disease that can be intensively studied. 
 
 
In vivo model of Huntington's disease: 3-NP animal model  
 
The mitochondrial toxin 3-nitropropionic acid (3-NP) is an irreversible inhibitor 
of the enzyme succinate dehydrogenase (SDH). The SDH enzyme is located in 
the mitochondrial inner membrane and functions both in the tricarboxylic acid 
cycle and in the mitochondrial complex II-III of the electron transport chain 
[28,61-165]. 3-NP interferes with energy metabolism by inhibiting SDH but the 
precise mechanism of inactivation of SDH by 3-NP remains essentially unclear 
(see Fig. 4). 
 
Figure 4. Structure of 3-NP, an irreversible inhibitor of SDH enzyme, and of succinic acid. 
 
3-NP dysregulates mitochondrial function and this metabolic impairment involves 
three interacting processes: energy impairment, oxidative stress and excitotoxicity. 
3-NP results in ATP depletion, which impairs intracellular calcium buffering 
capacity and leads to the production of damaging oxygen and nitrogen free 
radicals. 3-NP may also elicit secondary glutamate excitotoxicity [161,163], 
neuronal death as a result of chronic exposure to the excitatory amino acid 
glutamate. Excitotoxicity in HD might be the result of a reduced threshold for 
22  Chapter 1 
glutamate toxicity that would occur in neurons with a compromised energy 
metabolism, in which otherwise normal levels of this excitatory neurotransmitter 
to become toxic.  In this thesis, we focussed primarily on the 3-NP action causing 
energy impairment with the inhibition of ATP synthesis. 
The mitochondrial toxin 3-NP induces metabolic stress, resulting in 
neurodegeneration of the basal ganglia and, as a consequence, movement 
disorders in vivo [163]. In HD a defect in energy metabolism could contribute to 
neuronal death [166] as experimental work supports secondary mitochondrial 
dysfunction as a consequence of the HD mutation [54]. The relevance of 
impaired energy metabolism to HD pathology is also suggested by the effects of 
the natural plant toxin and mycotoxin 3-NP on humans. Humans that accidentally 
ate cane sugar contaminated by the mycotoxin 3-NP, survived 3-NP toxicity but 
developed choreiform movements and dystonia [165]. When 3-NP is administered 
chronically in low doses to animals, it impairs energy metabolism and results in 
striatal structural lesions (see Fig. 5), probably through a glutamate-dependent 
excitotoxic mechanism [150,166]. The 3-NP-induced striatal lesions in animals are 
characterised by loss of medium-sized spiny neurons and astroglial proliferation, 
thus closely replicating the neuropathological features of human HD [150]. The 3-
NP model has been commonly used as an animal model for the neuropathology 
of HD, although variable responses to the 3-NP treatment have been reported 
[28,150,167-170]. Moreover, the neurotoxin 3-NP is able to induce apoptosis in 
striatal neurons of 3-NP-treated animals [71,77,161,171-175], as evaluated by 
TUNEL labeling of induced DNA fragmentation and increased expression of 
apoptosis-related markers in striatum. In this thesis we used the in vivo 3-NP 
animal model because of the specific striatal lesions and cell death of medium-
sized spiny neurons. The 3-NP model mimics HD neuropathology best to 
examine apoptosis and mechanisms of apoptotic cell death. 
 
 
 
Figure 5. Nissl-stained vibratome section of a 3-NP-treated rat, showing the marked bilateral lesion in the 
striatum. 
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In vitro model of Huntington's disease: Organotypic slice cultures and 
exposure to 3-NP 
 
Organotypic slice cultures of the central nervous system are increasingly used to 
study neuronal death induced by hypoxia, hypoglycaemia, excitotoxins and other 
neurotoxins [176,177]. These in vitro models offer the advantages of good 
preservation of the organotypic organization of tissue in culture, control over the 
local environment of the cultured brain tissue, and the ability to monitor cellular 
mechanisms [177-179]. 
The apoptotic process takes only a few hours, from start to completion. 
Consequently, it may be difficult to visualize morphological features of apoptosis 
in chronic neurological diseases, in which only a few cells at any time would be 
expected to undergo cell death [69]. Another problem is that HD has a duration 
of about fifteen years, leaving even less transient apoptotic neurons to be found 
in postmortem tissue, when at time of death most affected neurons are already 
lost. In order to study the mechanisms of apoptotic cell death in HD and to 
increase experimental manipulation of apoptosis, organotypic corticostriatal slices 
cultured on semiporous membranes were exposed to 3-NP to investigate 
neurotoxic effects and the involvement of apoptosis in brain slices. 3-NP has 
been applied in neuronal cell cultures [180,181] as well as in organotypic striatal 
and hippocampal slice cultures [175, 182-185] obtained from rats or mice. The 3-
NP neurotoxic results in corticostriatal slice cultures were comparable to 3-NP in 
vivo models inducing predominantly striatal cell death. Of more interest is  that 
several studies reported that 3-NP induces apoptosis in cultured neurons 
[180,181] and in brain slice cultures [175,183,185]. 
 
 
4. Scope of this thesis 
 
This thesis investigates the occurrence of apoptotic cell death in the 3-NP animal 
model of HD, organotypic slice cultures and in human HD brains. To study 
apoptosis and which apoptotic signaling cascade predominantly occurs in HD 
pathogenesis, we investigated apoptotic features at various time points of the 
process, since not only the end-products like DNA degradation and apoptotic 
bodies, but also the expression of several regulatory proteins involved in the 
cascade, may provide evidence for activation of the apoptotic process. 
In order to study the mechanisms of apoptotic cell death in HD, we used 
the 3-NP animal model [150,166]. In Chapter 2 of this thesis, we used osmotic 
pumps for chronic systemic administration of 3-NP to rats, which resulted in 
selective striatal lesions. Both conventional staining and immunohistochemical 
labeling of neurons and astrocytes were applied to analyse these striatal lesions 
that displayed characteristic neuropathological features reminiscent of HD. 
In Chapter 3, we examined in three different 3-NP striatal lesion types the 
expression pattern of apoptosis-related markers (Bax and Bcl-2) in combination 
with the TUNEL method to detect both morphologically typical apoptotic cells 
and signals of apoptotic cell death, which may serve as evidence of activation of 
apoptosis. 
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In Chapter 4, the expression of several apoptosis-related markers was studied in 
samples of human HD brains, varying from grade 1 to severely affected grade 4 
specimens. In this thesis, we focussed on the caspase-mediated apoptotic cell 
death pathway by studying the expression of Bax, Bcl-2, caspase-3 and PARP and 
the presence of TUNEL-positive cells in the caudate nucleus of HD patients and 
compared these with control brains. 
To increase research strategies on apoptotic cell death in HD, we applied 
3-NP-treated corticostriatal brain slices as a model to study mechanisms of 
neuronal cell death [177,178,183]. In Chapter 5, the involvement of apoptosis in 
3-NP-exposed in organotypic slice cultures was evaluated using TUNEL and 
immunohistochemical labeling of the apoptotic markers Bax and Bcl-2. In 
addition, biochemical indicators for cell death and for altered energy metabolism 
present in the culture medium were quantified. 
In Chapter 6, we studied the neuroprotective effects of creatine in cultured 
3-NP-treated corticostriatal brain slices of one-day old mice. Creatine is a 
compound that improves energy metabolism and has possible neuroprotective 
properties by buffering energy levels in the brain. Neuroprotection by creatine 
was evaluated morphologically using standard histological staining techniques and 
quantified by measuring biochemical indicators for cell death and metabolic 
activity in the culture medium. Immunohistochemical staining of the pro-
apoptotic protein caspase-3 and DNA fragmentation visualized by the TUNEL 
method were performed to detect apoptotic cell death. 
The diversity of animal models presented in this thesis offers a wide range 
of complementary tools for studying the role and mechanisms of apoptotic cell 
death in HD. In Chapter 7, we summarize and discuss our 3-NP neurotoxicity 
results and conclusions and describe future prospects of HD research and 
therapy. 
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Abstract 
 
Systemic administration of the mitochondrial toxin 3-nitropropionic acid (3-NP) 
to rats results in selective striatal lesions and serves as an experimental model of 
Huntington’s disease (HD). However, the effects of the 3-NP treatment are 
unpredictable and result in lesions of variable severity. The present study was 
aimed at further characterising the variability of the striatal lesions induced by 
systemic administration of 3-NP using osmotic pumps. Hematoxylin-eosin (HE) 
and Nissl stains as well as immunohistochemical labeling of astrocytes and striatal 
neurons were performed to analyse the neurotoxic effects of 3-NP. In general, 
chronic systemic administration of 3-NP resulted in obvious bilateral striatal 
lesions, which ranged from mild to severe, together with a subtle, but detectable 
behavioural lesion. Severe type lesions showed marked neuronal loss and an 
increased expression of glial fibrillary acidic protein (GFAP) in astrocytes 
surrounding the lesion area, whereas in the core of the lesion GFAP 
immunoreactivity was absent. The mild type lesion was characterised by a 
substantial loss of striatal neurons and an increased expression of GFAP-positive 
astrocytes throughout the lesion. In a number of 3-NP-treated animals neither 
type of lesion was observed, although these animals demonstrated behavioural 
changes in the paw test compared to controls. In the striatum of these tested 3-
NP-treated animals, compromised ‘dark’ neurons were detected, suggestive of 
subtle and early 3-NP-induced neuronal injury. Similar dark neurons were also 
detected in mild and severe lesions and were immunocytochemically characterised 
as γ-aminobutyric acid (GABA) and substance P-containing spiny neurons, which 
belong to the neuronal population that is affected in early HD. These results 
indicate that systemic administration of 3-NP to rats may result in a spectrum of 
striatal pathology of which the morphology of the mild type lesion resembles the 
characteristic HD neuropathology most closely. 
 
 
Introduction 
 
Huntington's disease (HD) is an inherited neurodegenerative disorder 
characterised by involuntary movements, altered behaviour, and cognitive 
impairment [1,2]. HD is caused by expansion of a CAG-trinucleotide repeat in the 
coding region of the huntingtin gene, which is located on chromosome 4 [3,4]. 
The neuropathological hallmark of HD is severe atrophy of the neostriatum with 
extensive neuronal loss and reactive gliosis, although a marked variation in the 
extent of striatal neuropathology exists among HD brains [1,5]. Both macroscopic 
and microscopic examinations of pathological features in HD neostriatum formed 
the basis of a neuropathological classification system of five grades with 
ascending order of severity. The extent of neuronal loss increases from 30-40% in 
grade 0 to more than 95% associated with marked astrocytosis in grade 4 [1,5]. 
However, the precise mechanism of this selective neuronal cell death in the HD 
neostriatum remains unknown. It has been suggested that neuronal degeneration 
in HD involves the inappropriate activation of apoptosis [6-8]. 
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In order to study the mechanisms of neuronal cell death in HD, we used the 3-
nitropropionic acid (3-NP) animal model [9]. 3-NP, a plant and fungal toxin, is an 
irreversible inhibitor of succinate dehydrogenase, and inhibits both the Krebs 
cycle and the mitochondrial complex II of the electron transport chain [10,11]. In 
this animal model, chronic systemic administration of 3-NP to rats impairs energy 
metabolism and results in striatal lesions, probably through a glutamate-
dependent excitotoxic mechanism [9,12]. Beal et al. [9] found that the 3-NP model 
produces selective striatal lesions characterized by loss of medium-sized spiny 
neurons and astroglial proliferation, thus replicating histological and 
neurochemical features of HD. The 3-NP model has been commonly used as an 
animal model of HD, although variable responses to the 3-NP treatment have 
been reported [9,13-15]. In the present study we tried to further characterize this 
variability of 3-NP-induced striatal neuropathology. Both conventional staining 
procedures and immunohistochemical labeling of astrocytes and neurons were 
applied to analyse the striatal lesions. To detect subtle striatal alterations that may 
not be obvious morphologically, we used a behavioural test to examine the 
retraction capacity of the hindlimbs of 3-NP-treated and untreated rats. This paw 
test was initially developed to determine the influence of neuroleptics on the 
retraction time of rat limbs [16] and may be used as a sensitive indicator of striatal 
pathology. 
 
 
Material and Methods 
 
Animals 
 
Five months-old male Wistar rats with body weights between 400 and 450 grams 
were used in this study. Fourteen animals were treated with 3-NP (Sigma, St. 
Louis, MO, USA) for four weeks at a dose of 14 mg/kg/day by a subcutaneous 
Alzet pump (Alza Corporation, Palo Alto, CA, USA), and were sacrificed one 
week after the end of the treatment [9]. 3-NP was dissolved in ultra pure water, 
adjusted to pH 7.4, and passed through a 0.2 µm filter. Four rats became 
seriously ill after 10 to 17 days, at which time the pump was removed and the 
animals were sacrificed. Nine control rats received normal saline solution by a 
subcutaneous Alzet pump. 
 
 
Histology 
 
Animals were anaesthetised with pentobarbital (Narcovet: 60 mg/kg 
intraperitoneal) and were successively intracardially perfused with 50 ml Tyrode 
solution and 400 ml phosphate buffered 4% paraformaldehyde. Following 
perfusion, the brains were rapidly removed and immersed in the same fixative 
used for perfusion at 4°C for at least 18 hours. Brains were either serially 
sectioned on a vibratome into 50 µm thick sections or were paraffin-embedded 
and cut into 5 µm thick sections. Vibratome sections sampled every 600 µm and 
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paraffin sections sampled every 250 µm were stained with hematoxylin-eosin 
(HE) or stained for Nissl substance using cresylviolet. 
 
 
Immunohistochemistry 
 
Immunohistochemical labelling for glial fibrillary acidic protein (GFAP) was used 
to identify reactive astrocytes. Both deparaffinized and free floating vibratome 
sections were stained with a polyclonal antibody directed against GFAP (rabbit 
anti-cow GFAP, dilution 1:400 and 1:20,000 respectively; Dakopatts, Glostrup, 
Denmark). Subsequently, the sections were incubated with biotinylated goat anti-
rabbit antibody (Vector Laboratories, Burlingame, CA, USA) and a standard 
avidin-biotin-peroxidase-complex (Vector). The reaction product was visualised 
with 3,3’-diaminobenzidine (DAB, Sigma) and H2O2. Paraffin sections were 
counterstained with hematoxylin. 
 Immunocytochemical markers of various striatal neuron types were used to 
further characterise affected neurons in lesioned striatum that stained darker for 
Nissl substance. A commercially available polyclonal antibody directed against γ-
aminobutyric acid (GABA, rabbit anti-GABA-bovine serum albumin, Sigma) was 
used to identify spiny projection neurons [17]. Substance P antiserum, another 
neurochemical component of striatal spiny neurons [17], was obtained from the 
Netherlands Institute for Brain Research. It was raised in rabbits against 
substance P (S-6883, Sigma), which was conjugated to glutaraldehyde-
thyroglobuline. In our hands, this antibody recognised substance P-containing 
neurons in striatum and fibers projecting to substantia nigra in rat brain. 
Antiserum against somatostatin, a neuropeptide expressed in a certain population 
of aspiny interneurons [17], was obtained from Dr. R. Benoit (Montreal, CA). 
This antibody was raised in rabbits against the somatostatin-fragment 1-12 (S320), 
which was conjugated to bovine serum albumin [18]. Deparaffinized sections 
were pre-treated for 30 minutes in PBS with 2% H2O2 to remove endogenous 
peroxidase, followed by a microwave heating for antigen retrieval. Slides were 
placed in a plastic jar containing boiling citrate buffer (0.01M, pH 6), and were 
heated for 2x5 minutes at 150 Watt. Subsequently, slides were allowed to cool 
down to room temperature in the same citrate buffer for 15 minutes. Sections 
were then incubated with polyclonal antibodies against GABA (1:500), substance 
P (1:500) or somatostatin (1:2000). Antibody binding was visualized with a 
biotinylated goat anti-rabbit antibody (Vector), followed by avidin-biotin-
peroxidase-complex (Vector) and processed with DAB and H2O2. The signal of 
the reaction product was enhanced by incubating sections for 5 minutes in 0.5% 
copper sulphate in saline, and sections were counterstained with hematoxylin. 
 
 
Paw test 
 
Seven control animals and nine of the ten animals that survived the four week-
treatment of 3-NP, were tested in the paw test [16]. In this behavioural test, the 
animal is placed on a 20 cm high Perspex platform of 30 x 30 cm containing four 
3-NP induces a spectrum of Huntington's disease-like neuropathology  37 
holes; two holes of five cm diameter for the hindlimbs and two holes with a 
diameter of four cm for the forelimbs. The rat is placed on the platform by 
positioning first the hind- and then the forelimbs into the holes. The parameters 
in this test are the time it takes the animal to retract its first hindlimb and the 
time it takes the animal to retract its contralateral hindlimb. The difference 
between the retraction times of both hindlimbs is recorded. This is expected to be 
an important parameter to measure functional abnormalities of the hindlimbs, 
which are indicative for the formation of a striatal lesion. The test was done three 
times with a 45 minutes interval and data were calculated as mean ± SEM value 
for each tested animal. Results are presented as mean ± SEM value for the 3-NP-
treated animals and the control group. The statistical significance of the 
difference between these groups was determined by Student’s t-test and was 
considered significant at P < 0.05. 
 
 
Results 
 
3-NP-induced striatal lesions 
 
Systemic administration of 3-NP resulted in manifest bilateral striatal lesions 
displaying neuronal loss and gliosis in eight out of 14 animals, whereas in all 
control rats that received saline striatal lesions were absent. These 3-NP-induced 
lesions were confined to the dorsolateral part of the striatum (Fig. 1A) and 
extended from the anterior striatum to a level immediately caudal to the 
decussation of the anterior commissure. The striatal lesions were of variable 
severity and, in general, could be distinguished into three types: a severe lesion, a 
mild lesion, and a state in which subtle striatal alterations were observed that 
were accompanied by detectable behavioural abnormalities. Table 1 summarizes 
the neuropathological features of the different types of lesions found in this 
study. 
 
 
Table 1. Neuropathological characteristics of variable lesion types found in the 3-NP rat model 
Lesion type Number of 
rats 
Lesion size Neuronal loss 
(Nissl staining) 
Gliosis 
(GFAP staining) 
Nuclear 
fragmentation 
(HE staining) 
Severe 4 1.9 mm Core: +++ 
Margin: ++ 
Core: - 
Margin: ++ 
Core: + 
Margin: - 
Mild 4 1.6 mm + + - 
Subtle 6 - * # - 
The degree of neuropathological changes has been classified as follows: 
neuronal loss: +++ : severe; ++ : moderate; + : subtle * : dark neurons  
gliosis: ++ : strong ; + : moderate; #  GFAP expression around blood vessels;  - : absent 
nuclear fragmentation: + : present; - : absent 
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Characteristics of the severe type lesion 
 
The severe type 3-NP lesion was observed in four rats that did not complete four 
weeks of 3-NP regimen, but were sacrificed after 10 to 17 days, due to serious 
morbidity. The severe lesion was characterised by a marked loss of neurons in the 
striatum, especially in the core of the lesion, as demonstrated by Nissl staining 
(Fig. 1C). In HE-stained sections the core of the severe lesion was pale and 
showed nuclear fragmentation as well. The identity of these fragmented cells 
could not be determined. Although the severe lesion was confined to the 
striatum, in the overlying cortex at the level of the lesion core signs of 
morphological injury, represented by atrophic pyramidal neurons that stained 
darker than usually, were observed in Nissl-stained sections. These ‘dark’ neurons 
are predominantly present in layers III and V of the neocortex (Fig. 1D). Similar 
injured dark neurons were detected in the striatum as well, but only in the outer 
zones of the severe lesion, suggestive of expanding 3-NP-induced 
neuropathology. Enhanced GFAP expression indicative of reactive astrocytosis 
was observed surrounding the core of the 3-NP-induced lesion, whereas in the 
lesion core itself GFAP-immunoreactive astrocytes were absent (Figs. 1A,B). The 
severe striatal lesion had a globular shape with a diameter of approximately 1.9 
mm, based on the pattern of increased GFAP immunoreactivity in vibratome 
sections of three animals that were sampled every 600 µm. 
 
 
Characteristics of the mild type lesion 
 
The mild type of striatal lesion was identified in four out of ten animals that 
completed the entire four week-treatment of 3-NP and was characterised by a 
moderate neuronal loss and by a reactive astrocytosis throughout the lesion. In 
striata with a mild lesion, GFAP immunostaining revealed circumscribed gliosis 
with a moderate increase in the number of reactive astrocytes (Fig. 1E). The 
diameter of the mild lesion was approximately 1.6 mm, based on the pattern of 
GFAP-immunoreactive astrocytes in vibratome sections, and sampled every 500 
µm throughout the striatum of two animals. Nissl-stained sections demonstrated 
substantial neuronal loss accompanied with the appearance of shrunken dark 
neurons in the marginal areas of the striatal lesion (Fig. 1F). 
 
 
Characteristics of a subtle lesion displaying dark neuron pathology 
 
In the striatum of the six remaining 3-NP-treated animals, the above-described 
characteristic neuropathological features of the severe and mild lesion were not 
observed. However, a number of shrunken dark neurons, which stained darker 
for Nissl substance, together with a subtle increase of GFAP-positive astrocytes 
surrounding blood vessels were seen in the anterior region of the striatum. These 
abnormalities were not observed in control rats treated with saline.  
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Figure 1. 3-NP induces a spectrum of HD-like neuropathology in rat. AB, GFAP staining of a vibratome 
section (50 µm) from a severe type 3-NP lesion. GFAP-positive astrocytes surround the core of the severe 
lesion located in the dorsolateral part of the striatum. B, is a higher magnification of Fig. 1A, 
demonstrating reactive astrocytes on the margin of the severe striatal lesion. GFAP immunoreactivity is 
absent in the lesion core, possibly indicating that glial cells in the core were also affected. C, Nissl staining 
of a paraffin section (5 µm) demonstrating the severe type of lesion in the striatum of a 3-NP treated rat. 
Note the marked neuronal loss to the right of the image compared to normal brain tissue to the left of the 
image. D, Nissl staining of a paraffin section from a severely affected 3-NP-lesioned animal demonstrating 
atrophic dark pyramidal neurons in layers III and V of the overlying cortex, suggestive of subtle 3-NP-
induced associated morphological damage (arrows). E, GFAP staining of a vibratome section 
demonstrating increased GFAP expression in the striatum of a mild type 3-NP lesion. This reactive gliosis 
was detected throughout the lesioned area in the striatum. F, Nissl staining of a paraffin section of a mild 
type striatal lesion. 3-NP induced neuronal damage, as demonstrated by the substantial loss of neurons 
accompanied by compromised dark neurons in the lesioned striatum (arrows). G, GABA immunostaining 
of a paraffin section from a mildly affected 3-NP-lesioned animal demonstrating GABA-immunoreactive 
dark neurons located between apparently healthy neurons, in which GABA is perinuclearly localized in the 
cytoplasm. H, Immunocytochemical staining for substance P in a mildly lesioned striatum demonstrating 
dark neurons that are positive for the spiny neuron marker substance P. Note the elongated and bright 
uplifting nucleus of a dark neuron surrounded by immunoreactive substance P in the cytoplasm (arrow). I, 
Anti-somatostatin staining in the striatum of a mildly 3-NP-lesioned animal. Somatostatin is only 
immunoreactive in aspiny interneurons and surrounding fibers, whereas nearby dark neurons are negative 
for somatostatin (arrows). Scale bars represent in A (and E) = 50 µm, B = 150 µm, C (and DF) = 15 µm 
and G (and HI) = 15 µm. 
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Immunocytochemical characterisation of dark neurons in 3-NP-lesioned striatum 
 
The striatal dark neurons detected in the different types of lesions were identified 
using immunocytochemical labeling of GABA, substance P and somatostatin, 
which are markers for the various neuronal types in the striatum. These shrunken 
dark neurons are affected, and supposedly will undergo death. In 
immunocytochemistry experiments, these neurons could be discerned from 
apparently healthy neurons by their elongated nucleus that stained darker for 
hematoxylin. The shrunken dark neurons in 3-NP-lesioned striatum were found 
to be immunoreactive for GABA and substance P, which are both markers for 
medium-sized spiny neurons (Figs. 1G and 1H, for comparison of non-
immunoreactive dark neurons, see Fig. 1I). The neuropeptide somatostatin was 
not expressed in these dark neurons, whereas aspiny somatostatin-positive 
interneurons were present in the striatum of all animals that had received 3-NP 
(Fig. 1I). The number of dark neurons detected in mild and severe striatal lesions 
was much larger than the small number of somatostatin-immunoreactive 
interneurons observed in striatum. Therefore, it is unlikely that the dark neurons 
are derived from somatostatin-containing interneurons, and that indeed they 
represent damaged medium-sized spiny neurons, the major constituent of the 
striatum. 
 
 
Paw test 
 
The paw test was performed on nine animals that had received the neurotoxin 3-
NP for the entire period of four weeks and on seven control animals. Histological 
examination of these 3-NP-treated animals revealed four mild type lesions 
whereas five animals represented a subtle striatal lesion with dark neurons. As a 
result of striatal pathology, a significant increase in the difference between the 
retraction times of both hindlimbs was observed in the 3-NP-treated rats 
compared to controls (p<0.02), although overlap between 3-NP-treated animals 
and controls was noted. There was no apparent relation between the results in the 
paw retraction test and the severity of the resulting striatal lesion (Fig. 2). 
 
 
 
 
Figure 2. Effect of chronic systemic 3-NP 
administration for four weeks on the 
difference in retraction times of both 
hindlimbs in the paw test. The mean values 
of the control group (n=7) and of the 3-NP-
treated group (n=9) are indicated. Open 
circles indicate the mild type lesioned 
animals while closed circles represent the 3-
NP- treated animals demonstrating the 
subtle lesion type. P<0.02. (Student’s t-test, 
3-NP-treated animal group versus control 
group). 
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Discussion 
 
In this study we confirm that chronic systemic administration of 3-NP to rats 
induces bilateral striatal lesions displaying neurodegeneration and reactive gliosis, 
reminiscent of HD neuropathology. Animals showed variable susceptibility to the 
neurotoxin 3-NP. Some animals hardly showed characteristic neuropathological 
features, whereas other 3-NP-treated rats demonstrated neuronal loss and an 
increased expression of GFAP-immunoreactive astrocytes in the striatum. These 
findings are consistent with other studies using the 3-NP rat model in which 
variable susceptibility and response to the 3-NP treatment was found and 
explained by genetic variability between animals [9,13-15,19]. More importantly, 
we were able to distinguish three distinct types of striatal lesions: a severe, a mild 
and a subtle lesion. The severe type lesion demonstrated a marked neuronal death 
in the lesion core and gliosis in the margins of the lesion, whereas the mild type 
of lesion was characterised by a less pronounced neuronal loss accompanied by 
reactive astrocytosis throughout the lesion. The subtle lesion revealed only dark 
neuron pathology in the striatum and completes a spectrum of striatal lesions 
induced by systemic administration of 3-NP to rats. 
 In 3-NP-lesioned animals, the striatum was always and selectively affected. 
However, in severely affected animals atrophic ‘dark’ pyramidal neurons in the 
overlying cortex were observed as well, suggestive of subtle associated neocortical 
damage. Similar shrunken dark neurons were present in the striatum of all 3-NP-
treated animals. These neurons were immunocytochemically characterised as 
medium-sized spiny neurons expressing GABA and substance P, which is the 
neuronal population at risk in early HD [5]. In HD brains, Vonsattel et al. noted 
scattered atrophic neurons, which stained darker with Luxol fast blue and 
hematoxylin-eosin (LFB-HE) than the apparently healthy neurons. These 
neostriatal ‘dark’ neurons were scarce in both atrophic and preserved neostriatal 
zones but their density tended to increase in the intermediary zone, and they were 
considered to be suggestive of early HD neuropathology [5]. Interestingly, 3-NP-
lesioned animals with dark neuron pathology only, demonstrated in the paw test a 
significant difference in the retraction capacity of the hindlimbs compared to 
control animals, indicative of a pathologically affected striatum. Thus, the 
behavioural changes of these 3-NP-treated rats might relate to the compromised 
dark neurons as a feature of early and subtle neurotoxic effects of 3-NP [14,20]. 
Furthermore, dark spiny neurons were detected in all lesion types, although at 
different sites within the lesion, which might reflect the expanding 3-NP 
neurotoxicity in the striatum. A striatal lesion presumably starts with abnormal 
dark neurons ubiquitously located in the anterior striatum, and develops into a 
mild lesion with dark neurons accompanied with a subtle loss of neurons. In 
severely affected animals, compromised dark neurons were only present in the 
outer zones of the lesion whereas a marked degeneration of spiny neurons was 
observed in the lesion core. In parallel with this neuronal pathology induced by 3-
NP, a gradual increase of GFAP immunoreactivity was observed in the affected 
striatum. Locally enhanced GFAP expression surrounding blood vessels was 
noticed in the subtle lesion while the mildly lesioned striatum represented a 
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reactive gliosis throughout the lesion. Eventually, this may develop into loss of 
glial cells next to extensive neuronal death in the core of a severe striatal lesion. 
 We observed a striking variability in the onset and development of striatal 
neuropathology in the 3-NP-treated animals, resulting in different lesion types. A 
severe lesion was seen in seriously ill rats that were sacrificed after 10 to 17 days 
of 3-NP administration, whereas mild and subtle lesions were found in animals 
that were sacrificed after four weeks of 3-NP treatment. The mechanism of 3-NP 
toxicity is possibly based on a combination of impaired energy metabolism and 
secondary glutamate excitotoxicity, eventually resulting in neuronal death [15,21]. 
In previous studies it was reported that 3-NP induced a slow progressive neuronal 
death in the striatum, which may take up to seven days to be completed [22,23]. 
The neurotoxic threshold of succinate dehydrogenase (SDH) inhibition by 
systemic administration of 3-NP in the brain appears to be 50-60% of control 
levels in untreated animals [13]. In addition, Alexi et al. [24] found that a rapid 
decline in mitochondrial SDH activity in vulnerable rats corresponded to a 
marked cell death in striatum, whereas a more gradual inhibition possibly 
prevented acute striatal toxicity by recruitment of compensatory mechanisms. In 
our study, animals with a severe lesion became ill after a period of seven days and 
lost 25% of their body weight. This severe weight loss may have led to a higher 
systemic dose of 3-NP, which – in accord with the study of Alexi et al. [24] - may 
have resulted in a faster decline of SDH activity and may have accelerated the 
formation of a lesion. In contrast, animals with a mild lesion or with a subtle 
lesion became neither ill nor lost weight, although behavioural tests were 
indicative of a 3-NP affected striatum. These animals received a constant dose of 
3-NP for four weeks, and therefore maintained a constant level of SDH 
inhibition. This may have resulted in a more slowly evolving lesion, starting with 
abnormal dark neurons and eventually leading to neuronal loss associated with 
gliosis. Although it remains unclear what exactly causes the variable response to 
3-NP, blood-brain-barrier (BBB) dysfunction of the lateral striatal artery, which 
may lead to increased 3-NP levels in the striatum, may be an important factor in 
initiating neuronal death in the striatum [14,25,26]. This is supported by the 
observation that one severely affected animal sacrificed after 10 days of 3-NP 
administration demonstrated a haemorrhage in the lateral striatum, suggestive of 
BBB damage of the lateral striatal artery. Additionally, the enhanced local GFAP 
expression around blood vessels in 3-NP treated animals could be indicative of 
early BBB dysfunctioning as well. In summary, the 3-NP-induced neuropathology 
in the striatum could be accelerated by a higher local dose of 3-NP either due to 
loss of body weight or to dysfunctioning of the BBB, resulting in a progressively 
developing lesion. 
 The 3-NP rat model replicates the characteristic HD neuropathological 
features of neuronal loss and gliosis in a wide spectrum. The mild striatal lesion 
resembles HD pathology more closely than the other lesion types, and is in a way 
similar to HD brains grade 1 and 2 according to Vonsattel's neuropathological 
classification system. In addition, mildly lesioned animals were not seriously ill 
but were wobbly and had dystonic postures of their hindlimbs and in the paw 
test, these rats showed detectable changes in behaviour. In contrast, 3-NP-treated 
animals that appeared to have a severe lesion became recumbent and somnolent 
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and had to be sacrificed after 10 to 17 days of 3-NP administration. This severe 
lesion resembles those caused by intrastriatal and subacute administration of 3-
NP [9,15,19], and is commonly seen after treatment with glutamate-receptor 
agonists [22,23]. The severe lesion found in this study emerged in a relatively 
short period of 3-NP administration and possibly developed too fast into an 
advanced pathological state to be representative of HD. In HD patients, it takes 
10 to 15 years to develop extensive neuronal loss and gliosis [14]. Except for the 
glial loss in the lesion core, the neuropathology of the severe lesion resembles 
HD brains of Vonsattel grade 3 and 4 for the marked striatal neuronal death 
associated with subtle neocortical damage and the reactive gliosis found in the 
margins of the lesion. The dark neuron pathology observed in subtle 3-NP 
affected animals is comparable to the neostriatal dark neurons found in early 
affected HD neostriata. In conclusion, the 3-NP rat model, and in particular the 
mild type striatal lesion, which revealed a gradual neuronal loss in association 
with glial proliferation, may be the most appropriate model to study the 
pathogenesis of HD.  
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Abstract 
 
The mitochondrial toxin 3-nitropropionic acid (3-NP) causes selective striatal 
lesions in rats and serves as an experimental model for the neurodegenerative 
disorder Huntington’s disease (HD). Apoptotic cell death has been implicated for 
the neuronal degeneration that occurs in HD brains. The present study was 
designed to investigate whether the 3-NP-induced cell death in rats involves 
apoptosis and an altered expression of Bcl-2 family proteins. Systemic 
administration of 3-NP via subcutaneous Alzet pumps resulted in lesions of 
variable severity with neuronal loss and gliosis in the striatum. Using the terminal 
transferase-mediated biotinylated-UTP nick end-labeling (TUNEL) of DNA, 
TUNEL-positive cells exhibiting typical apoptotic morphology were detected only 
in the striatum of rats with a severe lesion. Furthermore, the neuronal expression 
of the pro-apoptotic protein Bax was strongly increased in the core of the severe 
lesion. Expression of the anti-apoptotic marker Bcl-2 was unchanged in this 
location, but was enhanced in the margins of the lesions. A moderately increased 
expression of both Bax and Bcl-2 was observed in dark neurons in the mild lesion 
and in the subtle lesion. The presence of nuclear DNA fragmentation, strong 
granular Bax expression and an increased Bax/Bcl-2 ratio in the centre of severe 
lesions suggests the occurrence of apoptotic cell death following 3-NP 
administration. In contrast, the dark compromised neurons observed in 3-NP-
treated animals revealed an equally enhanced expression of both Bax and Bcl-2, 
but lacked TUNEL labeling, and are therefore not apoptotic. 
 
 
Introduction 
 
Apoptosis or programmed cell death is a biological phenomenon that plays a 
crucial role in immune regulation, normal development, and tissue homeostasis 
[1]. It has been suggested that an inappropriate activation of this cell death 
pathway is involved in chronic neurodegenerative diseases such as Huntington’s 
disease (HD) [2]. HD is an inherited disorder and is characterized by severe 
atrophy of the neostriatum with marked neuronal loss and gliosis [3,4]. The 
precise mechanism of this selected neuronal death is unknown, but it may result 
from apoptosis. Interestingly, morphological evidence of apoptotic cell death has 
been reported in postmortem HD brains [5-7]. 
Cells undergoing apoptosis show characteristic morphological features such 
as membrane blebbing and nuclear condensation and can be characterized 
biochemically by the induction of DNA fragmentation [1,8]. This DNA 
fragmentation can be morphologically detected using the terminal transferase-
mediated biotinylated-UTP nick end-labeling (TUNEL), which specifically labels 
the 3’ hydroxyl terminals of DNA strand breaks in nuclei and apoptotic bodies 
[9]. However, careful assessment of the cellular morphology of TUNEL-positive 
cells is necessary, because the TUNEL method could detect extensive DNA 
damage due to necrosis as well [10]. 
Apoptotic cell death is considered to be an active process requiring 
increased synthesis of particular proteins that kill the cell [11]. In recent years, 
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many genes and proteins have been characterized that appear to regulate and 
execute the apoptosis pathway in the nervous system. Members of the Bcl-2 
family of proteins play a major role in determining whether neurons will undergo 
apoptosis under conditions that promote cell death. Both Bax and Bcl-2 proteins 
are expressed by healthy neurons at a basal level; increased expression of Bax has 
been found to promote apoptosis, whereas over-expression of Bcl-2 can inhibit 
apoptotic cell death [12-14]. The pro-apoptotic function of Bax homodimers can 
be directly antagonized by Bcl-2 through the formation of Bax/Bcl-2 
heterodimers. Therefore, the relative expression of members of the Bcl-2 family 
by neurons may be indicative of apoptosis [15-17]. 
The apoptotic process takes only a few hours, from start to completion. 
Consequently, the detection of morphological features of apoptosis may be 
difficult in a chronic disease like HD, in which only a few cells at any time would 
be expected to undergo cell death [8]. To study mechanisms of apoptotic cell 
death in HD, we therefore used the 3-nitropropionic acid (3-NP) rat model [18]. 
In this animal model, chronic systemic administration of the mitochondrial toxin 
3-NP using osmotic pumps results in selective striatal lesions, displaying 
characteristic neuropathological features of HD in a wide spectrum [19]. Several 
studies have reported that 3-NP is able to induce apoptosis in cultured neurons 
[20,21] and in striatal neurons of 3-NP-treated animals [11,22-25], as evaluated by 
TUNEL labeling. In order to examine the possibility of apoptotic cell death, we 
studied the expression of the apoptosis-related markers Bax and Bcl-2 in the 
striatum of 3-NP-treated rats using immunohistochemistry in addition to the 
TUNEL labeling. 
 
 
Material and Methods 
 
3-NP animal model 
 
Five-month-old male Wistar rats of 400-450 grams were used in this study. 
Eleven animals were treated with 3-NP (Sigma, St. Louis, MO, USA) for 4 weeks 
at a dose of 14 mg/kg/day by a subcutaneous Alzet pump and were killed at the 
end of the treatment [18]. Three other rats became seriously ill after 9, 11 and 17 
days of 3-NP administration, respectively, after which the animals were sacrificed. 
3-NP was dissolved in milliQ water, adjusted to pH 7.4 and passed through a 0.2 
µm filter to remove any bacterial contamination. Six control animals received 
normal saline. 
 
 
Histological studies 
 
For histologic examination animals were deeply anesthesized with pentobarbital 
(60 mg/kg, intraperitoneal) and perfused intracardially with 50 ml Tyrode 
solution, followed by 400 ml phosphate buffered 4% paraformaldehyde. 
Following perfusion, brains were removed and immersed in the same fixative 
used for perfusion at 4°C for at least 18 hours. Brains were either serially 
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sectioned on a vibratome into 50 µm free floating sections or were paraffin-
embedded, and cut into 5 µm sections. Sections were stained with hematoxylin 
and eosin (HE) or were stained with cresylviolet to visualize the Nissl substance. 
 Immunohistochemistry was performed on deparaffinized sections at 
intervals of 250 µm throughout the striatum using commercially available 
antisera. A polyclonal rabbit antibody directed against glial fibrillary acidic protein 
(GFAP) was obtained from Dako (Holstrup, Denmark) and was used at a dilution 
of 1:400 in 1% BSA/PBS. Polyclonal rabbit antisera directed against Bax (P-19) 
and Bcl-2 (N-19) were both obtained from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA), and were used at dilutions of 1:500 and 1:250 in 1% BSA/PBS, 
respectively. Prior to Bax and Bcl-2 immunohistochemistry, deparaffinized 
sections were subjected to a microwave treatment for 10 minutes in a boiling 
citrate solution pH 6.0. All deparaffinized sections were incubated for 30 minutes 
in 0.2% H2O2 (Merck, Darmstadt, Germany) in PBS to quench endogenous 
peroxidase activity and subsequently, unspecific binding was blocked by 30 
minutes incubation with 20% normal goat serum in PBS. Overnight incubation 
with the primary antibodies at 4°C was followed by incubation with a secondary 
biotinylated goat anti-rabbit antibody at a dilution of 1:200 in 1% BSA/PBS for 
45 minutes. To visualize antibody binding, a standard Avidin-Biotin-Complex 
(Vectastain Elite, Vector Laboratories, Burlingame, CA, USA) was applied to the 
sections and 3,3’-diaminobenzidine (DAB) (Sigma) was used as a chromophore. 
Finally, the signal of the reaction product was enhanced by incubating sections 
for 5 minutes in 0.5% copper sulphate in saline, and sections were counterstained 
with hematoxylin. For the pre-absorption experiments, Bax and Bcl-2 antisera 
were pre-incubated with P-19 Bax blocking peptide and N-19 Bcl-2 blocking 
peptide (both from Santa Cruz Biotechnology), respectively, for 2 hours at room 
temperature prior to overnight incubation of the sections. 
 Nuclear DNA fragmentation was visualized in deparaffinized sections using 
the Apoptag™ kit (Intergen Company/Oncor Inc., Gaithersburg, MD) containing 
TdT-mediated dUTP-digoxigenin 3’ nick-end labelling (TUNEL) according to the 
manufacturer’s recommendations. TUNEL-positive cells were visualized using 
DAB and 0.5% copper sulphate in saline, after which the sections were 
counterstained using ‘Kernechtrot’. 
Results were obtained by microscopic evaluation of immunostained 
sections taken every 250 µm throughout the striatal lesion (2 mm). 
Immunohistochemical labelling of neurones was determined by virtue of their 
typical neuronal cell morphology after counterstaining with hematoxylin. 
Percentages of cells expressing apoptosis-related markers and of apoptotic cells 
were estimated by counting the number of Bax, Bcl-2 and TUNEL-positive cells 
in eight consecutive sections of the striatum using a 25x objective. 
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Results 
 
3-NP lesions in rats 
 
Chronic systemic administration of 3-NP to rats induced bilateral striatal lesions 
with a marked neuronal loss and astrocytosis (Figs. 1A and 1B). The striatal 
lesions were previously described by Vis et al. [19] and were classified as severe 
(n=3), mild (n=6) or subtle (n=5). The severe lesion demonstrated a marked 
neuronal death in the lesion core and gliosis in the margins of the lesion, whereas 
the mild lesion was characterized by a less pronounced neuronal loss 
accompanied by reactive astrocytosis throughout the lesion. The subtle lesion 
revealed only compromised dark neurons in Nissl-stained sections, which were 
not observed in control animals. Moreover, similar dark neurons were also 
detected in the mild lesion type and in the margin of the severe lesions and they 
were identified as medium-sized spiny neurons [19]. Additionally, in HE and 
Nissl-stained sections of 3-NP-treated animals nuclear fragmentation and 
chromatin condensation were observed in the striatum (see below and Fig. 2H). 
Table 1 gives an overview of the characteristic neuropathology observed in the 
different 3-NP lesion types. 
 
Figure 1. Neuropathological characteristics of the 3-NP rat model. A, Vibratome section of a severe 
lesion immunostained for GFAP, demonstrating GFAP-positive astrocytes surrounding the lesion core in 
which GFAP expression is absent. Note that the neurotoxin 3-NP induced bilateral lesions in the 
striatum. B, Nissl-stained section of a severe lesion demonstrating extensive neuronal degeneration at the 
top right of the picture whereas compromised dark neurons (arrow) are present in the margins of the 
lesion at the bottom left of the picture. Scale bar in A represents 100 µm and in B = 15 µm. 
 
 
Bax and Bcl-2 expression in untreated and 3-NP-treated animals 
 
Bax and Bcl-2 immunohistochemistry were performed on deparaffinized sections, 
taken every 250 µm throughout the striatal lesions and consistent results for each 
3-NP lesion type were obtained. In all untreated animals (n=6), most striatal 
neurons revealed a diffuse perinuclear immunostaining for both Bax and Bcl-2, 
whereas only a few neurons expressed Bax or Bcl-2 in the cytoplasm (Figs. 2A 
and 2C). 
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Table 1. Neuropathological characteristics of lesion types found in the 3-NP rat model 
Lesion type Number 
of rats 
3-NP 
treatment 
(days) 
Neuronal loss 
(Nissl staining) 
Nuclear 
fragmentation 
(HE/Nissl) 
Gliosis 
(GFAP staining) 
Subtle/DN 5 28 - , DN only - + blood vessels 
Mild 6 28 +, DN - ++ 
Severe 3 9-11-17 Core: +++ 
Margin: ++, DN
Core: + 
Margin: - 
Core: - 
Margin: ++ 
DN: dark neurons  
Neuronal loss: - no neuronal loss, + subtle; ++ mild; +++ severe 
Nuclear fragmentation: - absent; + present 
Gliosis: + blood vessels: increased GFAP expression in astrocytes surrounding blood vessels; ++: strong 
gliotic reaction; -: GFAP expression is absent 
 
In 3-NP-treated rats with a subtle lesion (n=5), only scattered shrunken dark 
neurons were strongly immunoreactive for both Bax and Bcl-2, together with the 
normal perinuclear labelling for these proteins in striatal neurons. The six animals 
with a mild lesion demonstrated an enhanced immunostaining for both Bax and 
Bcl-2 in the cytoplasm of most striatal neurons compared to control animals. 
Interestingly, these apoptosis-related markers were strongly and predominantly 
expressed in the many present compromised dark neurons (Figs. 2B and 2D). 
Pronounced alterations in the expression of Bax and Bcl-2 were only 
observed in the striatum of the severe type of lesion (n=3). An increased Bcl-2 
immunoreactivity was detected in several neurons at the border of the lesion, 
while Bcl-2 was not expressed in neurons located in the lesion core. However, 
oligodendrocytes, recognized by their typical morphology and present in the core 
of the severe lesions did express the Bcl-2 protein. The pro-apoptotic protein Bax 
was highly expressed in this severe striatal lesion type, and demonstrated an 
intense and granular immunoreactivity in approximately half of the neurons 
located in the lesion core (Fig. 2E). Furthermore, this granular Bax expression 
was different compared to the perinuclear and cytoplasmic Bax expression 
observed in untreated and the other 3-NP-treated animals (compare with Figs. 2C 
and 2D). 
Pre-absorption of the Bax and Bcl-2 antiserum with their control peptides 
entirely abolished the Bax and Bcl-2 immunostaining in striatal neurons of the 
three different lesion types. Table 2 summarizes the expression pattern of the 
apoptosis-related markers Bcl-2 and Bax observed in the different 3-NP lesion 
types. 
 
 
TUNEL-positive cells in 3-NP-treated animals 
 
Nuclear DNA fragmentation was detected only in the lesion core of the three 
severely affected animals and more than a third of the cells within the striatal 
lesion core were TUNEL-positive (Fig. 2F). TUNEL labeling was absent in 
control animals and in the 3-NP-treated rats either with a subtle or mild lesion. 
Most TUNEL-positive cells demonstrated DNA fragmentation, typically localized 
in nuclei and in apoptotic bodies, which are both characteristic for apoptotic cell 
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death (Fig. 2G). Furthermore, adjacent sections stained with HE or cresylviolet 
revealed apoptotic features such as nuclear fragmentation and chromatin 
condensation, which was only observed in the core of severe lesions (Fig. 2H). 
The identity of the TUNEL-positive cells is not entirely clear but the marked 
neuronal cell loss observed in the striatum of these severely affected animals, 
strongly indicates that these TUNEL-positive cells are predominantly neurons. 
Table 2 summarizes the TUNEL labeling and the HE/Nissl staining observed in 
the different 3-NP lesion types. 
 
Table 2. Expression of apoptosis-related markers in various lesions of 3-NP rat model 
Lesion type       Bcl-2        Bax   TUNEL Nuclear fragmentation 
(HE/Nissl staining) 
Subtle/DN DN only DN only           -           - 
Mild + , DN + , DN           -           - 
Severe  
 
Core: * 
Margin: + 
Core: + 
Margin: ++ 
Core: + 
Margin: - 
Core: + 
Margin: - 
DN: dark neurons 
Bcl-2 and Bax expression in striatal neurons: * oligodendrocytes; + increased; ++ intense and granular 
TUNEL-positive cells: - absent; + present 
Nuclear fragmentation: - absent; + present 
 
 
Discussion 
 
Chronic systemic administration of 3-NP to rats resulted in lesions of variable 
severity, classified as severe, mild, or subtle demonstrating only dark neuron 
pathology [19]. The severe type of lesion demonstrated a marked neuronal 
degeneration in its centre and gliosis in the margins, whereas the mild type was 
characterized by a less pronounced neuronal loss accompanied by reactive 
astrocytosis throughout the lesion. The expression of the apoptosis-related 
proteins Bax and Bcl-2 was increased in all 3-NP-treated rats compared to control 
rats. However, the extent of the increase varied between the different lesion 
types. Bcl-2 was predominantly found in dark neurons that occur in all different 
lesion types and, in addition, was expressed in a few striatal neurons at the border 
 
Figure 2. Expression of apoptosis-related markers in the 3-NP rat model. A, Photomicrograph of a 
paraffin section from the striatum of an untreated animal showing the weak and diffuse perinuclear 
immunostaining for Bcl-2 in medium-sized spiny neurons (arrows). A single neuron is expressing Bcl-2 in 
the cytoplasm (arrowhead). B, The mild type lesion demonstrates an increased expression for Bcl-2 in 
compromised dark neurons (arrows). C, Photomicrograph of a paraffin section from a control animal 
showing predominantly the weak and diffuse perinuclear Bax immunolabeling in striatal neurons (arrows), 
whereas only a few neurons demonstrate the cytoplasmic Bax immunostaining (arrowhead). D, Enhanced 
expression for Bax protein in compromised dark neurons of the mild type of lesion (arrows). E, Strong 
and granular Bax expression in the centre of severe striatal lesions. F, Photomicrograph of a paraffin 
section demonstrating TUNEL-positive cells which were only detected in the core of the severe lesion 
type. G, TUNEL-labeled cells in the striatum of a severely lesioned animal showing DNA fragmentation 
typically localized in nuclei and in apoptotic bodies. H, Nissl-stained paraffin section from a severely 
lesioned animal showing a marked neuronal loss and apoptotic features such as nuclear fragmentation and 
chromatin condensation in the striatal lesion (arrows). Scale bar in A (also for B-F) represents 15 µm, and 
scale bars in G and in H both represent 15 µm. 
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of the severe lesion. The apoptosis-promoting protein Bax was also enhanced in 
compromised dark neurons. Besides, its expression was strongly induced in most 
striatal neurons of the severe lesion type. Interestingly, strong granular neuronal 
Bax immunoreactivity was observed in the core of the severe lesion, whereas only 
weak perinuclear and cytoplasmic expression was observed in untreated animals 
and in the other lesion types induced by 3-NP treatment. In addition, nuclear 
DNA fragmentation using the TUNEL method was only observed in the lesion 
core of severely affected animals, whereas TUNEL labeling was absent in the 
other lesions and in control rats. 
It has been postulated that high levels of Bax within a cell may indicate that 
the cell is particularly sensitive to apoptotic cell death, due to the formation of 
functional Bax homodimers that regulate and induce apoptotic cell death 
[12,13,26,27]. The strong granular Bax expression in the lesion core of the severe 
lesion type possibly reflects this enhanced Bax homodimerization. In addition to 
the altered expression pattern of Bax, Bcl-2 was also selectively increased in 
degenerating neurons and affected dark neurons. Especially, the severe lesion 
revealed a loss of Bcl-2 expression in the lesion core, whereas Bcl-2 was present 
in neurons at the border of this lesion type. A similar expression pattern for Bax 
and Bcl-2 was described in animal models of ischemia, revealing an increased Bax 
immunostaining in the centre of the lesion and elevated Bcl-2 in surviving 
neurons close to the penumbra [17,28,29]. According to the Bax dominant theory, 
Bax may have a major role in regulating apoptosis by means of Bax 
homodimerization, although the pro-apoptotic function of Bax can be directly 
antagonized by Bcl-2 through formation of Bax/Bcl-2 heterodimers [12,13]. 
Therefore, differential expression of these apoptosis-related proteins in neurons 
determines whether neurons will undergo apoptosis or not [16]. In our study, the 
strong granular Bax expression and the absence of Bcl-2 in the lesion core of 
severe lesions may be indicative of apoptosis after 3-NP administration. Indeed, 
apoptotic cell death in this region was confirmed by the presence of TUNEL-
labeled cells exhibiting typical apoptotic morphology. However, no TUNEL 
labeling and no obvious change in the relative expression of Bax and Bcl-2 was 
detected in dark neurons and surviving striatal neurons at the border of severe 
lesions. This might suggest that the level of Bax protein in the cytoplasm was not 
yet able to induce the apoptotic process, while the up-regulation of Bcl-2 
expression in these neurons might reflect an active survival mechanism protecting 
neurons [15,30]. Still, these compromised dark neurons might undergo apoptotic 
cell death at a later stage or might survive and recover from this sub-lethal 
neuronal intoxication. 
The identity of the TUNEL-positive cells observed in the severe lesions is 
unclear. However, these cells were located in an area of extensive neuronal 
degeneration, strongly suggesting that these apoptotic cells were predominantly 
neurons. Interestingly, the TUNEL labeling was observed only in severely 
affected animals that became ill and lost 25% of their body weight. This weight 
loss may have led to a higher systemic dose of 3-NP and could have resulted in a 
faster decline of succinate dehydrogenase (SDH) activity. 3-NP irreversibly 
inhibits the mitochondrial SDH enzyme and the 3-NP-induced cell death is linked 
to mitochondrial dysfunction of the injured neuron [31,32]. Alexi et al. [22] 
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reported that a rapid decline in SDH activity in vulnerable rats corresponded to a 
marked cell death and TUNEL labeling in the striatum, whereas a more gradual 
inhibition possibly prevented acute striatal toxicity and apoptotic cell death by 
recruitment of compensatory mechanisms. The latter might have occurred in 
compromised dark neurons of the mild and subtle lesions, in which a sub-lethal 
3-NP insult induced Bcl-2 expression as an active survival mechanism to protect 
these neurons from cell death [15]. On the contrary, in seriously ill animals that 
developed a severe lesion, it was likely that the disturbed energy metabolism was 
highly toxic and lethal to neurons. Furthermore, since 3-NP is chemically 
relatively unstable at neutral pH, and will decompose to the non-neurotoxic 
nitrite over a few days at body temperature [33], most of the damage to the 
striatum may have been concentrated at the earlier part of the four-week period 
of 3-NP application. Therefore, the methodology used in the present study may 
well have underestimated the degree of apoptotic cell death by looking too late in 
the process of pathogenesis. Currently, we are studying the apoptotic process at 
an earlier stage using intraperitoneal injections of 3-NP. 
The present study demonstrates that the 3-NP-induced cell death in rats 
involves an apoptotic mechanism, which is associated with changes in Bax and 
Bcl-2 expression by neurons. It has been suggested that the specific neuronal 
degeneration in HD appears to result from the inappropriate activation of 
apoptosis [2]. Available evidence supports an apoptotic mode of neuronal death 
in HD, demonstrating increased levels of DNA breaks and typical apoptotic cells 
observed by TUNEL labeling of HD brains. Besides the previously described 
neostriatal degeneration and gliosis, the occurrence of typical apoptotic cells in 
the striatum of 3-NP-lesioned animals demonstrates yet another similarity of this 
model with HD [5-7]. Furthermore, the 3-NP animal model demonstrated 
alterations in the expression pattern of the proteins Bax and Bcl-2 compared to 
untreated animals. Especially, the strong granular Bax expression and the absence 
of Bcl-2 in the lesion core of the severe lesion type suggest that the 3-NP-induced 
degeneration is due to apoptosis. This is consistent with several in vivo and in vitro 
studies reporting that 3-NP induced apoptosis in neurons as evaluated by TUNEL 
labeling and mRNA expression of the Bcl-2 family of genes [11,20-25]. In 
addition, we observed that 3-NP-affected dark neurons demonstrated an up-
regulation of both Bax and Bcl-2, which could suggest the involvement of an 
apoptotic mechanism. However, these dark neurons were not TUNEL-positive, 
implicating a neuroprotective role for the anti-apoptotic protein Bcl-2 in these 3-
NP-injured neurons. The mechanism by which apoptosis is induced in HD and in 
animals following 3-NP administration is unknown and requires further 
investigation. In the 3-NP rat model the induction of apoptosis is presumably 
related to the effects of 3-NP on mitochondrial function, and there are several 
ways in which blockade of electron transport and depletion of adenosine 
triphosphate (ATP) might lead to apoptosis [11,34]. Both events will 
progressively induce a massive increase of calcium ions, which, in turn, will 
activate calcium-dependent cytoplasmic enzymes, including caspases that are the 
executioners of the apoptotic pathway [35]. 
In conclusion, degenerating neurons in severe lesions demonstrated distinct 
apoptotic features, such as TUNEL labeling and differential expression of Bax 
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and Bcl-2, indicating that apoptosis may be involved in the 3-NP-induced cell 
death. In contrast, the expression of the apoptosis-related markers Bax and Bcl-2 
was increased in affected dark neurons observed in the 3-NP model, but remained 
relatively equal. Besides, these cells lacked TUNEL labeling and accordingly, the 
3-NP-induced mitochondrial injury in these cells was not lethal and did not cause 
apoptotic cell death. 
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Abstract 
 
Inappropriate apoptosis has been implicated in the mechanism of neuronal death 
in Huntington’s disease (HD). In this study, we report the expression of 
apoptotic markers in HD caudate nucleus (grade 1 to 4) and compared this with 
controls without neurological disease. Terminal transferase-mediated biotinylated-
UTP nick end-labeling (TUNEL)-positive cells were detected in both control and 
HD brains. However, typical apoptotic cells were present only in HD, especially 
in grade 3 and 4 specimens. Expression of the pro-apoptotic protein Bax was 
increased in HD brains compared to controls, demonstrating a cytoplasmic 
expression pattern in predominantly shrunken and dark neurons, which were 
most frequently seen in grades 2 and 3. Control brains displayed weak perinuclear 
expression of the anti-apoptotic protein Bcl-2, whereas in HD brains Bcl-2 
immunoreactivity was markedly enhanced, especially in severely affected grade 4 
brains, and was observed in both healthy neurons and dark neurons. Caspase-3, 
an executioner protease, was only found in four HD brains of different grades 
and was not expressed in controls. A strong neuronal and glial expression of poly 
(ADP-ribose) polymerase (PARP)-immunoreactivity was observed in HD brains. 
These data strongly suggests the involvement of apoptosis in HD. The exact 
apoptotic pathway occurring in HD neurodegeneration remains yet unclear. 
However, the findings of late apoptotic events, such as enhanced PARP 
expression and many TUNEL-positive cells accompanied with weak caspase-3 
immunoreactivity in severely affected HD brains, suggest that caspase-mediated 
neuronal death only plays a minor role in HD. 
 
 
Introduction 
 
Apoptosis is a form of programmed cell death that results in the orderly and 
efficient removal of damaged or redundant cells, e.g. occurring after DNA 
damage or during normal development, immune regulation, and tissue 
homeostasis [1,2]. Many factors contribute to the apoptotic cascade that lead to 
cell destruction, each demonstrating specificity of function, regulation, and 
pathway involvement [1,3]. Inappropriate activation of apoptosis has been 
implicated in the pathogenesis of several chronic-age-related neurological 
disorders, such as Huntington’s disease (HD) [4] by the demonstration of 
increased DNA degradation and typical apoptotic cells in postmortem HD brains 
[5-7]. Furthermore, in vitro studies provided evidence for a link between apoptosis 
and the mutant huntingtin protein [8,9]. In addition, apoptotic cell death has been 
reported in experimental models of HD, in which the mitochondrial toxin 3-
nitropropionic acid induced nuclear DNA fragmentation with an increased 
expression of apoptosis-related markers in rat striatum [10]. HD is caused by the 
abnormal expansion of CAG-trinucleotide repeats in the N-terminus of the 
huntingtin gene [11], but how this mutation leads to extensive and region specific 
neuronal degeneration in HD neostriatum remains unclear. 
 In recent years, various apoptotic cascades have been characterized in the 
nervous system, such as the extrinsic and intrinsic pathways of caspase-mediated 
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cell death, as well as caspase-independent apoptosis (Fig. 1). Caspases are cysteine 
aspartate-specific proteases and constitute a family of intracellular proteins that 
play an important role in the initiation and execution of apoptotic cell death [1]. 
The caspase-mediated extrinsic pathway, or the cell-death receptor pathway, is 
initiated by activation of the Fas receptor after binding to the Fas ligand, whereas 
the caspase-mediated intrinsic pathway, or the mitochondrial pathway, is 
regulated by the interaction of members of the Bcl-2 family of mitochondrial 
proteins, such as Bax and Bcl-2. The intrinsic pathway is triggered by Bax 
translocation to the mitochondrial outer membrane, which leads to the activation 
of several caspases. Caspase-3 is an important executioner protease in the 
apoptotic program and cleaves a broad array of proteins critical for cell survival, 
including the DNA-repairing enzyme poly (ADP-ribose) polymerase (PARP) into 
85 and 28 kDa fragments [12,13]. The huntingtin protein itself is also a substrate 
for caspase-3 [8]. Finally, caspase-independent apoptosis is activated by 
translocation of apoptosis-inducing factor (AIF) to the mitochondria and the 
nucleus and produces peripheral chromatin condensation and large-scale DNA 
strands [12,13]. 
 
Figure 1. Scheme showing key components of the various apoptotic pathways described. 
 
The detection of morphological features of apoptotic cell death may be difficult 
in a slowly progressive disorder like HD. To ascertain that apoptosis is involved 
in HD and to elucidate which apoptotic signaling cascade is predominantly 
involved in HD pathogenesis, we studied apoptotic features at various time points 
of the process, since not only the end-products like DNA degradation and 
apoptotic bodies, but also the expression of several regulatory proteins involved 
in the cascade, may provide evidence for activation of the apoptotic process. In 
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this study, we focus on the caspase-mediated apoptotic cell death by studying the 
expression patterns of Bax, Bcl-2, caspase-3 and PARP and the presence of 
apoptotic cells by using the Terminal deoxynucleotidyl transferase mediated dUtp 
biotin Nick End Labeling (TUNEL) in the caudate nucleus of HD patients and in 
control brains. 
 
 
Material and Methods 
 
Human tissue 
 
Caudate samples were obtained at post mortem examination from 18 HD patients 
(mean age 60.4±14.6 years, mean postmortem delay 20.1 hours) and six controls 
with no evidence of neurological disease on neuropathological examination (mean 
age 72.5±8.7 years, mean postmortem delay 18.0 hours). The clinical diagnosis of 
HD was confirmed neuropathologically and HD severity was graded according to 
the classification of Vonsattel et al. [14]. The characteristics of the HD patients 
and controls are summarized in Table 1. 
After removal at autopsy, whole brains were rapidly fixed with 10% 
paraformaldehyde in phosphate buffer. Tissue samples were then embedded in 
paraffin, cut into sections of 5µm and stained with standard neuropathological 
techniques, including hematoxylin and eosin, cresylviolet, or processed for 
immunohistochemistry using glial fibrillary acidic protein (GFAP) antibody as a 
marker of astrocytes. 
 
 
Immunohistochemistry 
 
Immunohistochemistry was performed on deparaffinized sections of the caudate 
nucleus using commercially available antisera that were all diluted in 1% 
BSA/PBS. A polyclonal rabbit antibody directed against GFAP (Dako, Holstrup, 
Denmark) was used at a dilution of 1:400. Anti-Bax antibody (Zymed 
laboratories, Uden, the Netherlands) is a mouse monoclonal raised against the N-
terminal end of the protein, which reacts specifically with Bax protein of mouse, 
rat and human origin, dilution 1:50. Polyclonal goat antiserum directed against 
Bcl-2 (N-19) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), was used at 
a dilution of 1:200. Anti-Bcl-2 antibody is directed against the N-terminal end of 
Bcl-2 of human origin, is specific for mouse, rat and human Bcl-2 and shows no 
cross-reactivity with other apoptosis-associated proteins. Caspase-3 (1:100) is a 
rabbit polyclonal antibody from Cell Signaling Technology Inc., Leusden, the 
Netherlands) and recognizes cleaved caspase-3 at aspartate residue 175. Anti-
PARP p85 Fragment pAb (Promega Benelux b.v., Leiden, the Netherlands) is a 
polyclonal rabbit antibody specifically directed against the 85 kDa caspase-cleaved 
fragment (p85) of human PARP, dilution 1:75. 
Prior to Bax, Bcl-2, caspase-3 and PARP immunohistochemistry, 
deparaffinized sections were subjected to microwave treatment for 10 minutes in 
a boiling citrate solution pH 6.0. All sections were incubated for 30 minutes in 
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1% H2O2 (Merck, Darmstadt, Germany) in PBS to quench endogenous peroxidase 
activity and subsequently, unspecific binding was blocked by 30 minutes 
incubation with 20% Normal Goat Serum (Bcl-2, caspase-3 and PARP) or 20% 
Normal Horse Serum (Bax) in PBS. Overnight incubation with the primary 
antibodies at 4°C was followed by incubation with a secondary biotinylated goat 
anti-rabbit antibody (Bcl-2, caspase-3 and PARP) or a secondary biotinylated 
horse anti-mouse antibody (Bax), all used at a dilution of 1:200 in 1% BSA/PBS 
for 45 minutes. To visualize antibody binding, a standard Avidin-Biotin-Complex 
(Vectastain Elite, Vector Laboratories, Burlingame, CA, USA) was applied to the 
sections and 3,3’-diaminobenzidine (DAB) (Sigma, St. Louis, MO, USA) was used 
as a chromophore. Finally, the signal of the reaction product was enhanced by 
incubating sections for 5 minutes in 0.5% copper sulphate in saline, and sections 
were counterstained with Mayers hematoxylin. Paraffin embedded rat intestine 
was used as a positive control for apoptotic markers used in this study. 
 Nuclear DNA fragmentation was visualized in deparaffinized sections using 
the Apoptag™ kit (Intergen Company/Oncor Inc., Gaithersburg, MD, USA) 
containing TdT-mediated dUTP-digoxigenin 3’ nick-end labeling (TUNEL) 
according to the manufacturer’s recommendations. TUNEL-positive cells were 
visualized using DAB and 0.5% copper sulphate in saline, after which the sections 
were counterstained using ‘Kernechtrot’. 
Results were obtained by microscopic evaluation of immunostained 
sections, in which labeled neurons were determined by virtue of their typical 
neuronal cell morphology after counterstaining with hematoxylin. Percentages of 
apoptotic cells and the number of neurons expressing apoptosis-related markers 
were estimated by counting Bax, Bcl-2, caspase-3, PARP and TUNEL-positive 
cells visible per microscopic field (20x objective). A semi-quantitative method was 
used to analyze the immunohistochemical results, with indications varying from 
absent (- = no positive cells) to weak (+ = 1-5 positive cells), moderate (++ = 5-
20 positive cells) and strong (+++ = >20 positive cells) in views obtained with a 
20x objective (see Table 1). Two independent observers validated a subset of 
immunostained sections and identical results were recorded. Digital images were 
captured using a Sony video camera mounted on a Zeiss Axioscope 2 plus and 
Adobe® Photoshop software. 
 
 
Results 
 
Histological findings 
 
The caudate nucleus of the HD brains revealed characteristic HD neuropathology 
and demonstrated neuronal cell loss that varied from moderate to extensive, 
together with increased GFAP immunoreactivity reflecting the gliotic process 
(Figs. 2A-C). Apoptotic features, such as nuclear fragmentation and chromatin 
condensation, were more frequently observed in the hematoxylin and Nissl-
stained sections of HD brains than in control brains (see below and Fig. 2C). 
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Expression pattern of apoptosis-related markers in control and HD brains 
 
Only a few control brains revealed a weak perinuclear immunostaining for both 
Bax and Bcl-2 proteins in the caudate nucleus, with only a few neurons expressing 
Bax or Bcl-2 diffusely in the cytoplasm. The overall and diffuse immunostaining 
was more intense and more evident for Bcl-2 (Fig. 2E). Astrocytes were only 
weakly positive for Bax and Bcl-2 (not shown). In HD, the caudate nucleus 
demonstrated an enhanced cytoplasmic immunostaining for both Bax and Bcl-2 in 
most caudate neurons compared to controls. Interestingly in HD brains, these 
apoptosis-related markers were strongly expressed in shrunken and dark neurons, 
which are most likely compromised by the disease (Figs. 2D and 2F). Increased 
Bax immunoreactivity was predominantly found in dark neurons that were 
moderately labeled (Fig. 2D, arrows) while the average perinuclear Bax staining of 
neurons in HD was weak and similar as in controls. The up-regulation of pro-
apoptotic protein Bax expression was maximal in HD brains grade 2 and 3, 
presenting most frequently dark neurons. The anti-apoptotic protein Bcl-2 was 
markedly enhanced in HD brains with an intense and diffuse cytoplasmic 
immunoreactivity in dark neurons but was also expressed in healthy neurons (Fig. 
2F). This expression pattern was more intense compared to the perinuclear Bcl-2 
expression observed in controls. The up-regulation of Bcl-2 expression was 
maximal in postmortem HD brains grade 3 and 4, reflecting HD patients with 
disease duration for more than 18 years (see Table 1). 
Caspase-3 immunoreactivity was not present in control brains. Only four 
HD caudate nucleus samples were caspase-3-positive and demonstrated scattered 
cells with a cytoplasmic granular immunoreactivity located next to a shrunken 
nucleus (Fig. 2G). The identity of these caspase-3-labeled cells is unclear, 
although it cannot be excluded that this immunostaining depicts pigment-laden 
macrophages present in HD brains. 
 In control brains, PARP immunoreactivity was predominantly found in 
neurons showing a perinuclear and diffuse cytoplasmic immunostaining, while the 
weaker perinuclear labeling was demonstrated in glial cells as well (Fig. 2H).  
Nuclear PARP immunoreactivity was rare. In HD brains, the neuronal 
cytoplasmic PARP expression was strongly increased and was especially visible as 
cytoplasmic granules in neurons (Fig. 2I). In addition, HD brains showed PARP 
immunoreactivity in the cytoplasm and cellular processes of activated astrocytes 
(Fig. 2K). The markedly enhanced PARP immunostaining in neurons was mainly 
observed in grade 3 and 4 HD brains and is shown in Table 1. 
 
 
TUNEL-labeling in control and HD brains 
 
TUNEL-positive cells were detected in both control and HD brains. In controls, 
diffusely labeled cells that lacked apoptotic features (up to 40 % of total brain 
cells) were regarded as non-apoptotic (Fig. 2L), whereas intensely stained 
TUNEL-positive cells (5 - 10 % of total TUNEL-labeled cells) that demonstrated 
typical DNA fragmentation in shrunken nuclei and in apoptotic bodies, were 
regarded  as  specific  for apoptotic cell death. Moreover, HD brains showed both 
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Figure 2. Neuropathological characteristics, expression pattern of apoptosis-related markers and 
TUNEL-labeling in control and in HD brains. 
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Figure 2. Neuropathological characteristics, expression pattern of apoptosis-related markers and 
TUNEL-labeling in control and in HD brains. A, Photomicrograph of a control paraffin section 
demonstrating a few GFAP-immunostained astrocytes in the caudate nucleus. B, Increased expression of 
GFAP-positive astrocytes in a paraffin section from a HD brain. Note the greater number of neurons in 
the control brain in comparison to the HD brain showing mainly affected dark neurons (arrowheads). C, 
Cresylviolet-stained section of a HD brain showing neuronal loss, dark neurons and apoptotic features 
such as nuclear condensation and fragmentation (arrows). D, The HD caudate nucleus demonstrated an 
increased cytoplasmic immunoreactivity for the pro-apoptotic protein Bax in neurons but predominantly 
in dark neurons (arrowheads). E, The perinuclear and diffuse cytoplasmic immunolabeling of the anti-
apoptotic protein Bcl-2 in neurons was found in control brain. F, HD caudate nucleus demonstrated 
enhanced expression for Bcl-2: strong Bcl-2 expression was found in neurons and dark neurons 
(arrowheads). G, A few scattered caspase-3-positive cells were found in the HD caudate nucleus and these 
were not present in control brains. H, In control brain, cytoplasmic PARP immunoreactivity was mainly 
found in neurons, nuclear PARP immunostaining was rare. I, In HD brains, PARP expression was 
markedly increased and a strong granular expression was observed in the cytoplasm and cellular processes 
of neuronal cells. K, PARP immunoreactivity was demonstrated in the cytoplasm and cellular processes of 
glial cells in HD brains. L, Diffusely TUNEL-labeled cells that did not exhibit characteristic apoptotic 
morphology, were frequently seen in the caudate nucleus of controls. M, HD brains with intensively 
labeled TUNEL-positive cells show DNA fragmentation mainly localized in shrunken nuclei (arrows) and 
in a few apoptotic bodies (arrowhead). These typical apoptotic cells were mostly detected in the neuropil 
of the caudate nucleus surrounded by more diffusely TUNEL-labeled cells that did not exhibit 
characteristic apoptotic morphology. Scale bar in 2A presents 20µm (A-C) and scale bar in 2D presents 
10µm (D-M). 
 
more and darker stained TUNEL-positive cells than control brains, and these 
typical apoptotic cells were markedly present in grade 4 HD brains (Fig. 2M). The 
identity of the dark and shrunken TUNEL-labeled cells is not entirely clear and 
includes possibly most brain cell types. However, the location of most darkly 
stained TUNEL-positive cells in an area of extensive neuronal degeneration in 
end-stage HD caudate nuclei strongly suggests that these TUNEL-positive cells 
are predominantly neurons. Furthermore, a minority of HD brains (n=3) and one 
control brain were TUNEL-negative. 
Table 1 summarizes the TUNEL labeling together with the results of Bax, 
Bcl-2, caspase-3 and PARP immunostaining observed in postmortem neostriatal 
tissue from HD patients and controls. 
 
 
Discussion 
 
The present study confirms that neostriatal neurodegeneration in Huntington’s 
disease (HD) brains involves an apoptotic mechanism, which is associated with 
enhanced Bax expression, weak caspase-3 expression, the presence of strong 
PARP immunoreactivity and many TUNEL-labeled cells exhibiting typical 
apoptotic morphology in comparison with controls without neurological disease. 
In a slowly progressive disorder like HD, in which only a few cells at any time 
would be expected to undergo cell death, the detection of morphological features 
of apoptosis may be difficult [15]. Another problem is that HD has a duration of 
about fifteen years, leaving even less transient apoptotic neurons to be found in 
postmortem tissue, when at the time of death most affected neurons are already 
dead and removed. Because most of the TUNEL-labeled cells were located in an 
area of extensive neuronal degeneration in end-stage HD brains, it is highly likely 
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that these apoptotic cells were predominantly neurons. Since the TUNEL method 
has methodological limitations and detects DNA strand breaks in necrotic cells as 
well [16-18], TUNEL labeling is not sufficient to demonstrate apoptosis in 
neurons and needs to be evaluated by the expression of other biochemical 
markers that are involved in the apoptotic cascade [3-19]. Therefore, the up-
regulation of pro-apoptotic proteins in the HD brains examined such as Bax, 
caspase-3 and PARP in association with the TUNEL labeling provides additional 
evidence for the hypothesis that specific loss of striatal medium-sized spiny 
GABAergic neurons in HD results from the inappropriate activation of apoptosis 
[4]. The altered expression patterns of apoptotic markers in neurons we found 
between HD brains and controls in this study are not likely to be due to 
differences in postmortem delay or fixation times since no obvious correlation 
was noted between these parameters. Instead, there appeared to be a correlation 
between the different grades of HD severity and enhanced expression levels of 
apoptosis-related markers. The finding of late apoptotic events in the cascade, 
such as PARP and TUNEL staining in the severe grade HD brains could reflect 
an increased and faster cell death at the end-stage of the neurodegenerative 
disorder, when compromised cells are at maximum to die, resulting in a maximum 
occurrence of apoptotic cell death. This is comparable with findings of Kiechle 
and co-workers [20], who reported increased expression of caspase-9 and 
cytochrome c in HD striatal neurons of severe-grade specimens, and suggested 
that apoptosis may play a greater role in neuronal death at end-stage disease. 
Furthermore, the grade 4 brains from patients suffering HD for more than 18 
years, displayed the highest expression of anti-apoptotic protein Bcl-2 implicating 
a neuroprotective role in the left-over and still surviving injured neurons at the 
end-stage of the disease [21,22]. 
 In line with other studies [23], we observed only a weak perinuclear and 
cytoplasmic expression for the apoptosis-related proteins Bax and Bcl-2 in 
controls, while in most HD brains the expression of both Bax and Bcl-2 was 
increased. This up-regulation of Bax and Bcl-2 proteins was predominantly found 
in degenerating and affected dark neurons, suggesting a battle for life or death, 
although anoxic circumstances could contribute to the injured state of these 
neurons as well. However, their maximal expression was at different stages of HD 
with Bax implicating the induction of the apoptotic process in grade 2 and 3 HD 
brains and Bcl-2 implicating a neuroprotective role in the left-over and still 
surviving injured neurons at the end stage of the disease [12,21]. Bax and Bcl-2 
expression in HD caudate nucleus have not been described before, but Bax and 
Bcl-2 up-regulation has been shown in Alzheimer's disease, Parkinson's disease, 
and amyotrophic lateral sclerosis (ALS) [23-27]. The increased Bax expression 
observed in HD brains possibly reflects the formation of functional and pro-
apoptotic Bax homodimers, probably preparing neostriatal neurons to die [15,28-
30]. In affected dark neurons of HD brains however, the level of Bax protein in 
the cytoplasm was not yet able to activate the apoptotic process and was probably 
counteracted by the up-regulation of Bcl-2 [21,28,31,32]. The enhanced anti- 
apoptotic  Bcl-2  expression might be explained as an ongoing survival attempt to 
protect these mildly injured neurons from death, because it was not or only 
weakly expressed in control brains. 
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HD brains, and especially the severe grade 4, demonstrated strong 
immunoreactivity of 85 kD PARP-fragments in the cytoplasm and was present as 
granules in neurons, in some nuclei of neurons and in glial cells as well, 
suggesting a role for the DNA-repair enzyme PARP in HD neurodegeneration. 
Cookson and co-workers [33] showed substantial cytoplasmic PARP expression in 
most neuron types, especially in motor neurons of the spinal cord. Cleaved PARP 
fragments have been demonstrated in Alzheimer's disease and Parkinson's disease 
[34,35] and in ALS patients [36]. Because of the dominant cytoplasmic PARP 
immunoreactivity, it was suggested that PARP up-regulation in HD might be 
associated with other subcellular components besides the nucleus [33], which 
indicates additional roles for this enzyme being effective in disease-affected 
neurons and in activated astrocytes that may contribute to neuronal dysfunction 
and death in HD. 
 In our study, scattered caspase-3-positive cells were only found in four HD 
brains and was not expressed in control brains. Caspase-3 expression was not 
shown before in the caudate nucleus of HD patients. The weak caspase-3 
immunostaining most likely depicts pigment-laden macrophages that are present 
and active in HD brains, clearing dying and disease-affected neurons away. In 
Parkinson's disease, an increased immunoreactivity of caspase-3 has been 
reported in a small proportion of the substantia nigra [27]. In transgenic mice 
models of HD, transcriptional up-regulation of caspase-1 and caspase-3 has been 
reported [37,38], and activation of caspase-8, caspase-9 and release of cytochrome 
c has been demonstrated in human striatal tissue of HD patients [20,39]. Usually, 
caspases are the major executioners of the apoptotic pathway [40] but the low 
caspase-3 immunoreactivity observed in our study may indicate that the caspase-
mediated apoptotic cell death was not intensively involved in HD. Moreover it 
was reported that caspase-3 and other caspases may be more activated in acute 
neuronal cell death, such as in brain damage after ischemia or trauma [13], 
whereas in chronic neurodegenerative diseases, the chronic and sublethal 
activation of caspases appears to mediate cell dysfunction, which precedes cell 
death [41,42]. The latter was not confirmed by us in this study, where we 
focussed on the intrinsic caspase-mediated apoptotic cell death that may 
contribute to delayed loss of neurons [13], as expected to occur in the slowly 
progressing neurodegenerative disorder HD. 
It remains unclear which apoptotic pathway predominantly occurs in HD. 
The findings of increased PARP expression and TUNEL labeling, which are both 
markers of the end-stage of the apoptotic process, accompanied by weak caspase-
3 immunoreactivity in severely affected HD brains, might favour a role for the 
non-caspase-mediated neuronal apoptotic pathway to be involved in HD 
pathogenesis. However, it seems that caspase-mediated neuronal death is not 
always accompanied by the morphological changes that are typical of apoptosis in 
other tissues [13]. This might explain differences in expression of apoptotic 
markers in nervous tissue compared to other tissues and may suggest that other 
markers and pathways are induced in HD. The precise pathway by which neurons 
in the HD caudate nucleus die requires further investigation, but this study shows 
that up-regulation of Bax and PARP are important factors in the apoptotic 
process. It is possible that at different stages of the disease particular apoptotic 
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proteins are important to prepare and induce cell death at the beginning of the 
disease (Bax) or to execute increased cell death (PARP) at end-stage HD. 
Knowledge about the pathway by which neurons die in HD, may help the 
development of therapies that are aimed at reducing cell degeneration and death 
in HD. 
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Abstract 
 
Exposure of organotypic rat corticostriatal slice cultures to the mitochondrial 
toxin 3-nitropropionic acid (3-NP) resulted in concentration-dependent loss of 
cresylviolet-stained cells and increase of lactate dehydrogenase and lactate efflux 
into the culture medium, indicators for cell death and metabolic activity in the 
slices, respectively. The involvement of apoptosis in these slices was suggested by 
using the terminal transferase-mediated biotinylated-UTP nick end-labeling 
(TUNEL) technique, and immunohistochemistry for the apoptosis-related 
markers Bax and Bcl-2. In 3-NP-exposed slices, TUNEL-positive cells were 
observed in both the striatum and the cortex but in different forms: striatal 
neurons were either diffusely stained or showed nuclear fragmentation, cortical 
neurons only exhibiting nuclear fragmentation. In 3-NP-exposed slices, the pro-
apoptotic protein Bax was abundantly expressed, whereas the anti-apoptotic 
protein Bcl-2 was not expressed in striatal neurons. We suggest that both 
apoptosis and necrosis are involved in the 3-NP-treated slices, apoptosis as well 
as necrosis in the striatum and apoptosis in the cortex. 
 
 
Introduction 
 
The mitochondrial complex II (succinate dehydrogenase) inhibiting neurotoxin 3-
nitropropionic acid (3-NP) induces selective striatal degeneration in aged rats. 
This degeneration is characterized by both neuronal loss and gliosis [1-3]. As such 
it has been used as a model for Huntington’s disease, an inherited 
neurodegenerative disorder characterized by severe atrophy of the neostriatum 
with marked neuronal loss and gliosis [4]. The precise mechanism of this selective 
neuronal death is unknown, but inappropriate activation of apoptosis may be 
involved [5-8]. 3-NP induced neurodegeneration has also been demonstrated in 
striatal and hippocampal cell cultures [9,10] and in organotypic striatal slice 
cultures [11], and may result from apoptosis [12]. 
Cells that undergo apoptosis show characteristic morphological features 
[13] such as nuclear fragmentation and condensed nuclei. DNA fragmentation can 
be demonstrated by the terminal transferase-mediated biotinylated-UTP nick end-
labeling (TUNEL) [14]. Members of the Bcl-2 family of proteins, including Bcl-2 
and Bax play an important role in regulating the apoptotic cascade [12,15], Bax 
promoting apoptosis, and Bcl-2 inhibiting apoptotic cell death. Previously, we 
showed that in a rat model in vivo chronic 3-NP intoxication induces differential 
expression patterns of these apoptosis-related markers in the striatum [16]. In the 
present study we studied the expression of Bax and Bcl-2 in relation to DNA 
fragmentation in organotypic slice cultures. This model allows continuous 
monitoring of morphological and biochemical alterations over the lifetime of the 
cultures, information that is not easily obtained in in vivo models. Corticostriatal 
slices of one-day old rats [17-19], cultured for two weeks, were exposed to 3-NP 
for 24 hours, and, after a recovery period of 24 hours, we analyzed the neurotoxic 
effects. As biochemical indicators for cell death and metabolic activity, we 
measured lactate dehydrogenase and lactate efflux into the culture medium. 
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Material and Methods 
 
Corticostriatal slice cultures 
 
Corticostriatal slice cultures were prepared using the interface culture method 
[17]. One-day old Wistar rat pups were decapitated, and their forebrains were 
quickly removed under sterile conditions. The forebrain was mounted on the 
specimen holder of a vibratome, held on ice, and embedded in agarose. The 
forebrain was divided into the two hemispheres, and transverse, 400 µm thick 
sections through the entire forebrain were cut with the vibratome. Sections were 
easily released from the agarose and were collected in chilled Gey's balanced salt 
solution with glucose (final concentration 11 mM). Four adjacent frontal 
corticostriatal slices of each hemisphere were placed on one membrane insert 
(Millicell-CM, 0.4 µm; Millipore Corp. Bedford, MA, USA). The inserts were 
transferred to culture trays with 6 wells, each well containing 1 ml of medium, 
containing 25% inactivated horse serum, 25% Hank’s balanced slat solution and 
50% OPTI-MEM culture medium, supplemented with D-glucose (final 
concentration 11 mM) and penicillin/streptomycin (100 IU/ml) (all from Gibco 
Brl, Life Technologies Ltd., Paisley, Scotland). The culture trays were placed in an 
incubator at 37°C with 5% CO2. After 3 days, the culture medium was replaced 
by 1 ml of serum-free Neurobasal medium, supplemented with D-glucose (final 
concentration 28 mM), L-glutamine (1 mM), B-27-supplement and 
penicillin/streptomycin (100 IU/ml) (all Gibco Brl). The medium was changed 
twice a week during the entire culturing period of 14 days. During the culturing 
period, the slices were regularly examined by light and phase contrast microscopy. 
Initial studies were conducted using P-culture medium for the whole culturing 
period and for the dose-effect experiments of 3-NP, the main difference in 
composition being 50% MEM-Eagle instead of 50% OPTI-MEM. 
 
 
3-NP exposure experiments 
 
The dose-effect relation of 3-NP (Sigma, St. Louis, MO, USA) was studied in 
one-week-old interface cultures exposed for 24 hours to 3-NP dissolved in P-
culture medium in concentrations varying from 25 µM to 1 mM, respectively 
(n=4 membrane inserts for each concentration; n=4 for controls). Based on these 
experiments a concentration of 100 µM 3-NP was thereafter used and similar and 
consistent results were obtained using Neurobasal medium. In subsequent 
studies, two-week-old interface cultures were exposed to 100 µM 3-NP for 24 
hours in Neurobasal medium, followed by a recovery period of 24 hours in 
normal Neurobasal medium. Parallel control experiments were performed without 
3-NP in the culture medium. In two independent experiments, lactate 
dehydrogenase (LDH), lactate and pyruvate efflux into the medium were 
measured before 3-NP exposure, after 24 hours 3-NP (25-500 µM) exposure and 
after a 24 hours recovery period, and compared with control slices. LDH, lactate 
and pyruvate concentrations (in U/L) were analyzed using a Cobas Mira 
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automatic turbidometric analyzer (ABX, Eindhoven, the Netherlands) according 
to the manufacturer’s instructions. LDH is an indicator for cell damage, whereas 
the levels of lactate and pyruvate give insight into the amount of mitochondrial 
stress, resulting in a rise of anaerobic metabolism from glucose to lactate. 
 
 
Histological studies 
 
After the 3-NP exposure, standard histological staining techniques, 
immunohistochemical detection of the apoptotic markers Bax and Bcl-2 as well as 
in situ labeling of DNA fragmentation were performed on cryosectioned slices of 
3-NP treated slices (n=32) and control slices (n=18). The cultures were fixed in 
4% paraformaldehyde in PBS for one hour, kept in a 20% sucrose solution at 4°C 
for at least 24 hours, frozen using liquid nitrogen, embedded in Tissue-Tek 
(O.C.T. compound, Sakura, Japan), and cut into 8 µm thick frontal sections. 
Cryosections were immunostained using rabbit polyclonal antibodies directed 
against Bax and Bcl-2 (P-19 and N-19; dilution 1:250 and 1:100, respectively; 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Endogenous peroxidase 
activity was blocked by incubation in 0.3% H2O2 in PBS for 10 minutes, and 
nonspecific binding was blocked by 30 minutes incubation with 100% normal 
goat serum (Vector Laboratories, Burlingame, CA, USA). The primary antibodies 
were incubated overnight at 4°C. Antibody binding was visualized with a 
secondary biotinylated goat anti-rabbit antibody (Vector Laboratories, dilution 
1:200 in PBS/1% BSA), followed by avidin-biotin-peroxidase-complex 
(Vectastain Elite, Vector Laboratories), and processed with diaminobenzidine 
(DAB; Sigma) and H2O2. The signal of the reaction product was enhanced by 
incubating sections for 5 minutes in 0.5% copper sulphate in saline, and sections 
were counterstained with hematoxylin. The specificity of the Bax and Bcl-2 
antibodies was tested by incubating these antisera at room temperature with P-19 
Bax blocking peptide and N-19 Bcl-2 blocking peptide (both from Santa Cruz 
Biotechnology), respectively, for 2 hours prior to incubation of the sections. 
Nuclear DNA fragmentation was visualized using the Apoptag™ kit (Intergen 
Company, Gaithersburg, MD, USA) for terminal transferase-mediated 
biotinylated-UTP nick end labeling (TUNEL) according to the manufacturer’s 
recommendations. TUNEL-positive cells were stained using DAB as a 
chromophore. Staining was enhanced in 0.5% copper sulphate in saline, after 
which sections were counterstained using ‘Kernechtrot’. 
 
 
Results 
 
In general, during culture and after immunohistochemical staining the 
corticostriatal slices displayed the same organotypic histological organization as 
described by others [11]. Cresylviolet-stained corticostriatal slices demonstrated a 
dose-dependent effect of 3-NP on neuronal degeneration; with increasing 3-NP 
concentration, the number of cresylviolet-stained cells appeared to decrease in the 
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striatum (Figs. 1A-C). Cultures exposed to 500 µM or 1 mM 3-NP displayed 
extensive striatal and cortical damage which disrupted the slices. 
The mechanism of 3-NP-induced cell death may be different in the cortex 
and the striatum. The number of TUNEL-positive cells was strongly increased in 
both the striatum and the cerebral cortex of the 3-NP-exposed sections compared 
to control slices. But many TUNEL-positive cells in the striatum after 3-NP 
treatment did not show the typical apoptotic morphology, with the nuclei being 
diffusely stained. In some striatal neurons, however nuclear fragmentation was 
observed in TUNEL-positive cells (Fig. 1D). In contrast, in the overlying deep 
parts of the cerebral cortex, both without and with 3-NP, the majority of the 
TUNEL-positive neurons exhibited characteristic apoptotic morphology and 
extensive labeling (Fig. 1E). Cortical cell loss and apoptotic features were also 
present in cresylviolet-stained cryosections of control brain slices, but only in the 
deeper layers nearest to the membrane insert. Here, DNA fragmentation was 
evident by TUNEL staining, suggesting the occurrence of apoptotic cell death 
(see Fig. 1E). This cortical apoptosis may have been either an artifact of the 
sectioning or culturing procedures, or part of the physiologic brain modeling. 
 The expression of the pro-apoptotic protein Bax was dramatically increased 
in the 3-NP-exposed slices, both in the striatum and in the deeper layers of the 
cerebral cortex. In the striatum, Bax expression was not restricted to the 
cytoplasm of cells, but was dispersed and detected in the neuropil (Fig. 1F). In 
the deeper layers of the cortex close to the membrane insert, however, Bax 
expression was predominantly observed in the cytoplasm of neurons that 
demonstrate nuclear fragmentation (Fig. 1G). The anti-apoptotic marker Bcl-2 
was absent in striatal neurons of both 3-NP-treated and untreated brain slices 
(Fig. 1H). In the cortex of 3-NP-exposed slices Bcl-2 was weakly expressed, and 
was mainly observed in glial cells (Fig. 1I). Remarkably, it was generally not 
expressed in deep cortical cells that revealed nuclear fragmentation. Control 
experiments using Bax and Bcl-2 blocking peptides revealed no immunostaining 
of the cryoslices. 
We found a 5 to 10-fold increase of LDH-efflux into the medium in 
response to increasing concentrations of 3-NP (Fig. 2A). This increase was only 
noted in the recovery period after the incubation with 3-NP, i.e. 48 hours after 
the onset of the experiment, suggesting delayed cell damage after 3-NP. The 
lactate concentration in the medium also increased (2 to 3-fold) in response to 3-
NP treatment (Fig. 2B), but this increase in lactate was an early event, already 
evident during 24 hours of 3-NP incubation and not during the recovery period, 
i.e. after 48 hours. The pyruvate concentration was decreased both during the 3-
NP incubation period and the recovery phase (Fig. 2C), resulting in a strong 
increase in the lactate/pyruvate ratio (up to 10-fold) after incubation with 50 µM 
3-NP or more (Fig. 2D), consistent with mitochondrial inhibition and a switch to 
anaerobic metabolism. 
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Figure 1. A-C, Low-power photomicrographs of cresylviolet-stained corticostriatal slices of control and 
3-NP-exposed cultures. D-I, Expression of apoptosis-related markers in 3-NP-exposed corticostriatal 
slices. 
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Figure 1. A-C, Low-power photomicrographs of cresylviolet-stained corticostriatal slices of control and 
3-NP-exposed cultures (P-medium). A, One-week-old control slice demonstrating major morphological 
features, including the cerebral cortex (Ctx), striatum (Str) consisting of the caudate-putamen, the anterior 
commissure (ac) and the corpus callosum (cc). The asterisk marks the deep part of the cerebral cortex, 
characterized by a decreased number of cresylviolet-stained cells. B, Slice culture exposed to a 
concentration of 100 µM 3-NP for 24 hours. Note the marked loss of Nissl-stained cells (arrow) in the 
dorsolateral part of the 3-NP-exposed striatum. C, Corticostriatal slice culture exposed to 250 µM 3-NP 
revealing a marked and widespread neuronal degeneration in the striatum. The deeper layers of the 
cerebral cortex are also involved. D-I, Expression of apoptosis-related markers in 3-NP-exposed 
corticostriatal slices (Neurobasal medium). D, TUNEL-positive cells (dark-brown) in the 3-NP-treated 
striatum contained diffusely stained, condensed nuclei or showed nuclear fragmentation (arrows). E, In 
the overlying, deep part of the cerebral cortex of unexposed slices the majority of the TUNEL-positive 
neurons exhibited characteristic apoptotic morphology (arrows) and extensive, brown TUNEL labeling. 
The sections shown in D and E are counterstained with ‘Kernechtrot’. F, Increased expression of the pro-
apoptotic protein Bax in the striatum of a 3-NP-exposed cryosection. G, In the deep cortex of 3-NP-
treated brain slices, Bax expression was increased and predominantly observed in the cytoplasm of 
neurons, demonstrating nuclear fragmentation. H, Bcl-2 immunostaining of an untreated cryosection 
demonstrating the striatum. The anti-apoptotic protein Bcl-2 was not detected in striatal neurons. I, Bcl-2 
is not expressed by the dying cells in the deep parts of the cerebral cortex, exhibiting fragmentation 
(arrows). Scale bars represent 100 µm in A-C, D = 15 µm in D and E (also for F-I) = 15 µm. 
 
 
Discussion 
 
This study demonstrates that in organotypic slice cultures, prepared from the 
cerebral hemispheres of neonatal rats, 3-NP induces a concentration-dependent 
increase in neuronal death in the striatum of corticostriatal slice cultures. This 
striatal degeneration is accompanied by a dramatic increase of the LDH and 
lactate efflux into the culture medium. Our data are consistent with in vivo studies 
on systemic 3-NP [1-3,12] and intrastriatal 3-NP [20] injections reporting 
extensive damage in rat striatum. Since we used low glucose concentrations, 3-NP 
neurotoxicity was observed after relatively low 3-NP concentrations in line with 
recent data [11]. 
 After 3-NP treatment both the striatum and the cortex contain numerous 
TUNEL-labeled cells, while in control slices only the deeper layers of the cortex 
do. The up-regulation of Bax as well as the presence of DNA fragmentation in 3-
NP-exposed brain slices, suggests that 3-NP induces an apoptotic mode of cell 
death in organotypic slice cultures. This is in line with in vivo and other in vitro 3-
NP studies [6,9,10,16]. Many TUNEL-labeled cells in the striatum of 3-NP-
exposed slices do not show the morphology typical for apoptosis. Their nuclei are 
more diffusely stained. In some striatal neurons, however, nuclear fragmentation 
was observed. This is in contrast to the overlying cerebral cortex in which the 
majority of the TUNEL-positive neurons exhibits characteristic apoptotic 
morphology and extensive TUNEL labeling. TUNEL labeling may detect early 
stages of DNA fragmentation but careful assessment of the cellular morphology 
is necessary because not every TUNEL-positive cell is an apoptotic cell [16]. In 3-
NP-exposed slices the striatal diffuse TUNEL labeling raises the possibility of 
DNA damage as part of a necrotic type of cell death. However, the presence of 
nuclear fragmentation in TUNEL-stained cells and the diffuse Bax 
immunostaining  of  striatal  neurons,  both  cytoplasmic  and  dispersed  into the 
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Figure 2. 3-NP Dose-effect relations on LDH, lactate and pyruvate efflux into corticostriatal slice 
cultures. In two independent experiments, one-week-old interface cultures were exposed to 3-NP 
dissolved in culture medium. Before 3-NP exposure, 24 hours after 3-NP exposure and after a 24 hours 
recovery period, the efflux of LDH, lactate and pyruvate was measured in the culture medium to 
determine cellular degeneration and metabolic activity, respectively. Additionally the lactate/pyruvate ratio 
is shown. Bars represent standard errors. 
 
neuropil, supports the notion of apoptosis as a mode of 3-NP-induced neuronal 
death. If even more specific markers of apoptosis, like activated caspases, could 
be demonstrated in the 3-NP-treated striatum, apoptosis would become even 
more likely. 
 In primary cell cultures, both excitotoxic necrosis and apoptosis are 
implicated in cell death induced by metabolic impairment [21]. In dissociated 
hippocampal cultures exposed to 3-NP, Pang and Geddes [9] found both necrotic 
cell death characterized by cell swelling and nuclear shrinkage, and a delayed and 
more slowly evolving apoptotic cell death resulting in nuclear fragmentation. The 
mode of cell death is linked to mitochondrial dysfunction of the injured neuron 
[21], meaning that low doses of 3-NP induce less damage and an apoptotic-like 
cell death, while higher doses result in acute injury and necrotic neurons, 
although apoptosis could still occur in longer surviving neurons. Moreover, 
Portera-Cailliau et al. [22] showed that after excitotoxic lesions neuronal death in 
the striatum of newborn rats represent a morphological apoptosis-necrosis 
continuum, which depends on cell type, location and brain maturity. Our data are 
in line with their observations. Striatal neurons in newborn slice cultures may 
3-NP neurotoxicity in rat corticistriatal slice cultures   79 
 
have a higher potential vulnerability to 3-NP than cortical neurons, in being less 
mature and having less resistance to extensive mitochondrial dysfunction. 
Therefore, it is attractive to speculate that in our model the more severely 
affected striatal neurons underwent necrosis whereas less vulnerable striatal and 
cortical neurons were directed into the slower apoptotic pathway. 
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Abstract 
 
In murine corticostriatal slice cultures, we studied the protective effects of the 
bioenergetic compound creatine on neuronal cell death induced by the 
mitochondrial toxin 3-nitropropionic acid (3-NP). 3-NP caused a dose-dependent 
neuronal degeneration accompanied by an increased lactate dehydrogenase (LDH) 
activity in the cell culture medium. An increased ratio of lactate to pyruvate 
concentration in the medium suggested that metabolic activity shifted to 
anaerobic energy metabolism. These effects were predominantly observed in the 
24 hours recovery period after 3-NP exposure. Creatine protected against 3-NP 
neurotoxicity: LDH activity was reduced and aerobic respiration of pyruvate was 
stimulated, which resulted in lower lactate levels and less cell death. In both 
striatum and cortex, apoptosis in 3-NP-exposed slices was demonstrated by 
increased activation of the pro-apoptotic protein caspase-3 and by numerous cells 
exhibiting DNA fragmentation detected by the terminal transferase-mediated 
biotinylated-UTP nick end-labeling (TUNEL) technique. Creatine administration 
to the 3-NP-exposed corticostriatal slices resulted in a reduced number of 
TUNEL-positive cells in the recovery period. However, in the striatum, an 
unexpected increase of both TUNEL-positive cells and caspase-3-immunostained 
cells was observed in the exposure phase in the presence of creatine. In the 
recovery phase, caspase-3-immunostaining decreased to basal levels in both 
striatum and cortex. These findings suggest that 3-NP-induced neuronal 
degeneration in corticostriatal slices results from apoptosis that in the cortex can 
be prevented by creatine, while in the more vulnerable striatal cells it may lead to 
an accelerated and increased execution of apoptotic cell death, preventing further 
necrosis-related damage in this region. 
 
 
Introduction 
 
The mitochondrial toxin 3-nitropropionic acid (3-NP) induces metabolic stress, 
resulting in neurodegeneration of the basal ganglia and movement disorders in vivo. 
In aged rats, chronic administration of 3-NP causes selective striatal lesions [1,2], 
and this effect has been used as a model for the neuropathology of Huntington's 
disease (HD) [3]. 3-NP is an irreversible inhibitor of the enzyme succinate 
dehydrogenase (SDH), which functions both in the tricarboxylic acid cycle and 
electron transport chain complex II-III [4-6]. 3-NP impairs energy metabolism by 
inhibiting SDH which leads to adenosine triphosphate (ATP) depletion and the 
accumulation of lactate [5,7]. The precise mechanism of SDH inactivation by 3-NP 
remains essentially unclear. As a neurotoxin, 3-NP has been applied in striatal and 
hippocampal cell cultures [8,9] as well as in organotypic slice cultures [10-13]. 
Systemically administered 3-NP is able to induce neuronal apoptotic cell death in 
the striatum [13,14]. 
Mitochondrial dysfunction by 3-NP interferes with ATP synthesis and 
causes oxidative stress in neurons [5] which may be prevented by administration 
of creatine, a compound that improves energy metabolism. Creatine, together 
with the enzyme creatine kinase, constitutes an intricate cellular energy buffering 
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and transport system, connecting sites of energy production, like mitochondria 
with sites of energy consumption [15]. Creatine increases phosphocreatine levels 
and ATP generation, stabilizes intracellular calcium concentrations and inhibits 
the activation of the mitochondrial permeability transition pore [16,17]. Most of 
these activities of creatine can be linked to prevention of the induction of 
apoptotic cell death in neurons. 
In this report, we studied the possible neuroprotective effects of creatine in 
cultured corticostriatal brain slices of one-day old mice [18-20], and exposed 
these to 3-NP for 24 hours, in the presence or absence of creatine. We 
hypothesized that creatine supplementation would offer protection against ATP 
depletion. Both after the 3-NP incubation and after a recovery period of 24 hours 
in culture medium with or without creatine, the 3-NP neurotoxicity was evaluated 
morphologically using standard histological staining techniques and quantified by 
measuring biochemical indicators for cell death and altered metabolic activity in 
the culture medium. Immunohistochemical staining of the pro-apoptotic protein 
caspase-3 and nuclear DNA fragmentation visualized by the terminal transferase-
mediated biotinylated-UTP nick end-labeling (TUNEL) were performed to detect 
apoptotic cell death. 
 
 
Material and Methods 
 
Corticostriatal slice cultures 
 
Corticostriatal slice cultures were prepared using a modified [13] interface culture 
method, originally described by Stoppini et al. [20]. In brief, one-day old BALB/c 
mouse pups were sacrificed, their forebrains quickly removed under sterile 
conditions, and embedded in one drop of agarose. Transverse, 250 µm thick 
vibratome sections through the entire forebrain were cut and were collected in 
chilled Gey's balanced salt solution with D-glucose (final concentration 11 mM). 
Four adjacent frontal corticostriatal slices of each hemisphere were placed on a 30 
mm membrane insert (Millicell-CM, 0.4 µm; Millipore Corp. Bedford, MA, USA) 
in a 6 well culture tray. Each well contained 1 ml of medium, consisting of 25% 
inactivated horse serum, 25% Hank’s balanced salt solution and 50% OPTI-MEM 
culture medium, supplemented with D-glucose (final concentration 11 mM) and 
penicillin/streptomycin (100 IU/ml) (all from Gibco Brl, Life Technologies Ltd., 
Paisley, Scotland). The culture trays were placed in an incubator at 37°C with 5% 
CO2. After 3 days, the culture medium was replaced by 1 ml of serum-free 
Neurobasal medium, supplemented with D-glucose (final concentration 28 mM), 
L-glutamine (1 mM), 2% B-27 and penicillin/streptomycin (100 IU/ml) (all from 
Gibco Brl). During the culturing period, the slices were regularly examined by 
light and phase contrast microscopy. 
 
 
84  Chapter 6 
 
3-NP exposure experiments and creatine neuroprotection 
 
The dose-response neurotoxicity of 3-NP (Sigma, St. Louis, MO, USA) was 
studied in one-week-old interface cultures by exposure to 3-NP (dissolved in 
Neurobasal medium in concentrations varying from 50 µM to 500 µM) for 24 
hours with n=7 membrane inserts for each concentration and n=8 for controls. 
This was followed by a recovery period of 24 hours in normal Neurobasal 
medium. Parallel control experiments were performed without 3-NP in the 
culture medium. 
 For the creatine neuroprotection experiments, one-week-old corticostriatal 
slice cultures were exposed to 200 µM 3-NP for 24 hours dissolved in Neurobasal 
medium and supplemented with creatine monohydrate (Fluka AG, Buchs, 
Switzerland). The dose-effect of creatine on 3-NP neurotoxicity was studied using 
creatine concentrations varying from 6 mM to 24 mM (n=4-6 membrane inserts 
for each creatine concentration; n=7 for controls). The 3-NP incubation period 
was followed by a recovery period of 24 hours in normal Neurobasal medium, 
supplemented only with creatine. Parallel control experiments were performed 
without 3-NP administration to the culture medium but supplemented with 0 
mM, 12 mM and 24 mM creatine (n=4 membrane inserts for each creatine 
concentration), respectively. 
 
 
Metabolic markers in culture medium 
 
Lactate dehydrogenase (LDH), lactate and pyruvate concentrations in the medium 
were measured after 24 hours 3-NP exposure as well as after the 24 hours 
recovery period, and compared with control slices to quantify changes in cellular 
degeneration and metabolic activity. LDH, lactate and pyruvate concentrations (in 
U/L) were analyzed using a Cobas Mira automatic turbidometric analyzer (ABX, 
Eindhoven, the Netherlands) according to the manufacturer's instructions. LDH 
is an indicator for cell damage, whereas the levels of lactate and pyruvate give 
insight into the amount of mitochondrial stress, which is characterized by a rise 
of anaerobic metabolism resulting in a shift from glucose to lactate. 
 
 
Histological studies 
 
After the 3-NP and creatine exposure, slice cultures were fixed in 4% 
paraformaldehyde in PBS for 30 minutes, stained for NADPH-diaphorase while 
they were still attached to the insert membrane to obtain an overview of the 
organotypic organization of the slices and to demonstrate gross effects of 3-NP 
neurotoxicity. NADPH-diaphorase-stained interneurons are generally less 
vulnerable to 3-NP-induced cell death in comparison to medium-sized spiny 
neurons. Slices were first permeabilized for 15 minutes in 0.1 M Tris/0.1% 
Triton-X-100, followed by a 15 minutes reaction in 0.1 M Tris/0.1% Triton-X-
100 with 0.05% ß-nicotinamide-adenine-dinucleotide-phosphate-reduced 
tetrasodium salt (ß-NADPH) and 0.0125% nitrotetrazolium blue chloride (both 
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from Fluka AG) at 37°C. The reaction was terminated with ice-cold 0.1M Tris 
buffer, whereafter slices were kept in a 20% sucrose solution in PBS at 4°C for at 
least 24 hours. For staining with cresylviolet, anti-caspase-3 or TUNEL, brain 
slices were frozen using liquid nitrogen, embedded in Tissue-Tek (O.C.T. 
compound, Sakura, Japan), and cut into 5 µm thick frontal sections. Cryosections 
were stained with cresylviolet or immunostained using a rabbit polyclonal 
antibody directed against activated caspase-3 protein resulting from cleavage 
adjacent to (Asp175) (dilution 1:100 in PBS/1% BSA; Cell Signaling Technology 
Inc., Leusden, the Netherlands). Endogenous peroxidase activity was blocked by 
incubation in 0.3% H2O2 in PBS for 10 minutes, and the primary antibody was 
incubated overnight at 4°C. Antibody binding was visualized with a secondary 
biotinylated goat anti-rabbit antibody (Vector Laboratories, Burlingame, CA, 
USA, dilution 1:200 in PBS/1% BSA), followed by avidin-biotin-peroxidase-
complex (Vectastain Elite, Vector Laboratories), and processed with 
diaminobenzidine (DAB; Sigma) and H2O2. The signal of the reaction product 
was enhanced by incubating sections for 5 minutes in 0.5% copper sulphate in 
saline, and sections were counterstained with hematoxylin. To assess non-specific 
binding, the primary antibody was omitted. Nuclear DNA fragmentation was 
visualized in cryosections using the Apoptag™ kit (Intergen Company, 
Gaithersburg, MD, USA) for terminal transferase-mediated biotinylated-UTP nick 
end labeling (TUNEL) according to the manufacturer’s recommendations. 
TUNEL-positive cells were labeled using DAB/nickel as a chromophore and 
counterstained using hematoxylin. For double-labeling, cryosections were first 
labeled by TUNEL, followed by caspase-3 immunostaining, both performed as 
described above. 
Results were obtained by microscopic evaluation of cresylviolet, caspase-3 
and TUNEL-labeled cryosections, in which labeled neurons were identified by 
virtue of their typical neuronal cell morphology and after counterstaining with 
hematoxylin. A semi-quantitative method was used to analyze the numbers of 
neurons and expression level of apoptosis-related markers, with indications 
varying from many or strong (+++), moderate (++), low (+), and loss (-). 
Neuronal loss and caspase-3 and TUNEL-positive cells were estimated in sections 
using a 20x objective. Digital images were captured using a Sony video camera 
mounted on a Zeiss Axioscope 2 plus and Adobe® Photoshop software. 
 
 
Results 
 
3-NP dose effect on metabolic activity and neuronal loss in corticostriatal slice 
cultures 
 
LDH activity in the medium increased in response to increasing concentrations of 
3-NP exposure (Fig. 1A). Remarkably, this increased LDH efflux was only 
observed in the 24 hours recovery period after 3-NP exposure, and not during the 
initial 24 hours exposure period. A four to eight-fold enhanced LDH activity was 
found after exposure to 250 and 500 µM 3-NP compared with controls. In 
contrast, the lactate concentration in the  medium increased  two to three times in  
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Figure 1. 3-NP-dose effect on neuronal degeneration and creatine neuroprotection in 3-NP-exposed 
slices, as assessed by markers of cell death and metabolic activity. 3-NP dose-effect relations on LDH 
(A,E), lactate (B,F) and pyruvate (C,G) concentration and the lactate/pyruvate ratio (D,H) in mouse 
corticostriatal slice cultures. One-week-old interface cultures were exposed to 3-NP concentrations 
ranging from 50 µM to 500 µM to determine a 3-NP dose effect (1A-D), whereas other brain slices were 
exposed to 200 µM 3-NP supplemented with increasing concentrations of creatine to establish 
neuroprotection. After 24 hours 3-NP exposure and 24 h recovery period, the efflux of LDH, lactate and 
pyruvate, and the lactate/pyruvate ratio were analyzed in culture medium to demonstrate cellular 
degeneration induced by 3-NP and neuronal survival in creatine-treated brain slices and to determine 
altered cellular energy metabolism. Data are means ± S.E.M. 
 
response to 3-NP exposure during the 3-NP incubation but returned to normal 
values in the following recovery period (Fig. 1B). The concentration of pyruvate 
decreased during both the 3-NP exposure and the recovery phases, although this 
decrease was most obvious in the 3-NP incubation period and with higher 3-NP 
doses  (Fig. 1C).  As a result, the lactate to pyruvate ratio was increased during 
the exposure period in comparison to control slices (Fig. 1D). 
 In cresylviolet-stained cryosections of the cultured murine corticostriatal 
slices, a similar dose-dependent effect of 3-NP on neurotoxicity was 
demonstrated. Minimal loss of neurons was observed in the striatum after 
exposure to 100 µM 3-NP, but after exposure to 200 µM or higher 3-NP 
concentrations, cell loss dominated in both striatum and cortex (see Figs. 2A,B). 
This preferential vulnerability of striatal neurons in murine corticostriatal slices to 
3-NP neurotoxicity was similar to our previous findings in rat corticostriatal slices 
[13]. Furthermore, increase of 3-NP doses led to an increasing number of Nissl-
stained cells with nuclear condensation or fragmentation. The 3-NP-induced 
neuronal degeneration in our corticostriatal slice cultures was most striking in the 
24 hours recovery period after 3-NP incubation. 
 
 
Creatine protection of neuronal degeneration in 3-NP-exposed slices 
 
To study whether and how 3-NP neurotoxicity could be antagonized, one-week-
old slice cultures were exposed to 200 µM 3-NP in the presence of creatine, in 
concentrations that ranged from 6 to 24 mM. With increasing creatine 
concentrations, we found substantially lower LDH activity in the medium and 
enhanced neuronal survival in comparison to untreated 3-NP-exposed slices. This 
neuroprotective effect of creatine was already observed at a concentration of 12 
mM creatine, whereas concentrations of 18 and 24 mM resulted in almost 
complete reversal to base-line levels. Creatine protection was predominantly 
noted in the 24 hours recovery phase after 3-NP exposure (Fig. 1E). Furthermore, 
creatine induced a dose-dependent two to eight-fold decrease in lactate 
concentration in both exposure and recovery phase (Fig. 1F). The concentration 
of pyruvate was marginally reduced in both the 3-NP exposure and recovery 
phases of creatine-treated as well as untreated brain slices in comparison to 
control slices (Fig. 1G). This led to a decrease in lactate/pyruvate ratio with 
increasing doses of creatine as illustrated in Fig. 1H. Data presented in Figures 
1A-D and Figures 1E-H were obtained in independent experiments of at least 
three different cultures each. Although, both lactate and pyruvate levels in the 
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medium of controls are twice as high as in Figures 1B-C in comparison to figures 
1F-G, their lactate/pyruvate ratio is approximately the same, indicating that their 
metabolic activity is similar which is important when these slices are treated with 
3-NP or co-treated with 3-NP and creatine. 
Neuronal survival after creatine supplementation was shown in cresylviolet-
stained cryosections of brain slices that demonstrated reduced neuronal loss and 
nuclear fragmentation in both striatum and cortex in comparison to untreated 3-
NP-exposed brain sections (Figs. 2B-D). However, the number of cells with 
nuclear condensation was increased in creatine-treated brain slices, especially 
during the 3-NP exposure period and in the striatum (Fig. 2C). Furthermore, the 
striatum was temporarily and relatively more sensitive to 3-NP neurotoxicity than 
the cortex, as could be demonstrated by neuronal cell loss in the exposure phase 
and therefore probably less susceptibility to creatine neuroprotection, resulting in 
reduced striatal neuron survival in comparison to the cortex. In addition, in 30-
40% of the 3-NP-exposed slices supplementation of high creatine (18 and 24 mM) 
resulted in macroscopically visible tissue damage in the striatum after the 24 
hours recovery period. This is in contrast to most untreated 3-NP-exposed brain 
slices, in which the striatum was almost totally desintegrated compared to 
creatine-neuroprotected brain slices after both the exposure and recovery period. 
Summarizing these morphological results, we found that creatine was especially 
neuroprotective in the recovery phase, with the cerebral cortex particularly 
demonstrating a marked survival of cells. 
 
 
Creatine effect on the expression of apoptotic markers in 3-NP-exposed brain 
slices 
 
3-NP induced neuronal degeneration with cresylviolet-stained cells exhibiting 
apoptotic features such as nuclear fragmentation and condensed nuclei in both 
striatum and cortex of the murine slice cultures (see Figs. 2B-D). Apoptotic cell 
death in 3-NP-exposed brain slices was indicated by activation of the pro-
apoptotic protein caspase-3 in cells with a condensed nucleus or with fragmented 
nuclei, and by numerous cells exhibiting DNA fragmentation  detected  by  the  
terminal  transferase-mediated  biotinylated-UTP  nick  end- labeling (TUNEL)  
technique. In the 3-NP exposure phase, these apoptotic markers were increased in 
both striatum (Figs. 2E,F,I,K) and cortex (Figs. 2H,M) in comparison to control 
brain slices, whereas in the subsequent recovery period a different expression 
pattern was observed. The cortex demonstrated even more TUNEL-positive cells, 
although diffusely labeled (not shown), whereas in both cortex and striatum 
expression of activated caspase-3 was reduced and comparable to control brain 
slices (see Fig. 2E and Table 1). 
 3-NP-exposed brain slices that were supplemented with 12 mM creatine 
were used to show neuroprotection and temporal changes in expression of 
apoptotic markers after co-treatment with creatine. This was based on the 
morphological findings that supplementation of 18 and 24 mM creatine could 
result in severe tissue damage of the 3-NP-exposed striatum after the 24 hours 
recovery period, while biochemical results demonstrated that treatment with 12
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Table 1. 3-NP-neurotoxicity, creatine neuroprotection and expression of apoptotic markers in mouse 
corticostriatal slices 
Brain slices 
 
Striatum* 
Nissl 
Striatum § 
caspase-3 
Striatum § 
TUNEL 
Cortex * 
Nissl 
Cortex § 
caspase-3 
Cortex § 
TUNEL 
 Exposure/Recovery Exposure/Recovery Exposure/Recovery Exposure/Recovery Exposure/Recovery Exposure/Recovery
Control          **/**           +/+           +/+         ***/***           +/+           +/+ 
200µM 3-NP            */- 
   cond↑/ cond↑ 
       ++/+        ++/++           **/- 
Cond↑,frag↑/ # 
       ++/+        ++/+++ 
200µM 3-NP + 
12 mM creatine 
           */* 
cond↑, frag↑/ # 
     +++/+      +++/+          **/** 
   cond↑/# 
       ++/+        ++/++ 
 
Exposure = 24 hours 200 µM 3-NP exposure period; Recovery = 24 hours recovery period following 3-NP exposure period 
* Number of neurons: *** = many, >400; ** = moderate, 40-400; * = low, 5-40; - = 0-5 neurons visible per microscopic field (20x 
objective). The presence of apoptotic features are indicated by the following abbreviations: cond↑= increased condensed nuclei; 
frag↑= increased fragmented nuclei; # = no fragmented or condensed nuclei 
§ Level of expression: +++ = strong, >50; ++ = moderate, 5-50; + = low, 1-5 positive cells in views obtained with 20x objective 
 
 
mM creatine was already neuroprotective. Administration of 12mM creatine was 
neuroprotective against 3-NP-induced neurotoxicity, resulting in less 
neurodegeneration (Figs. 2B-D) and a markedly decreased number of TUNEL-
positive cells in both the cortex (not shown) and striatum (Fig. 2K). In 3-NP-
exposed brain slices that were supplemented with 12 mM creatine in the culture 
medium, less TUNEL-positive cells were present in the striatum (Fig. 2K) and the 
cortex (not shown). This neuroprotective effect was observed in the 24 hours 
recovery period. During exposure to 3-NP, creatine led to an unexpected increase 
of TUNEL-labeled cells (Figs. 2K,L) and caspase-3-immunostained cells in the 
striatum (Figs. 2F,G). In the 3-NP exposure phase, the enhanced cytoplasmic 
caspase-3 immunostaining was mainly detected in cortical and striatal cells 
exhibiting nuclear fragmentation (Figs. 2F,G). In the recovery phase, caspase-3 
immunostaining decreased to basal levels in both 3-NP-exposed striatum and 
cortex, comparable to caspase-3 expression in control brain slices (Fig. 2E). When 
we looked at an earlier time point, i.e. at 12 hours 3-NP exposure to monitor 
possible rapid neuroprotective effects of creatine, we found for both apoptotic 
markers caspase-3 (Figs. 2N,P) and TUNEL (Figs. 2O,Q) an increased number of 
positive cells in the striatum of creatine-treated brain slices. In the cortex of these 
12 hours creatine-treated brain slices, only caspase-3 expression, but not TUNEL, 
was enhanced (not shown). Table 1 shows a summary of the above described 
morphological results for 3-NP-induced neurotoxicity, creatine neuroprotection 
and expression of apoptotic markers examined in the three different treated groups 
of cultured mouse brain slices. 
 
 
Discussion 
 
The present study shows that the mitochondrial toxin 3-NP induces dose-
dependent neuronal cell death in mouse organotypic corticostriatal slice cultures 
and shifted metabolic activity towards anaerobic energy metabolism. Exposure to 
3-NP accelerated glycolysis in an attempt to maintain cellular energy levels, 
leading to enhanced anaerobic metabolism with the production of high and 
possible toxic lactate levels [11]. In our 3-NP-exposed slices, increased lactate in 
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the medium marked mitochondrial inhibition and the shift towards anaerobic 
energy metabolism that could precede neuropathological events, while elevated 
LDH activity is a late phenomenon occurring in the recovery period serving as a 
measure of actual cell death. The data in this report are comparable with other in 
vitro studies using the neurotoxin 3-NP in rat corticostriatal slices cultured in high 
glucose medium [10,11,13]. However, our mouse slice cultures showed higher 
resistance to metabolic stress induced by 3-NP and required a higher 3-NP dose 
to induce neuronal death in comparison to rat corticostriatal slices [13]. A similar 
finding was noted in an in vivo study on the effect of 3-NP on rat versus mouse 
striatum [21]. 
 Of more interest is that supplementation of 12 mM creatine and higher to 
3-NP-exposed cultured brain slices was neuroprotective: it reduced the lactate and 
LDH concentrations in the medium and stimulated aerobic respiration of 
pyruvate resulting in less lactate acidosis and less neuronal degeneration in the 
brain slices. This neuroprotective effect of creatine was mainly observed in the 24 
hours recovery period, which is the phase with marked neuronal loss and 
increased efflux of LDH activity from the 3-NP-exposed corticostriatal slices. 
Increased neuronal survival after creatine administration is in line with other in 
vitro and in vivo studies, reporting that creatine protects against depletions of 
phosphocreatine and adenosine triphosphate (ATP), reduces striatal lactate 
concentrations and attenuates 3-NP-induced striatal lesions [16,17,22]. In another 
report using cortical and striatal astrocytes in vitro, creatine buffered against toxin-
induced depletions of calcium and delayed increases in intracellular calcium 
produced by 3-NP [23]. Furthermore, creatine appears to have direct effects on 
ATP-dependent glutamate uptake [24], thereby reducing extracellular glutamate 
concentrations and contributing to its neuroprotective effects against glutamate 
and β-amyloid toxicity in cultured hippocampal neurons [25]. In summary, the 
neuroprotective effect of creatine is most likely multifactorial, including buffering 
of phosphocreatine and ATP, improving citric acid cycle activity, increasing 
glutamate uptake, stabilizing intracellular calcium, and inhibiting activation of the 
mitochondrial permeability transition pore [11,15-17,23,26], of which the latter is 
closely related to apoptotic cell death or necrotic cell death, depending on the rate 
of ATP consumption. At this moment, we have no evidence that glutamate 
uptake, predominantly by glial cells, is impaired in 3-NP-exposed corticostriatal 
slice cultures and that high intracellular calcium levels produced by 3-NP are 
reduced by creatine treatment. Therefore, our hypothesis on the neuroprotective 
mechanism of creatine in 3-NP-exposed brain slices is primarily based on the 
biochemical alterations. We hypothesize that in our 3-NP mouse slice model, 
creatine supplementation is neuroprotective by providing more phosphocreatine 
and preserving ATP levels that leads to less stimulation of anaerobic glycolysis, an 
intensified pyruvate metabolism and, consequently, less accumulation of lactate. 
 Creatine administration prevented both neurodegeneration and apoptotic 
cell death in the recovery period of 3-NP-exposed slices when compared to 
untreated 3-NP-exposed brain slices. Unexpectedly, during the 3-NP exposure 
phase creatine administration strongly induced apoptosis in striatal cells that led 
to increased numbers of TUNEL-positive cells exhibiting DNA fragmentation 
and an increased activation of the pro-apoptotic protein caspase-3. Both 
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apoptotic markers were already activated in the first 12 hours of 3-NP exposure 
in the striatum, but returned to basal levels in the following recovery period. 
These findings suggest that most energetically compromised neurons in 3-NP-
treated corticostriatal slices that would die through apoptosis can be rescued by 
energy booster creatine, while in striatal cells it may instead lead to increased and 
completed execution of apoptotic cell death, possibly to prevent further damage 
caused  by  the  more slowly occurring process of cell lysis. The apoptotic process 
itself is ATP-dependent and requires energy that may be provided by creatine in 
3-NP-injured striatal cells in order to initiate apoptosis through mitochondrial 
permeability transition pore-dependent activation of caspase-3. Conversely, ATP 
depletion during the early phases of apoptosis can preclude caspase activation, 
and consequently switch execution of cell death towards mitochondrial 
permeability transition pore-dependent necrosis [27]. On the other hand, creatine 
is able to delay decreases in ATP and could prevent 3-NP-induced activation of 
mitochondrial permeability transition pore that would have triggered apoptosis in 
3-NP-exposed cortical neurons [28]. 
 This apparent paradox with regional susceptibility for creatine 
neuroprotection could result from the different neuronal vulnerability to 3-NP-
induced mitochondrial dysfunction, as we noticed for the striatum in our 3-NP-
exposed cultured mouse slices and which was demonstrated in rat brain slices as 
well [11,13]. Striatal cells are more sensitive to rapid changes in intracellular ATP 
levels and cell death than cortical neurons after altering the cellular energy status 
by 3-NP [29]. Furthermore, 3-NP-induced apoptotic cell death in organotypic 
slice cultures seems to be highly dependent on the developmental stage and 
region [11], which is in line with our previous findings that both apoptosis and 
necrosis are involved in the striatum of 3-NP-exposed slices, whereas only 
apoptotic cell death occurred in the cortex [13]. In other neuronal cultures, 3-NP 
may trigger apoptosis, necrosis, or both modes of cell death [9,29] but this 
depends on the culture system used, the severity of the insult [30] and the energy 
balance of the cell [27,31]. In our 3-NP brain slice model, and under ATP-
supplying conditions using creatine, 3-NP exposure induced and increased the 
number of apoptotic cells in the striatum, suggesting that the presence of 
sufficient intracellular ATP favours a shift from necrosis to apoptosis through 
caspase-3 activation. This may indicate that creatine had partly neuroprotective 
effects in the 3-NP-exposed striatum as well. Although apoptotic cell death was 
stimulated by co-treatment with creatine, we can conclude from our data that 
overall cell death and predominantly necrotic cell death, as assessed by 
cresylviolet-staining and by LDH measurements, was reduced in the striatum. 
 The 3-NP model of striatal neurodegeneration has been used as a model 
for the neuropathology of Huntington's disease (HD) [3]. The present study 
demonstrates that organotypic slice cultures, prepared from the cerebral 
hemispheres of neonatal mice, can be maintained remarkably well in culture and 
are easy to manipulate pharmacologically, providing a model system to screen new 
therapies in neurodegenerative diseases, such as HD. Several lines of evidence 
support a role of impaired energy metabolism in the pathogenesis of HD [7], 
based on elevated lactate in the cortex and basal ganglia of HD patients [32] and 
reductions in mitochondrial electron transport enzymes in HD postmortem tissue 
92  Chapter 6 
 
 
 
Figure 2. Creatine neuroprotection against 3-NP toxicity (2A-D) and creatine effects on the expression of 
apoptosis-related markers in 3-NP-exposed corticostriatal slices (2E-Q). 
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Figure 2. Creatine neuroprotection against 3-NP toxicity (2A-D) and creatine effects on the expression of 
apoptosis-related markers in 3-NP-exposed corticostriatal slices (2E-Q). Cryosections of the striatum of a 
control brain slices (A,E,I), 200 µM 3-NP-exposed slices (B; enlarged in C,F,K) and 200 µM 3-NP-
exposed slices with 12 mM creatine (D,G,L) (all exposure phase). Cresylviolet-staining shows neuronal 
degeneration in the striatum with increased cell loss, many injured cresylviolet-stained cells exhibiting 
apoptotic features such as condensed nuclei (arrow) and nuclear fragmentation (arrowhead) in 3-NP-
exposed cryosections in comparison with controls (A-C). Creatine supplementation was neuroprotective 
against 3-NP-induced neurotoxicity resulting in survival of neurons (D). Caspase-3-immunostaining shows 
activation of pro-apoptotic protein caspase-3 in 3-NP-exposed slices in comparison with controls (E,F). 
Creatine supplementation resulted in an unexpectedly enhanced caspase-3 expression in striatal cells, 
usually localized in the cytoplasm of cells with fragmented nuclei (G, arrowhead), whereas in the recovery 
period caspase-3 expression decreased to basal levels. Increased caspase-3 expression was found in 3-NP-
exposed cortex (H, exposure phase), similar to what was observed in the cortex of creatine-treated 3-NP-
exposed slices. TUNEL-labeled cells were found in the 3-NP-exposed striatum exhibiting darkly stained 
nuclei (arrow) or DNA fragmentation (I,K arrowhead). In the exposure phase, creatine co-treatment 
resulted in an increased number of TUNEL-positive cells (L). However, in the recovery period, TUNEL 
labeling was markedly reduced. An increased number of TUNEL-positive cells was found in the cortex of 
3-NP-exposed slices (M, exposure phase), whereas in creatine-neuroprotected 3-NP-exposed slices, 
TUNEL-labeling in the cortex was reduced. Caspase-3 immunostaining and TUNEL labeling of 
cryosections of the striatum of a 200 µM 3-NP-exposed slice (N,O) and 200 µM 3-NP-exposed slice with 
12 mM creatine (P,Q), both at 12 hours 3-NP exposure phase, shows activation of caspase-3 expression 
(O) and abundance of TUNEL-positive cells (Q) in the creatine-treated 3-NP-exposed striatum in 
comparison to untreated 3-NP-exposed slices; both scale bars represent 15 µm and 2A applies also for the 
rest of Fig. 2. All immunostained cryosections were counterstained using hematoxylin. NADPH-
diaphorase interneurons (*) are labeled as well showing dark blue stained dendrites or cytoplasm. 
 
[33,34]. Compounds that improve energy metabolism may reduce neuronal 
dysfunction and loss with creatine increasing phosphocreatine levels and ATP 
generation and reducing striatal lactate concentrations in vivo produced by 3-NP 
[17]. This neuroprotective effect of creatine was observed in two different 
transgenic mouse models of HD, even after onset of clinical symptoms in these 
mice [15,16,35,36]. In our 3-NP in vitro model creatine modified 3-NP 
neurotoxicity and improved neuronal survival predominantly in the cortex and to 
a lesser extent in the more vulnerable striatum. This regional difference for 
creatine neuroprotection may be dose-dependent or influenced by the larger 
existing energy reserves in cortical cells [16,25,37]. Moreover, our conclusions are 
in part arguable because improvement of energy generation by creatine may in 
fact stimulate apoptosis instead of preventing neuronal cell death. The question 
arises if this limited and selective neuroprotection efficacy noticed in our study 
for creatine is to be expected for other agents that may have beneficial effects on 
energy metabolism such as co-enzyme Q10 which are currently used in clinical 
trials in an attempt to slow down the disease process in neurodegenerative 
disorders [7]. 
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Summary and Discussion 
 
This thesis investigates the possible role of apoptosis in Huntington's disease 
(HD). HD is caused by an expanded polyglutamine tract in the N-terminal region 
of the huntingtin protein leading to specific neostriatal and regional cortical 
neurodegeneration. The sequence of events that leads to this selective neuronal 
death is unknown, but inappropriate activation of apoptosis may be involved, 
whether as the initial cause or as a consequence of the disease. To study 
mechanisms of apoptotic cell death in HD, we developed animal models using the 
mitochondrial toxin 3-nitropropionic acid (3-NP) that induces specific neuronal 
death in the striatum. The studies described in this thesis focussed on the 
occurrence of apoptosis in the 3-NP in vivo rodent model of HD, in organotypic 
brain slice cultures, and in human HD brains. In addition, we examined 
neuroprotective effects of creatine on 3-NP neurodegeneration in the 3-NP in 
vitro animal model. These issues were addressed in Chapters 2-6 and are 
summarized below. Furthermore, in this chapter we discuss our 3-NP 
neurotoxicity results and compare the expression patterns of apoptotic markers 
obtained in HD and in 3-NP animal models. Finally, future prospects of HD 
research and potential therapies are suggested. 
 
 
1. Summary 
 
In Chapter 1 the theoretical background of the three major topics, i.e. 
Huntington's disease, apoptosis, 3-NP animal models of HD and the scope of this 
thesis is given. The clinical and neuropathological characteristics of HD and the 
huntingtin mutation are described, while factors that may contribute to the 
selective vulnerability of neostriatal neurons are listed. Furthermore, 
characteristic features and techniques for the detection of apoptotic cell death, 
key components of the apoptosis cascade and several apoptotic pathways are 
given. The 3-NP animal model of HD (developed by Beal et al. between 1990 and 
1993), the use of 3-NP-exposed organotypic slice cultures of rodent brains and 
HD transgenic mice models are described. 
 In Chapter 2, the 3-NP animal model is presented in which striatal neuronal 
degeneration was used as a neuropathological model of HD to study mechanisms 
of apoptotic cell death. We used osmotic pumps for chronic systemic 
administration of the neurotoxin 3-NP that induced neurodegeneration and 
reactive gliosis in the striatum. Animals showed variable susceptibility to the 
neurotoxin and three distinct types of striatal lesions (severe, mild and subtle) 
were distinguished using both conventional staining and immunohistochemical 
labeling of astrocytes and neurons. The severe type lesion demonstrated a marked 
neuronal degeneration in the lesion core and gliosis in the margins of the lesion, 
whereas the mild type of lesion was characterized by a less pronounced neuronal 
loss accompanied by reactive astrocytosis throughout the lesion. A behavioural 
test that examined the retraction capacity of the hind limbs of 3-NP-treated and 
untreated rats was used as a sensitive indicator of striatal pathology. This paw test 
detected also clinical abnormalities associated with the subtle lesion type that 
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displayed compromised ‘dark’ neurons, only, in the striatum. These dark neurons 
were present in all lesion types and were immunocytochemically characterized as 
γ-aminobutyric acid and substance P containing spiny neurons. These results 
indicate that systemic administration of 3-NP to rats induces a wide spectrum of 
striatal pathology, of which the morphology of the mild lesion type resembles the 
characteristic HD neuropathology most closely. 
In Chapter 3 of this thesis, the expression patterns of several apoptosis-
related markers in the three different 3-NP striatal lesion types were examined 
using immunohistochemical techniques (Bax and Bcl-2) in combination with 
terminal deoxynucleotidyl transferase mediated biotinylated-UTP nick end 
labeling (TUNEL). The expression of apoptotic markers Bax and Bcl-2 was 
increased in all 3-NP-treated rats compared to control rats, but the increase 
varied between the striatal lesion types. Anti-apoptotic Bcl-2 was predominantly 
found in dark neurons that are present in all lesion types and was also expressed 
in a few striatal neurons at the border of the severe lesion. The apoptosis-
promoting protein Bax was enhanced in compromised dark neurons as well, but 
its expression was strongly induced in the severe lesion type that displayed a 
strong granular Bax immunoreactivity in the lesion core. Of more interest, typical 
apoptotic and TUNEL-positive cells were only observed in the striatum of 
severely affected animals, whereas TUNEL labeling was absent in the other 
lesions and in the controls. The presence of nuclear DNA fragmentation, strong 
granular Bax expression and an apparently increased Bax/Bcl-2 ratio in the centre 
of severe lesions indicated that 3-NP-induced cell death involves the activation of 
the apoptotic process. In affected dark neurons, observed in all 3-NP-treated 
animals, the expression of Bax and Bcl-2 was increased but remained relatively 
equal and lacked TUNEL labeling, suggesting that these cells were not apoptotic. 
In Chapter 4, the expression of several apoptotic markers in samples of 
human HD neostriatum, varying from Vonsattel grade 1 to severely affected 
grade 4 specimens were presented and compared with controls without 
neurological disease. Expression of Bax was increased in HD brains compared to 
controls, demonstrating a cytoplasmic expression pattern in predominantly 
shrunken and dark neurons, which were most frequently seen in grades 2 and 3. 
In HD brains, Bcl-2 immunoreactivity was markedly enhanced, especially in 
severely affected grade 4 brains, and was observed in both healthy neurons and 
dark neurons. Caspase-3, an important executioner protease, was only found in 
four HD brains of different grades and was not expressed in controls. A relatively 
prominent neuronal and glial expression of poly (ADP-ribose) polymerase 
(PARP)-immunoreactivity was observed in HD brains. Typical apoptotic and 
TUNEL-positive cells were detected only in HD brains and were especially 
present in grade 3 and 4 specimens. The findings of late apoptotic events, such as 
enhanced PARP expression and many TUNEL-positive cells in severely affected 
HD brains, indicate the involvement of apoptosis in HD. The weak caspase-3 
immunoreactivity in the caudate nucleus of HD patients suggests that caspase-
mediated neuronal death plays only a minor role in HD. 
In Chapter 5, we present an in vitro model of 3-NP-exposed organotypic 
corticostriatal slices to study mechanisms of apoptotic cell death. 3-NP 
neurotoxicity in these rat brain slice cultures was evaluated morphologically using 
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cresylviolet staining and quantified by measuring biochemical indicators for cell 
death and altered metabolic activity in the culture medium. 3-NP exposure 
induced a concentration-dependent increase in neuronal death in the striatum of 
these brain slices that was accompanied by a dramatic increase of lactate and 
lactate dehydrogenase (LDH) concentration into the culture medium, indicating 
cellular degeneration. The involvement of apoptosis in these 3-NP treated slices 
was demonstrated using TUNEL and Bax/Bcl-2 immunohistochemistry. In 3-NP-
exposed corticostriatal slices, TUNEL-positive cells were detected in both the 
striatum and the cortex but in different forms. Striatal neurons were either 
diffusely stained or showed nuclear fragmentation, whereas cortical neurons 
exhibited nuclear fragmentation. In 3-NP-exposed slices, the pro-apoptotic 
protein Bax was abundantly expressed in both the striatum and the cortex, 
whereas the anti-apoptotic protein Bcl-2 was not expressed in striatal neurons at 
all. In the cortex, Bcl-2 was weakly expressed, and was mainly observed in glial 
cells. The upregulation of pro-apoptotic Bax and the presence of DNA 
fragmentation in the 3-NP-treated corticostriatal slices suggest that 3-NP induces 
apoptotic cell death in the cortex and the striatum, but shows that necrosis is 
involved in the striatum as well. 
In Chapter 6, we focussed on the protective effects of the bioenergetic 
compound creatine on neuronal cell death induced by the neurotoxin 3-NP in 
murine corticostriatal slice cultures. 3-NP caused a dose-dependent neuronal 
degeneration accompanied by an increased LDH activity in the cell culture 
medium. An increased ratio of lactate to pyruvate concentration in the medium 
suggested that metabolic activity shifted to anaerobic energy metabolism. Of 
more interest is that supplementation of 12 mM creatine and higher was 
neuroprotective against 3-NP neurotoxicity: LDH activity was reduced and 
aerobic respiration of pyruvate was stimulated, which resulted in lower lactate 
levels and less cell death in the brain slices. In both the striatum and the cortex of 
3-NP-exposed slices, apoptosis was demonstrated by increased activation of 
caspase-3 and by numerous cells exhibiting DNA fragmentation detected by the 
TUNEL technique. Creatine administration to the 3-NP-exposed corticostriatal 
slices resulted in a reduced number of TUNEL-positive cells in the recovery 
period. However, in the striatum, an unexpected increase of both TUNEL-
positive cells and caspase-3-immunostained cells was observed in the exposure 
phase in the presence of creatine. These findings suggest that 3-NP-induced 
neuronal degeneration in corticostriatal slices results from apoptosis that can be 
prevented by creatine in the cortex, while in striatal cells it may lead to 
accelerated and increased execution of apoptotic cell death in order to prevent 
further necrosis-related damage in this region. 
 
 
2. Discussion 
 
3-NP-induced neurodegeneration in experimental models of HD 
 
In this thesis we confirm that the 3-NP in vivo animal model provides an useful 
neuropathological model to study mechanisms of apoptotic cell death in HD. 
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Chronic systemic administration of 3-NP to rats induces striatal lesions that 
mimics the HD neuropathological features of neuronal loss and gliosis. We 
distinguished three lesion types; the dark neuron pathology, the mild and the 
severe lesion type. Moreover, striatal neurodegeneration in the 3-NP model 
revealed nuclear fragmentation and chromatin condensation after cresylviolet and 
hematoxylin staining, suggestive of apoptotic-like cell death at the light-
microscopy level. Indeed, TUNEL labeling demonstrated DNA fragmentation, 
typically localized to nuclei and in apoptotic bodies in the severe striatal lesions, 
suggesting the involvement of apoptosis. However, TUNEL-positive cells were 
absent in the other lesion types. Because the TUNEL labeling assay has 
methodological limitations in demonstrating neuronal apoptosis [1-4], it needs to 
be evaluated in combination with the expression of other biochemical markers 
that are involved in the apoptotic cascade [5-7]. The expression of both Bax and 
Bcl-2 was increased in the 3-NP rat model compared to untreated animals, but 
varied between the different lesion types. Therefore, the presence of typical 
TUNEL-labeled cells in association with strong granular neuronal Bax 
immunoreactivity and the differential expression of Bax and Bcl-2 in the severe 
lesion types supported the notion that apoptosis occurred in 3-NP-induced cell 
death. This is in contrast to the non-apoptotic 3-NP-affected dark neurons that 
demonstrated a relatively equally increased expression of Bax and Bcl-2 but 
lacked TUNEL. 
Besides the 3-NP in vivo model, we used 3-NP-exposed organotypic brain 
slices as another model for studying apoptotic cell death in HD. In contrast to 
the in vivo model in which the effects of fixed doses of 3-NP were quite 
unpredictable, our corticostriatal slice cultures did demonstrate a dose-dependent 
effect of 3-NP on neuronal degeneration. Furthermore, 3-NP did induce 
apoptotic cell death in the in vitro model, as determined by Bax up-regulation, the 
presence of TUNEL-positive cells that demonstrated typical apoptotic 
morphology and an increased activation of the pro-apoptotic protein caspase-3 in 
the striatum of the corticostriatal slice cultures. Although, the diffuse TUNEL 
labeling of many nuclei in the striatum of these 3-NP-exposed slices did not 
support the occurrence of apoptosis, we suspect that these degenerating cells 
were apoptotic at first and that necrosis occurred secondary to the 3-NP induced 
apoptotic cell death. It is known that in vivo apoptotic cells are eliminated within a 
few hours but in in vitro situations, phagocytosing cells are either absent or not 
activated [8]. This may lead in time to leaky and disintegrating striatal cells, that 
represent themselves as necrotic cells with diffuse TUNEL labeling. This in vitro 
artefact is called secondary necrosis [9,10]. In other culture systems, 3-NP has 
been shown to trigger apoptosis, necrosis, or both modes of cell death [11,12], 
but this depends on the severity of the insult and the energy balance of the cell 
[13-15]. Moreover, a different neuronal susceptibility to 3-NP existed in our 3-
NP-exposed cultured slices, which is in line with other data [16]. Striatal cells 
were more sensitive to 3-NP-induced mitochondrial dysfunction than cortical 
neurons and they did reveal both modes of cell death. Interestingly, in our in vitro 
model, creatine administration modified 3-NP neurotoxicity and improved 
neuronal survival predominantly in the cortex and to a lesser extent in the 
striatum. Unexpectedly, creatine treatment was associated with an increase in 
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apoptosis in striatal cells that led to increased numbers of TUNEL-positive cells 
with increased caspase-3 activation. This suggests that the limited and selective 
neuroprotective effect of creatine is in part arguable. Most energetically 
compromised neurons in 3-NP-treated corticostriatal slices can be rescued by the 
energy booster creatine, whereas in striatal cells it may in fact stimulate apoptosis, 
possibly to prevent further necrosis-related damage caused by the more slowly 
occurring process of cell lysis. Collectively, 3-NP-treated organotypic slice 
cultures, prepared from cerebral hemispheres of neonatal rodents, can be 
maintained remarkably well in culture, are easy to manipulate pharmacologically 
with neurotoxic and neuroprotective compounds, and may provide an useful 
model system to study mechanisms of neuronal cell death in HD. 
 
 
Neuropathological and apoptotic similarities in human HD and the 3-NP 
animal model 
 
Chronic systemic administration of 3-NP to rats induces striatal pathology that 
replicates the characteristic HD neuropathology in a wide spectrum. The 
morphology of the mild striatal lesion type resembles the HD neuropathological 
features of neuronal loss and gliosis more closely than the other lesion types, and 
is in a way similar to HD brains grade 1 and 2 according to Vonsattel's 
neuropathological classification system. The neuropathology of the severe lesion 
resembles HD brains grade 3 and 4 for the marked striatal neuronal death 
associated with the reactive gliosis found in the margins of the lesion. Although, 
the severe 3-NP lesion possibly developed too fast into an advanced state to be 
representative of HD neuropathology, it may be an appropriate lesion to study 
mechanisms of cell death because of the marked striatal degeneration. The dark 
neuron pathology observed in all 3-NP-treated animals is comparable to the 
neostriatal dark neurons found in early affected HD neostriatum [17]. Both are 
suggestive of subtle striatal damage. 
We demonstrated an increased Bax/Bcl-2 immunoreactivity in HD brains. 
The up-regulation of Bax and Bcl-2 proteins was not equal in affected dark 
neurons and was maximal at different stages of HD. In most HD brains, 
increased Bax expression was found predominantly in shrunken and dark neurons 
that were most frequently seen in grades 2 and 3, whereas Bcl-2 immunoreactivity 
was markedly enhanced in severely affected grade 4 brains, and was expressed in 
both healthy neurons and in dark neurons. More importantly, neostriatal dark 
neurons in HD were not TUNEL-positive, which is in line with the observations 
in the 3-NP in vivo model. In these affected dark neurons observed in HD brains 
and in the 3-NP model as well, the level of Bax protein was probably 
counteracted by the up-regulation of Bcl-2 [18-22] that prevented further 
activation of the apoptotic process. The occurrence of similar morphological 
features of apoptotic cell death, such as typical TUNEL labeling and Bax and Bcl-
2 up-regulation, in HD brains and in the 3-NP-lesioned striatum, do favour the 
role of apoptosis in both human HD and in the rodent 3-NP in vivo model. Taken 
all these results together, the 3-NP rat model offers a good neuropathological 
model for HD and is useful for studying the possible role of apoptosis in HD. In 
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particular the mild striatal lesion type mimics HD neuropathology best, but 
displayed no apoptotic cells. Thus, the severe lesion with marked neuronal loss 
may be the most appropriate model to study mechanisms of apoptotic cell death. 
The mechanism by which apoptosis is induced in human HD and in animal 
models following 3-NP administration is unknown and requires further 
investigation. 
 
 
Enhanced expression of apoptotic markers, Bax and PARP, at different 
stages of HD 
 
In this thesis, we provided additional evidence for the hypothesis that specific 
loss of striatal medium-sized spiny GABAergic neurons in HD results from the 
inappropriate activation of apoptosis as was first demonstrated by increased 
levels of DNA breaks and TUNEL labeling in HD brains [23-27]. We showed the 
involvement of apoptosis in various HD caudate nucleus specimens by the up-
regulation of Bax, caspase-3 and PARP in association with many TUNEL-positive 
cells exhibiting typical apoptotic morphology. Interestingly, altered expression 
patterns of these apoptotic markers were found between the HD brains that 
correlated with the different grades of HD severity. Late apoptotic events, such 
as a markedly enhanced PARP expression and many TUNEL-positive cells, were 
observed in the severely affected HD brains. This indicates that apoptosis plays a 
greater role in neuronal death at the end-stage of the disease. The highest 
expression of the anti-apoptotic protein Bcl-2 was displayed in HD brains grade 
4, which suggests an increased compensatory neuroprotective role for survival of 
the remaining and possibly injured neurons in late-stage HD brains [18,22,28]. We 
hypothesized that the intrinsic caspase-mediated apoptotic cell death contributes 
to delayed loss of neostriatal neurons [29], but the few caspase-3 immunoreactive 
cells observed in only four caudate nucleus samples of HD patients did not 
support this idea. It has been reported that caspase-3 and other caspases are 
primarily activated in acute neuronal cell death than in chronic neurodegenerative 
diseases [29]. To illustrate this, acute neuronal cell death occurring in our 3-NP 
slice model may represent apoptosis, as is revealed by the presence of DNA 
fragmentation and caspase-3 immunoreactivity in apoptotic striatal cells. 
The precise apoptotic pathway by which neurons in HD brains 
predominantly die is currently not known, but this thesis offers evidence for the 
notion that up-regulation of Bax and PARP proteins are important factors in the 
apoptotic process acting at different stages of the disease. Bax may be important 
to prepare and induce cell death at the beginning and mid-stages of the disease, 
whereas PARP is essential for the execution of increased cell death at end-stage 
HD. The strong PARP immunoreactivity present in both neurons and in glial 
cells, could suggest an additional, but still unknown, role for the DNA-repair 
enzyme PARP that may contribute to neuronal dysfunction and death in HD. 
Knowledge about the apoptotic pathway by which neurons die in HD, may help 
the development of therapeutic agents that are aimed at reducing cell 
degeneration and death in HD. 
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Future prospects of new HD therapies 
 
A focus on impaired mitochondrial function and energy metabolism may offer 
prospects for future therapy trials in HD. Currently, substantial evidence already 
suggests that bioenergetic defects and mitochondrial dysfunction in HD might be 
a direct or indirect consequence of interactions between the mitochondria and N-
terminal fragments of huntingtin [30-34]. The 3-NP animal models used in this 
thesis were based on mitochondrial dysfunction and impaired energy metabolism 
that resulted in specific striatal lesions. Substances that improve cellular energy 
production, such as co-enzyme Q10 and creatine [32,35], may slow down HD, 
and may therefore be an important neuroprotective strategy for the future [36]. 
Studies have shown that co-enzyme Q10 supplementation in HD patients reduced 
impaired mitochondrial function [37,38]. Creatine supplementation did not 
improve functional, neuromuscular, and cognitive status in HD patients with 
grade 1 to 3 [39], but cellular neuroprotective effects are unknown. In our 3-NP 
in vitro model, creatine administration improved neuronal survival predominantly 
in the cortex and to a lesser extent in the striatum. Unexpectedly, creatine 
treatment was associated with increased apoptotic cell death in striatal cells and 
suggests that the limited and selective neuroprotective effect of creatine is in part 
arguable. Moreover, if these therapeutic effects of creatine in our organotypic 
slice cultures appear to be predictive of beneficial effects in man, then this culture 
system could be used for rapid screening of new therapeutic agents for HD. 
Another important therapeutic strategy for HD neuroprotection may be the 
use of anti-excitotoxic agents that counteract the mechanism of neurotoxicity due 
to secondary glutamate excitotoxicity [36]. So far, most HD therapies tested in 
clinical trials are based on this anti-excitotoxicity model and riluzole and 
amantadine are recommended for treatment of movement disorders [40], 
although their efficacy needs to be determined. Recently, treatment with 
memantine, a glutamate receptor antagonist, resulted in retardation of the 
progression but this effect was examined in a trial of only 27 HD patients [41]. 
Our 3-NP animal model is suitable and has good clinical applications for testing 
anti-excitotoxicity HD therapies as well, because the 3-NP striatal neuropathology 
could develop through an excitotoxic mechanism due to glutamate neurotoxicity 
as well [42]. 
Mitochondria are important organelles in apoptosis and serve as the main 
link between cellular stress signals activated during neuronal injury and the 
execution of neuronal cell death. Several death-associated factors are released 
from the mitochondria, such as Bcl-2 family of proteins, cytochrome c and 
caspases, that all play a central role in the apoptotic process. Most of these 
factors are up-regulated in human HD and animal models of HD providing 
evidence for activation of the apoptotic process in HD in relation to mutant 
huntingtin [43-46]. Based on these findings, the use of apoptosis inhibitors may 
possibly function as a therapeutic approach targeting downstream effects of 
mutant huntingtin to treat HD neurodegeneration as well. Caspase inhibitors and 
cannabinoids showed reproducible protection in a cell-based screening model for 
drugs to treat HD and are appealing candidates for further investigation [47]. 
Minocycline is an antibiotic with caspase-inhibiting properties and it has been 
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shown to delay progression in the R6/2 HD mouse model. Recently, a pilot study 
in HD patients revealed that minocycline was well tolerated without serious 
adverse events during a six months period [48]. The testing of other apoptosis 
inhibitors in HD transgenic mice may reveal new insights in the processes that 
influence neuronal death and may be therefore potential targets for new HD 
therapeutics. Particularly, the mutant huntingtin knock-in mice may be a better 
and precise model of HD than other mice lines to study HD pathogenesis. In 
combination with 3-NP exposure experiments, these HD transgenic mouse 
models may show interesting results leading to new therapeutic agents for HD. 
Other hopeful, but invasive treatments are stem cell transplantation into the 
neostriatum [49,50] or the use of adenovirus-mediated gene transfer of 
neurotrophic factors [51,52]. The ultimate treatment for HD would be gene 
therapy, but these therapies require several years before they are safe and 
clinically applicable. At the present time, most treatment options available in HD 
are only symptomatic and treat motor symptoms and depression. 
 
 
Concluding remarks 
 
In this thesis, apoptotic features at various time points of the process were 
studied in the 3-NP in vivo rodent model of HD, in organotypic slice cultures and 
in brains of HD patients. We found an increased expression of several regulatory 
proteins involved in the apoptotic cascade combined with typical TUNEL 
labeling, thus providing evidence for activation of apoptosis in both the 3-NP 
models of HD and in human HD. Although, the in vivo and in vitro 3-NP models 
used in this thesis represent one aspect of human HD, they are suited to perform 
different types of studies. The 3-NP slice culture system may be useful for 
screening new therapeutic agents, whereas the 3-NP in vivo model may be used 
neuropathologically for further elucidating apoptotic processes and pathways that 
are involved in the selective striatal neurodegeneration. It may well be that 
cellular processes involved in the apoptosis cascade and their interaction with 
mutant huntingtin, rather than apoptotic cell death itself, are more important for 
HD neurodegeneration than we believe at this moment. HD transgenic mice were 
not used in this thesis, but the use of novel transgenic mice lines and specific 
knock-in transgenic mice models of HD may complement our presented 3-NP 
animal models to represent a wide range of models that act together on small 
parts of the human disorder. All together, this may eventually lead to further 
understanding of the pathogenesis of HD and to possible combinations of 
therapeutic strategies that may halt HD progression in the future. 
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Samenvatting 
 
De ziekte van Huntington 
 
De ziekte van Huntington (HD) is een erfelijke en voortgaande aandoening die 
bepaalde delen van de hersenen aantast. Opvallend bij HD is het grote verlies van 
een bepaalde groep zenuwcellen, namelijk de ‘medium sized-spiny’ GABAerge 
projectieneuronen in het neostriatum. Het ziektebeeld van HD wordt gekenmerkt 
door onwillekeurige bewegingen (chorea), persoonlijkheidsveranderingen en 
dementie. In 1872 werden deze symptomen bij HD patiënten voor het eerst in 
detail door George Huntington beschreven. De eerste symptomen openbaren zich 
gewoonlijk op latere leeftijd, tussen het 35e en het 45e levensjaar en de ziekte leidt 
gemiddeld na 15-20 jaar tot de dood van de patiënt. De ziekteverschijnselen 
kunnen ook eerder of later in het leven optreden, zoals bij patiënten met de 
juveniele vorm van HD, waarbij de leeftijd van ontstaan van de symptomen voor 
het 20e levensjaar ligt. Deze jeugdige vorm van HD kenmerkt zich door 
gedragsstoornissen, cognitieve problemen, epilepsie en spierstijfheid. Op dit 
moment is er geen effectieve behandeling om de ziekte te genezen of om zelfs het 
verloop te remmen. De behandeling is gericht op het verlichten van de klachten 
van de patiënt. In Nederland zijn er ongeveer 1300 patiënten die lijden aan HD. 
De ziekte kent een prevalentie van 7-10 per 100.000 inwoners en komt vooral 
voor in West-Europa en Noord-Amerika. In Japan en Afrika komt de ziekte bij 
minder dan 1 op 1.000.000 mensen voor. 
HD wordt veroorzaakt door een abnormale verlenging van het huntingtine 
gen (HD-gen), dat is gelokaliseerd op de korte arm van chromosoom 4. Hoe 
groter het aantal verlengingen van CAG repeats in het HD-gen, hoe eerder de 
symptomen optreden. Het HD-gen codeert voor het eiwit huntingtine dat in de 
meeste lichaamsweefsels voorkomt. Huntingtine is veelvuldig aanwezig in 
zenuwcellen maar de precieze functie van het normale huntingtine eiwit is 
vooralsnog onbekend. 
De bijdrage van het verlengde huntingtine eiwit en de manier waarop 
zenuwcellen selectief afsterven in HD is niet duidelijk. Uit neuropathologisch 
onderzoek komen steeds meer aanwijzingen naar voren dat onjuiste activering van 
apoptose, of geprogrammeerde celdood, hierbij betrokken zou kunnen zijn. Dit 
omdat typisch apoptotische cellen werden gevonden in het aangedane neostriatum 
van overleden HD patiënten. De hypothese in dit proefschrift is dan ook dat in 
HD zenuwcellen doodgaan via het mechanisme van apoptose. 
 
 
Apoptose 
 
Er bestaan twee fundamenteel verschillende manieren van celdood, namelijk 
apoptose en necrose. Necrose wordt gezien als een passief proces waarbij de cel 
afsterft als gevolg van membraanschade en wat leidt tot ontstekingsreacties en 
een willekeurige DNA fragmentatie. Daarentegen is apoptose een actief en goed 
gereguleerd proces waarbij cellen volgens een vastgesteld programma afsterven. 
Apoptotische cellen vertonen een karakteristiek patroon van gestructureerde 
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veranderingen, zoals condensatie van de kern, DNA fragmentatie in gelijke 
stukken en vorming van membraanomvattende ‘apoptotische bodies’. Apoptose is 
essentieel voor de embryonale ontwikkeling, het in balans houden van 
lichaamsweefsels en de verdere vorming van het centrale zenuwstelsel. De 
belangrijkste fase van apoptotische celdood is de endonucleolyse, dat is het 
knippen van DNA in kleinere fragmenten van elk 180 basenparen groot. Deze 
specifieke DNA fragmentatie wordt gebruikt voor de biochemische detectie van 
apoptose en voor het zichtbaar maken van apoptotische cellen m.b.v. de TUNEL-
kleuring. 
Apoptose is een snel en dynamisch proces. De laatste jaren zijn er veel 
genen en eiwitten ontdekt die betrokken zijn bij de regulatie en uitvoering van de 
nucleaire en cellulaire gebeurtenissen die met apoptose geassocieerd zijn. Bcl-2, 
Bax en caspases zijn belangrijke eiwitten in het apoptotische proces die een pro-
apoptotisch of een anti-apoptotisch effect kunnen hebben. Ook is bekend dat 
apoptotische celdood via verschillende signaalpaden kan plaatsvinden, maar in 
zenuwcellen komt de caspase-gemedieërde apoptotische celdood het meest voor. 
 
 
3-NP diermodellen 
 
Om de rol van apoptotische celdood in HD te kunnen onderzoeken, zijn in dit 
proefschrift twee diermodellen gebruikt waarbij het mitochondriële toxine 3-
nitropropionzuur (3-NP) celdood veroorzaakt van zenuwcellen in het striatum. 
Het eerste gebruikte 3-NP diermodel werd oorspronkelijk ontwikkeld door 
onderzoeker Beal en zijn collega’s tussen 1990 en 1993 en wordt nog steeds 
veelvuldig gebruikt als diermodel voor de ziekte van Huntington. Hierbij werd de 
stof 3-NP vier weken lang in lage dosering aan ratten gegeven, wat leidt tot een 
specifieke lesie in het striatum met vergelijkbare neuropathologische kenmerken 
als bij patiënten met HD. 
Voor het tweede diermodel werden organotypische weefselkweken van 
hersenen afkomstig van ratten of muizenpups gebruikt. Hierbij werden de 
hersenplakjes twee weken in kweek gehouden en daarna blootgesteld aan de stof 
3-NP om neurotoxische effecten en mechanismen van apoptotische celdood te 
onderzoeken. Toediening van 3-NP aan dit kweeksysteem leidt tot specifieke 
celdood van zenuwcellen in het striatum van de hersenplakjes. 
 
 
Doelstelling 
 
In dit proefschrift werd onderzocht of apoptose betrokken is in HD en welke 
apoptotische signaalpaden betrokken zijn bij de pathogenese van HD. Met behulp 
van bovenstaande 3-NP diermodellen die celdood in het striatum vertonen zijn 
apoptotische kenmerken op verschillende tijdstippen van het proces onderzocht. 
Dit omdat niet alleen de eindproducten, zoals specifieke DNA fragmentatie en 
‘apoptotische bodies’, maar ook de aanwezigheid van verschillende regulatie-
eiwitten of markers, die betrokken zijn in het apoptotische proces, mogelijk als 
bewijs kunnen dienen voor de activatie van apoptose. 
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In het eerste deel van dit proefschrift werd onderzocht of het 3-NP diermodel 
voldoet als neuropathologisch model voor humane HD en of apoptose betrokken 
is bij de 3-NP-geïnduceerde celdood in het striatum. Hiervoor werd gebruik 
gemaakt van celkleuringen, immunohistochemische technieken om de 
aanwezigheid van apoptose-markers zoals Bax, Bcl-2, caspase-3 aan te tonen en 
de TUNEL-kleuring voor de detectie van apoptotische DNA fragmenten. Deze 
apoptose markers werden later getest op humaan materiaal, afkomstig van 
overleden HD patiënten om hierin verschillende stadia van apoptotische cellen te 
kunnen detecteren (hoofdstuk 2, 3, 4). 
Het tweede deel van het proefschrift is gericht op cellulaire gebeurtenissen 
die betrokken zijn bij de neuronale celdood in het 3-NP kweekmodel. Apoptose is 
een dynamisch proces waarbij de aanwezigheid van bepaalde apoptose-markers in 
het 3-NP kweekmodel gerelateerd kan worden aan de status van het apoptose 
proces (hoofdstuk 5). Daarnaast hebben we een mogelijk beschermend effect van 
de stof creatine op de door 3-NP veroorzaakte celdood onderzocht in de 
organotypische hersenkweken (hoofdstuk 6). Creatine is een energie booster en 
kan mogelijk neuroprotectief werken voor de behandeling van HD. Dit wordt 
momenteel in de kliniek getest. 
 
In hoofdstuk 1 van dit proefschrift wordt een beschrijving gegeven van de 
klinische en neuropathologische kenmerken van de ziekte van Huntington, het 
apoptose proces en de gebruikte 3-NP diermodellen. Ook worden de theoretische 
achtergronden van de hypothese en de doelstelling van dit proefschrift 
weergegeven. 
In hoofdstuk 2 wordt het 3-NP diermodel gepresenteerd en hierin werden 
drie verschillende typen van striatale lesies onderscheiden, namelijk zwaar, mild 
en subtiel. De zware lesie vertoonde een duidelijk verlies van zenuwcellen in het 
striatum met actieve astrocyten die alleen zichtbaar waren aan de randen van de 
lesie. Het milde type werd gekarakteriseerd door een minder opvallend verlies van 
neuronen maar met een toename van geactiveerde astrocyten die door de gehele 
lesie in het striatum was te zien. Een gedragstest om de terugtrekreactie van de 
achterpoten van 3-NP-behandelde ratten t.o.v. controle ratten te onderzoeken 
werd gebruikt als gevoelige indicator van subtiele striatale pathologie. Deze 
poottest detecteerde abnormaliteiten in ratten met een subtiele lesie, die in het 
striatum alleen aangedane ‘dark’ neuronen vertoonden. Overigens waren deze 
dark neuronen aanwezig in alle lesie types en deze cellen werden gekarakteriseerd 
als de neuronenpopulatie die ook bij HD selectief verdwijnt. Deze studie laat zien 
dat chronische en systematische toediening van 3-NP aan ratten een breed 
spectrum van striatale pathologie induceert. De morfologische aspecten van de 
milde lesie benaderde de karakteristieke neuropathologie van HD het meest. 
Hoofdstuk 3 is gewijd aan het expressiepatroon van verschillende 
apoptose-markers in de drie lesie types van het 3-NP model. Dit gebeurde met 
behulp van immunohistochemische technieken in combinatie met de TUNEL-
kleuring van specifieke apoptotische DNA fragmenten. De expressie van de 
apoptose markers Bax en Bcl-2 was verhoogd in alle 3-NP-behandelde ratten in 
vergelijking met controle ratten, maar de mate van verhoging varieerde tussen de 
verschillende striatale lesies. Typisch apoptotische en TUNEL-positieve gekleurde 
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cellen werden alleen gevonden in het striatum van de dieren met een zware lesie, 
terwijl TUNEL-kleuring afwezig was in de andere lesie types en in de controle 
ratten. De aanwezigheid van DNA fragmentatie, de sterke Bax expressie en de 
verhoogde ratio van Bax/Bcl-2 in het centrum van de zware lesie toont aan dat 
het apoptotische proces is betrokken bij 3-NP-geïnduceerde celdood in het 
striatum. In de beschadigde dark neuronen, die in alle lesie typen voorkomen, was 
de expressie van Bax en Bcl-2 verhoogd maar niet verschillend van elkaar. Ook 
waren deze dark neuronen niet TUNEL-positief, wat suggereert dat deze 
aangetaste cellen op dit moment niet apoptotisch zijn maar zeer waarschijnlijk 
later wel apoptose zullen ondergaan. 
In hoofdstuk 4 is de expressie van verschillende apoptose-markers in de 
hersenen van HD patiënten bepaald en vergeleken met controle breinen. 
Hiervoor werd het neostriatum van verschillende HD patiënten gebruikt, die 
neuropathologisch varieerden van graad 1 tot de vergevorderde en zeer aangetaste 
graad 4 breinen. De expressie van Bax en Bcl-2 was verhoogd in HD breinen in 
vergelijking met controle breinen. Bax was frequent aanwezig in de 
verschrompelde dark neuronen, en dan met name in graad 2 en graad 3 HD 
breinen. Bcl-2 immunoreactiviteit was opvallend sterk toegenomen in graad 4 HD 
breinen van patiënten in een vergevorderd stadium van de ziekte. Caspase-3 
kwam alleen tot expressie in een viertal breinen van HD patiënten en werd niet 
gevonden in controles. In HD breinen werd een opvallende toename van PARP-
immunoreactiviteit gezien in neuronen en astrocyten t.o.v. controle breinen. 
Typische apoptotische en TUNEL-positieve cellen werden alleen aangetoond in 
HD breinen en waren vooral aanwezig in graad 3 en 4. De bevindingen van de 
vooral laat-apoptotische gebeurtenissen, zoals de verhoogde PARP-
immunoreactiviteit en de vele TUNEL-positieve cellen in de breinen van HD 
patiënten met vergevorderde stadia, suggereren de betrokkenheid van apoptose in 
HD. De zwakke expressie van caspase-3 leidt tot de conclusie dat de caspase-
gemedieërde neuronale dood een kleine rol speelt in de pathogenese van HD. 
De studies beschreven in hoofdstuk 2, 3 en 4 laten zien dat in breinen van 
patiënten met HD en in het 3-NP diermodel vergelijkbare neuropathologische 
kenmerken zoals dark neuronen, verlies van striatale neuronen en gliose werden 
aangetoond. Daarnaast werd een verhoogde expressie van Bax, Bcl-2 en de 
aanwezigheid van TUNEL-positieve cellen vastgesteld en deze apoptotische 
verschijnselen ondersteunen de rol en activatie van apoptose in HD en het 3-NP 
model. Het precieze apoptotische signaalpad waardoor neuronen in HD doodgaan 
is op dit moment nog onbekend. Dit proefschrift laat zien dat Bax vooral 
belangrijk is tijdens de voorbereiding en inductie van celdood in de vroege stadia 
van HD, terwijl PARP essentieel is voor de executie van de verhoogde celdood 
tijdens het eindstadium van de ziekte van Huntington. 
In hoofdstuk 5 wordt een kweekmodel van 3-NP-behandelde 
corticostriatale hersenplakjes gepresenteerd om mechanismen van apoptotische 
celdood te onderzoeken. De 3-NP blootstelling veroorzaakte een dosis-
afhankelijk verlies van neuronen in het striatum van de hersenplakjes afkomstig 
van rattenpups. De betrokkenheid van apoptose in het 3-NP kweeksysteem werd 
aangetoond door de toegenomen Bax expressie en de aanwezigheid van DNA 
fragmentatie. In de 3-NP-behandelde hersenplakjes werden TUNEL-positieve 
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cellen gezien in het striatum en de cortex, maar deze kwamen in verschillende 
vormen voor. De striatale neuronen waren diffuus gekleurd of ze vertoonden 
DNA fragmentatie, terwijl de corticale neuronen alleen de typische DNA 
fragmentatie vertoonden. Naast apoptose induceert het neurotoxine 3-NP in het 
striatum ook necrose, dat mogelijk als secundaire necrose moet worden geduid in 
dit kweeksysteem. Uit andere studies is gebleken dat de vorm van dode striatale 
neuronen in kweek afhankelijk is van de 3-NP dosis. Behandeling met een lage 
dosis neurotoxine leidde tot apoptotische celdood waarbij alle stadia van 
apoptose, zoals condensatie en fragmentatie van de kern, werden doorlopen. 
Echter na blootstelling aan een te hoge dosis stopte het apoptose proces in een 
vroeg stadium, dat werd gevolgd door necrotische dood van de neuronen. Dit 
fenomeen staat bekend als secundaire necrose en dit artefact werd waarschijnlijk 
gezien in de striatale neuronen van ons kweeksysteem. Hieruit blijkt ook dat de 
striatale neuronen veel gevoeliger zijn voor mitochondriële dysfunctie dan de 
zenuwcellen in de cortex. 
Hoofdstuk 6 behandelt de mogelijke neuroprotectieve effecten van de 
bioenergetische stof creatine op de neuronale celdood, die werd geïnduceerd door 
3-NP in corticostriatale hersenplakjes. Ook in dit kweeksysteem met muizen 
hersenplakjes veroorzaakte 3-NP een dosis-afhankelijk celverlies en werd 
apoptose aangetoond door de activatie van caspase-3 en de vele cellen met 
typische DNA fragmentatie na aankleuring met de TUNEL-techniek. Door 
toevoeging van creatine werd de 3-NP-geïnduceerde neuronale celdood voor een 
groot deel voorkomen en was met name in de cortex de overleving van neuronen 
aanzienlijk verbeterd. Behandeling met creatine resulteerde ook in een verminderd 
aantal apoptotische en TUNEL-positieve cellen in het 3-NP kweeksysteem. Maar 
in het striatum, werd juist in de 3-NP blootstellingfase en door de aanwezigheid 
van creatine, een onverwachte toename van zowel TUNEL-positieve cellen als 
van caspase-3-immunopositieve cellen aangetoond. Deze bevindingen suggereren 
dat creatine celdood door 3-NP in de hersenplakjes vermindert door apoptose te 
voorkomen in de cortex, maar dat creatine juist in de striatale cellen kan leiden 
tot een verhoogde en versnelde executie van apoptotische celdood om mogelijk 
verder necrose-gerelateerde schade in deze regio te voorkomen. 
Uit de resultaten van hoofdstuk 5 en 6 blijkt dat de 3-NP-behandelde 
hersenplakjes afkomstig van neonatale ratten of muizen goed kunnen worden 
gehouden in een kweeksysteem en zeer bruikbaar zijn als een modelsysteem om 
mechanismen van neuronale celdood in HD te onderzoeken. Ook is het 
kweeksysteem farmacologisch te manipuleren met neurotoxische en 
neuroprotectieve stoffen en is het te gebruiken voor screening van nieuwe 
therapeutische stoffen voor HD. 
In hoofdstuk 7 worden de resultaten uit de voortgaande hoofdstukken 2-6 
samengevat en bediscussiëerd. 
 
 
Tenslotte 
 
In dit proefschrift zijn kenmerken van apoptotische celdood op verschillende 
tijdstippen van het proces aangetoond in het 3-NP diermodel van HD, in 
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weefselkweken van 3-NP-behandelde hersenplakjes en in breinen van HD 
patiënten, die de activatie van apoptose in beide 3-NP modellen en in HD 
ondersteunen. Hoewel, de gebruikte 3-NP diermodellen maar een enkel aspect 
van de ziekte van Huntington presenteren, zijn zij geschikt om te gebruiken bij 
verschillende studies. Dit proefschrift laat zien dat het ontwikkelde 3-NP 
kweeksysteem gebruikt kan worden voor de screening van nieuwe farmaca voor 
behandeling van HD, terwijl het 3-NP diermodel gebruikt kan worden om verdere 
apoptotische processen en signaalpaden op te helderen. De ziekte van Huntington 
is een heterogeen ziektebeeld waarbij verschillende factoren en mechanismen een 
rol spelen. Het is goed mogelijk dat in HD juist de cellulaire processen, die 
betrokken zijn in het apoptose proces en hun interactie met het verlengde 
huntingtine eiwit, belangrijker zijn voor de pathogenese van HD dan de 
apoptotische celdood van de neostriatale zenuwcellen op zichzelf. Voor de 
toekomst bieden genetisch gemanipuleerde muizen met het mtante huntingtine-
gen waarschijnlijk uitkomst om de oorzaak en mechanismen van apoptotische 
celdood in HD te ontrafelen. Het testen van apoptose remmers in deze transgene 
muismodellen van HD kan leiden tot nieuwe inzichten in de processen die 
neuronale celdood beïnvloeden en mogen daardoor aanleiding geven tot nieuwe 
therapieën die in de toekomst de voortgang van de ziekte remmen. 
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Chapter 3, Figure 2. Expression of apoptosis-related markers in the 3-NP rat model.  
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Chapter 4, Figure 2. Neuropathological characteristics, expression pattern of apoptosis-related markers 
and TUNEL-labeling in control and in HD brains. 
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Figure 2. Expression of apoptosis-related markers in the 3-NP rat model. A, Photomicrograph of a 
paraffin section from the striatum of an untreated animal showing the weak and diffuse perinuclear 
immunostaining for Bcl-2 in medium-sized spiny neurons (arrows). A single neuron is expressing Bcl-2 in 
the cytoplasm (arrowhead). B, The mild type lesion demonstrates an increased expression for Bcl-2 in 
compromised dark neurons (arrows). C, Photomicrograph of a paraffin section from a control animal 
showing predominantly the weak and diffuse perinuclear Bax immunolabeling in striatal neurons (arrows), 
whereas only a few neurons demonstrate the cytoplasmic Bax immunostaining (arrowhead). D, Enhanced 
expression for Bax protein in compromised dark neurons of the mild type of lesion (arrows). E, Strong 
and granular Bax expression in the centre of severe striatal lesions. F, Photomicrograph of a paraffin 
section demonstrating TUNEL-positive cells which were only detected in the core of the severe lesion 
type. G, TUNEL-labeled cells in the striatum of a severely lesioned animal showing DNA fragmentation 
typically localized in nuclei and in apoptotic bodies. H, Nissl-stained paraffin section from a severely 
lesioned animal showing a marked neuronal loss and apoptotic features such as nuclear fragmentation and 
chromatin condensation in the striatal lesion (arrows). Scale bar in A (also for B-F) represents 15 µm, and 
scale bars in G and in H both represent 15 µm. 
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Figure 2. Neuropathological characteristics, expression pattern of apoptosis-related markers and 
TUNEL-labeling in control and in HD brains. A, Photomicrograph of a control paraffin section 
demonstrating a few GFAP-immunostained astrocytes in the caudate nucleus. B, Increased expression of 
GFAP-positive astrocytes in a paraffin section from a HD brain. Note the greater number of neurons in 
the control brain in comparison to the HD brain showing mainly affected dark neurons (arrowheads). C, 
Cresylviolet-stained section of a HD brain showing neuronal loss, dark neurons and apoptotic features 
such as nuclear condensation and fragmentation (arrows). D, The HD caudate nucleus demonstrated an 
increased cytoplasmic immunoreactivity for the pro-apoptotic protein Bax in neurons but predominantly 
in dark neurons (arrowheads). E, The perinuclear and diffuse cytoplasmic immunolabeling of the anti-
apoptotic protein Bcl-2 in neurons was found in control brain. F, HD caudate nucleus demonstrated 
enhanced expression for Bcl-2: strong Bcl-2 expression was found in neurons and dark neurons 
(arrowheads). G, A few scattered caspase-3-positive cells were found in the HD caudate nucleus and these 
were not present in control brains. H, In control brain, cytoplasmic PARP immunoreactivity was mainly 
found in neurons, nuclear PARP immunostaining was rare. I, In HD brains, PARP expression was 
markedly increased and a strong granular expression was observed in the cytoplasm and cellular processes 
of neuronal cells. K, PARP immunoreactivity was demonstrated in the cytoplasm and cellular processes of 
glial cells in HD brains. L, Diffusely TUNEL-labeled cells that did not exhibit characteristic apoptotic 
morphology, were frequently seen in the caudate nucleus of controls. M, HD brains with intensively 
labeled TUNEL-positive cells show DNA fragmentation mainly localized in shrunken nuclei (arrows) and 
in a few apoptotic bodies (arrowhead). These typical apoptotic cells were mostly detected in the neuropil 
of the caudate nucleus surrounded by more diffusely TUNEL-labeled cells that did not exhibit 
characteristic apoptotic morphology. Scale bar in 2A presents 20µm (A-C) and scale bar in 2D presents 
10µm (D-M). 
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Figure 1. A-C, Low-power photomicrographs of cresylviolet-stained corticostriatal slices of control and 
3-NP-exposed cultures (P-medium). A, One-week-old control slice demonstrating major morphological 
features, including the cerebral cortex (Ctx), striatum (Str) consisting of the caudate-putamen, the anterior 
commissure (ac) and the corpus callosum (cc). The asterisk marks the deep part of the cerebral cortex, 
characterized by a decreased number of cresylviolet-stained cells. B, Slice culture exposed to a 
concentration of 100 µM 3-NP for 24 hours. Note the marked loss of Nissl-stained cells (arrow) in the 
dorsolateral part of the 3-NP-exposed striatum. C, Corticostriatal slice culture exposed to 250 µM 3-NP 
revealing a marked and widespread neuronal degeneration in the striatum. The deeper layers of the 
cerebral cortex are also involved. D-I, Expression of apoptosis-related markers in 3-NP-exposed 
corticostriatal slices (Neurobasal medium). D, TUNEL-positive cells (dark-brown) in the 3-NP-treated 
striatum contained diffusely stained, condensed nuclei or showed nuclear fragmentation (arrows). E, In 
the overlying, deep part of the cerebral cortex of unexposed slices the majority of the TUNEL-positive 
neurons exhibited characteristic apoptotic morphology (arrows) and extensive, brown TUNEL labeling. 
The sections shown in D and E are counterstained with ‘Kernechtrot’. F, Increased expression of the pro-
apoptotic protein Bax in the striatum of a 3-NP-exposed cryosection. G, In the deep cortex of 3-NP-
treated brain slices, Bax expression was increased and predominantly observed in the cytoplasm of 
neurons, demonstrating nuclear fragmentation. H, Bcl-2 immunostaining of an untreated cryosection 
demonstrating the striatum. The anti-apoptotic protein Bcl-2 was not detected in striatal neurons. I, Bcl-2 
is not expressed by the dying cells in the deep parts of the cerebral cortex, exhibiting fragmentation 
(arrows). Scale bars represent 100 µm in A-C, D = 15 µm in D and E (also for F-I) = 15 µm. 
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Figure 2. Creatine neuroprotection against 3-NP toxicity (2A-D) and creatine effects on the expression of 
apoptosis-related markers in 3-NP-exposed corticostriatal slices (2E-Q). Cryosections of the striatum of a 
control brain slices (A,E,I), 200 µM 3-NP-exposed slices (B; enlarged in C,F,K) and 200 µM 3-NP-
exposed slices with 12 mM creatine (D,G,L) (all exposure phase). Cresylviolet-staining shows neuronal 
degeneration in the striatum with increased cell loss, many injured cresylviolet-stained cells exhibiting 
apoptotic features such as condensed nuclei (arrow) and nuclear fragmentation (arrowhead) in 3-NP-
exposed cryosections in comparison with controls (A-C). Creatine supplementation was neuroprotective 
against 3-NP-induced neurotoxicity resulting in survival of neurons (D). Caspase-3-immunostaining shows 
activation of pro-apoptotic protein caspase-3 in 3-NP-exposed slices in comparison with controls (E,F). 
Creatine supplementation resulted in an unexpectedly enhanced caspase-3 expression in striatal cells, 
usually localized in the cytoplasm of cells with fragmented nuclei (G, arrowhead), whereas in the recovery 
period caspase-3 expression decreased to basal levels. Increased caspase-3 expression was found in 3-NP-
exposed cortex (H, exposure phase), similar to what was observed in the cortex of creatine-treated 3-NP-
exposed slices. TUNEL-labeled cells were found in the 3-NP-exposed striatum exhibiting darkly stained 
nuclei (arrow) or DNA fragmentation (I,K arrowhead). In the exposure phase, creatine co-treatment 
resulted in an increased number of TUNEL-positive cells (L). However, in the recovery period, TUNEL 
labeling was markedly reduced. An increased number of TUNEL-positive cells was found in the cortex of 
3-NP-exposed slices (M, exposure phase), whereas in creatine-neuroprotected 3-NP-exposed slices, 
TUNEL-labeling in the cortex was reduced. Caspase-3 immunostaining and TUNEL labeling of 
cryosections of the striatum of a 200 µM 3-NP-exposed slice (N,O) and 200 µM 3-NP-exposed slice with 
12 mM creatine (P,Q), both at 12 hours 3-NP exposure phase, shows activation of caspase-3 expression 
(O) and abundance of TUNEL-positive cells (Q) in the creatine-treated 3-NP-exposed striatum in 
comparison to untreated 3-NP-exposed slices; both scale bars represent 15 µm and 2A applies also for the 
rest of Fig. 2. All immunostained cryosections were counterstained using hematoxylin. NADPH-
diaphorase interneurons (*) are labeled as well showing dark blue stained dendrites or cytoplasm. 
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Chapter 5, Figure 1. A-C, Low-power photomicrographs of cresylviolet-stained corticostriatal slices of 
control and 3-NP-exposed cultures. D-I, Expression of apoptosis-related markers in 3-NP-exposed 
corticostriatal slices. 
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Chapter 6, Figure 2. Creatine neuroprotection against 3-NP toxicity (2A-D) and creatine effects on the 
expression of apoptosis-related markers in 3-NP-exposed corticostriatal slices (2E-Q). 
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HIP-1 huntingtin-interacting protein-1 
ISEL  in situ end labeling 
kb  kilobase pair 
kD  kilodalton 
LDH  lactate dehydrogenase 
LFB-HE luxol fast bleu-hematoxylin and eosin 
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